

STIC-Biotech/ChemLib

118996

From: Slobodyansky, Elizabeth  
Sent: Wednesday, April 07, 2004 5:41 PM  
To: STIC-Biotech/ChemLib  
Subject: 10/076,604

Please search for case 10/076,604:

SEQ ID NO: 208 against commercial databases.

Thank you.

Elizabeth Slobodyansky, PhD

Primary Examiner

Art Unit 1652  
REM 3A65  
571-272-0941  
MAILBOX 3C70

RECEIVED  
APR - 8 2004  
STIC

Searcher: \_\_\_\_\_  
Phone: \_\_\_\_\_  
Location: \_\_\_\_\_  
Date Picked Up: 4/8/04  
Date Completed: 4/8/04  
Searcher Prep/Review: \_\_\_\_\_  
Clerical: \_\_\_\_\_  
Online time: \_\_\_\_\_

TYPE OF SEARCH:  
NA Sequences: \_\_\_\_\_  
AA Sequences: 1  
Structures: \_\_\_\_\_  
Bibliographic: \_\_\_\_\_  
Litigation: \_\_\_\_\_  
Full text: \_\_\_\_\_  
Patent Family: \_\_\_\_\_  
Other: \_\_\_\_\_

VENDOR/COST (where applic.)  
STN: \_\_\_\_\_  
DIALOG: \_\_\_\_\_  
Questel/Orbit: \_\_\_\_\_  
DRLink: \_\_\_\_\_  
Lexis/Nexis: \_\_\_\_\_  
Sequence Sys.: ADSP  
WWW/Internet: \_\_\_\_\_  
Other (specify): \_\_\_\_\_

GenCore version 5.1.6  
Copyright (c) 1993 - 2004 Compugen Ltd.

OM protein - protein search, using sw model

Run on: April 8, 2004, 09:27:16 ; Search time 55 Seconds

(Without alignments)  
313.371 Million cell updates/sec

Title: US-10-076-604-208

Perfect score: 351  
Sequence: 1 EVVREVCSQAETGPCRAI.....GNRNNDETEYCAVAGSAI 61

Scoring table: BLOSUM62

Gapop 10.0, Gapext 0.5

Searched: 1586107 seqs, 282547505 residues

Total number of hits satisfying chosen parameters: 1586107

Minimum DB seq length: 0

Maximum DB seq length: 200000000

Post-processing: Minimum Match 0%

Maximum Match 100%  
Listing first 45 summaries

Database: A\_Geneseq\_29Jan04.\*

1: geneseqp1980s.\*  
2: geneseqp1990s.\*  
3: geneseqp2000s.\*  
4: geneseqp2001s.\*  
5: geneseqp2002s.\*  
6: geneseqp2003as.\*  
7: geneseqp2003bs.\*  
8: geneseqp2004s.\*

Pred. No. is the number of results predicted by chance to have a score greater than or equal to the score of the result being printed, and is derived by analysis of the total score distribution.

## SUMMARIES

Result No.	Score	Query Match	Length	ID	Description
1	351	100.0	61	AAV68159	AAV68159 Kunitz pr
2	351	100.0	61	AAV68056	AAV68056 Kunitz pr
3	351	100.0	146	AAV68055	AAV68055 Yeast mat
4	347	98.9	61	AAV68169	AAV68169 Kunitz pr
5	347	98.9	61	AAV68175	AAV68175 Kunitz pr
6	347	98.9	61	AAU09329	AAU09329 Human KPI
7	347	98.9	61	AAU09335	AAU09335 Human KPI
8	346	98.6	61	AAV68058	AAV68058 Kunitz pr
9	346	98.6	61	AAV68050	AAV68050 Kunitz pr
10	346	98.6	61	AAV68157	AAV68157 Kunitz pr
11	346	98.6	61	AAV68168	AAV68168 Kunitz pr
12	346	98.6	61	AAU09319	AAU09319 Human KPI
13	346	98.6	61	AAU09317	AAU09317 Human KPI
14	346	98.6	146	AAV68049	AAV68049 Yeast mat
15	346	98.6	146	AAV68057	AAV68057 Yeast mat
16	343	97.7	61	AAV18427	AAV18427 KPI(-4 to
17	343	97.7	61	AAV18401	AAV18401 KPI(-4 to
18	343	97.7	61	AAV68182	AAV68182 Kunitz pr
19	343	97.7	61	AAV68124	AAV68124 Kunitz pr
20	343	97.7	61	AAV68036	AAV68036 Kunitz pr
21	343	97.7	61	AAV68162	AAV68162 Kunitz pr
22	343	97.7	61	AAU09322	AAU09322 Human KPI
23	343	97.7	61	AAU09316	AAU09316 Human KPI
24	343	97.7	146	AAV18448	AAV18448 Alpha mat
25	343	97.7	146	AAV68027	AAV68027 Yeast mat

26	343	97.7	146	AAV68181	AAV68181 Yeast mat
27	343	97.7	146	AAU09207	AAU09207 Yeast alp
28	342	97.4	61	AAV68167	AAV68167 Kunitz pr
29	342	97.4	61	AAV68174	AAV68174 Kunitz pr
30	342	97.4	61	AAU09327	AAU09327 Human KPI
31	342	97.4	61	AAU09334	AAU09334 Human KPI
32	341	97.2	61	AAV68166	AAV68166 Kunitz pr
33	341	97.2	61	AAV68155	AAV68155 Kunitz pr
34	341	97.2	61	AAV68052	AAV68052 Kunitz pr
35	341	97.2	61	AAU09315	AAU09315 Human KPI
36	341	97.2	61	AAU09326	AAU09326 Human KPI
37	341	97.2	61	AAU09328	AAU09328 Human KPI
38	341	97.2	146	AAV68051	AAV68051 Yeast mat
39	340.5	97.0	62	AAV18433	AAV18433 KPI(-4 to
40	340	96.9	61	AAV68170	AAV68170 Kunitz pr
41	340	96.9	61	AAU09330	AAU09330 Human KPI
42	339	96.6	61	AAV18404	AAV18404 KPI(-4 to
43	339	96.6	61	AAV18430	AAV18430 KPI(-4 to
44	339	96.6	61	AAV18426	AAV18426 KPI(-4 to
45	339	96.6	61	AAV68122	AAV68122 Kunitz pr

## ALIGNMENTS

RESULT 1  
AAV68159  
ID AAV68159 standard; protein, 61 AA.

AAV68159;

13-APR-2000 (first entry)

Kunitz protease inhibitor variant BG022.

Kunitz protease inhibitor; KPI; serine protease; kallikrein; plasmin;  
amyloid precursor protein; coagulation factor; blood loss; cardiac;  
cardiopulmonary bypass surgery; antithrombotic; anti-inflammatory;  
anti-arthritic; thrombolytic; antineurotic; antipsoriatic;  
immunosuppressant; pancreatitis; deep vein thrombosis; psoriasis;  
rheumatoid arthritis; myocardial infarction; transplant rejection.

OS Homo sapiens.  
Synthetic.

PN WO9963090-A2.

PD 09-DEC-1999.

PF 03-JUN-1999; 99WO-US012276.

PR 03-JUN-1998; 98US-0087885P.

PA (SCIO-) SCIOS INC.

PI White RT, Damm D, Lesikar DD, McFadden K, Garrick BL, Lucas AB;  
Pollitt NS, Lam AO;

PT WPI; 2000-105699/09.

PS Novel enzyme inhibitors especially used to reduce postoperative bleeding.

XX Example 4; Fig 64; 15tp; English.

CC The present invention describes protease inhibitors that are analogues of  
CC the Kunitz protease inhibitor (KPI) domain of the amyloid precursor  
CC protein. The protease inhibitors can be used used to treat or prevent  
CC disorders associated with increased activity of serine proteases.  
CC specifically blood loss during surgery (particularly cardiopulmonary  
CC bypass surgery where plasma proteases are activated by contact with  
CC surfaces in the heart-lung machine), but also other conditions such as  
CC pancreatitis; deep vein thrombosis; rheumatoid arthritis; psoriasis;  
CC myocardial infarction; and transplant rejection. They are also for organ

CC preservation and to promote wound healing. In vitro the protease  
CC inhibitors may be used to inhibit serine proteases during preparation of  
CC cell extracts. The protease inhibitors are based on a human peptide  
CC sequence so are unlikely to be immunogenic, can be produced at high  
CC levels in recombinant expression systems, and can inhibit a wide range of  
CC serine proteases. They are more potent or specific than known inhibitors.  
CC The present sequence represents a KPI variant which is given in an  
CC example from the present invention

XX Sequence 61 AA;

Query Match 100.0%; Score 351; DB 3; Length 61;  
Best Local Similarity 100.0%; Pred. No. 1.1e-31;  
Matches 61; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 EVREVCSEQAEFGPCRAAIHWYFDYTGKCAFFYGGCGGNRNNDTEECMAVCGSA 60  
DB 1 EVREVCSEQAEFGPCRAAIHWYFDYTGKCAFFYGGCGGNRNNDTEECMAVCGSA 60

QY 61 I 61  
DB 61 I 61

RESULT 2  
ID AAY68056  
XX AAY68056 standard; protein, 61 AA.

AC AAY68056;

DT 13-APR-2000 (first entry)

DE Kunitz protease inhibitor analogue protein sequence Fig 40.

XX Kunitz protease inhibitor; KPI; serine protease; kallikrein; plasmin;  
KM amyloid precursor protein; coagulation factor; blood loss; cardiac;  
KM cardiopulmonary bypass surgery; anticoagulant; anti-inflammatory;  
KM anti-arthritic; thrombolytic; antithrombotic; antipsoriatic;  
KM immunosuppressant; pancreatitis; deep vein thrombosis; psoriasis;  
KM rheumatoid arthritis; myocardial infarction; transplant rejection.

OS Homo sapiens.  
OS Synthetic.

PN WO9963090-A2.

PD 09-DEC-1999.

PF 03-JUN-1999; 99WO-US012276.

PR 03-JUN-1998; 98US-0087885P.

PA (SCIO-) SCIOS INC.

PI White RT, Damm D, Lesikar DD, McFadden K, Garrick BL, Lucas AB;  
PI Pollitt NS, Lam AO;

DR WPI; 2000-105699/09.

XX Novel enzyme inhibitors especially used to reduce postoperative bleeding.

XX Example 3; Fig 40; 151pp; English.

XX The present invention describes protease inhibitors that are analogues of  
CC the Kunitz protease inhibitor (KPI) domain of the amyloid precursor  
CC protein. The protease inhibitors can be used to treat or prevent  
CC disorders associated with increased activity of serine proteases,  
CC specifically blood loss during surgery (particularly cardiopulmonary  
CC bypass surgery where plasma proteases are activated by contact with  
CC surfaces in the heart-lung machine), but also other conditions such as  
CC pancreatitis; deep vein thrombosis; rheumatoid arthritis; psoriasis;  
CC myocardial infarction; and transplant rejection. They are also for organ  
CC preservation and to promote wound healing. In vitro the protease

CC inhibitors may be used to inhibit serine proteases during preparation of  
CC cell extracts. The protease inhibitors are based on a human peptide  
CC sequence so are unlikely to be immunogenic, can be produced at high  
CC levels in recombinant expression systems, and can inhibit a wide range of  
CC serine proteases. They are more potent or specific than known inhibitors.  
CC The present sequence is given in an example from the present invention

XX Sequence 61 AA;

Query Match 100.0%; Score 351; DB 3; Length 61;  
Best Local Similarity 100.0%; Pred. No. 1.1e-31;  
Matches 61; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 EVREVCSEQAEFGPCRAAIHWYFDYTGKCAFFYGGCGGNRNNDTEECMAVCGSA 60  
DB 1 EVREVCSEQAEFGPCRAAIHWYFDYTGKCAFFYGGCGGNRNNDTEECMAVCGSA 60

QY 61 I 61  
DB 61 I 61

RESULT 3  
ID AAY68055  
XX AAY68055 standard; protein, 146 AA.

AC AAY68055;

DT 13-APR-2000 (first entry)

DE Yeast mating-factor-KPI-(4-57) fusion protein sequence Fig 23.

XX Kunitz protease inhibitor; KPI; serine protease; kallikrein; plasmin;  
KM amyloid precursor protein; coagulation factor; blood loss; cardiac;  
KM cardiopulmonary bypass surgery; anticoagulant; anti-inflammatory;  
KM anti-arthritic; thrombolytic; antithrombotic; antipsoriatic;  
KM immunosuppressant; pancreatitis; deep vein thrombosis; psoriasis;  
KM rheumatoid arthritis; myocardial infarction; transplant rejection.

OS Homo sapiens.  
OS Saccharomyces cerevisiae.  
OS Synthetic.

PN WO9963090-A2.

PD 09-DEC-1999.

PF 03-JUN-1999; 99WO-US012276.

PR 03-JUN-1998; 98US-0087885P.

PA (SCIO-) SCIOS INC.

PI White RT, Damm D, Lesikar DD, McFadden K, Garrick BL, Lucas AB;  
PI Pollitt NS, Lam AO;

DR WPI; 2000-105699/09.  
DR N-PSDB; AA257538.

XX Novel enzyme inhibitors especially used to reduce postoperative bleeding.

XX Example 3; Fig 23; 151pp; English.

XX The present invention describes protease inhibitors that are analogues of  
CC the Kunitz protease inhibitor (KPI) domain of the amyloid precursor  
CC protein. The protease inhibitors can be used to treat or prevent  
CC disorders associated with increased activity of serine proteases,  
CC specifically blood loss during surgery (particularly cardiopulmonary  
CC bypass surgery where plasma proteases are activated by contact with  
CC surfaces in the heart-lung machine), but also other conditions such as  
CC pancreatitis; deep vein thrombosis; rheumatoid arthritis; psoriasis;  
CC myocardial infarction; and transplant rejection. They are also for organ  
CC preservation and to promote wound healing. In vitro the protease

CC inhibitors may be used to inhibit serine proteases during preparation of  
 CC cell extracts. The protease inhibitors are based on a human peptide  
 CC sequence so are unlikely to be immunogenic, and can inhibit a wide range of  
 CC levels in recombinant expression systems, and can inhibit a wide range of  
 CC serine proteases. They are more potent or specific than known inhibitors.  
 CC The present sequence represents a KPI variant which is given in an  
 CC example from the present invention

XX Sequence 146 AA;

Query Match 100.0%; Score 351; DB 3; Length 146;  
 Best Local Similarity 100.0%; Pred. No. 2,6e-31;

Matches 61; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 EVREVCSEQAEFGPCRAAIYHWYFDVTEGKAPFFYGGCGGNRNNDTEEYCMAVCGSA 60  
 DB 86 EVREVCSEQAEFGPCRAAIYHWYFDVTEGKAPFFYGGCGGNRNNDTEEYCMAVCGSA 145

QY 61 I 61  
 DB 146 I 146

RESULT 4  
 AAY68169 standard; protein; 61 AA.

XX AAY68169;

DT 13-APR-2000 (first entry)

DE Kunitz protease inhibitor variant BG034.

XX Kunitz protease inhibitor; KPI; serine protease; kallikrein; plasmin;  
 KW amyloid precursor protein; coagulation factor; blood loss; cardiant;  
 KW cardiopulmonary bypass surgery; anticoagulant; anti-inflammatory;  
 KW anti-arthritic; thrombolytic; antirheumatic; antipsoriatic;  
 KW immunosuppressant; pancreatitis; deep vein thrombosis; psoriasis;  
 KW rheumatoid arthritis; myocardial infarction; transplant rejection.

OS Homo sapiens.  
 OS Synthetic.

PN W09963090-A2.

PD 09-DEC-1999.

PF 03-JUN-1999; 99MO-US012276.

PR 03-JUN-1998; 98US-0087885P.

PA (SCIO-) SCIOS INC.

PI White RT, Damm D, Lesikar DD, Mcfadden K, Garrick BL, Lucas AB;  
 PI Pollitt NS, Lam AO;

DR WPI; 2000-105699/09.

PT Novel enzyme inhibitors especially used to reduce postoperative bleeding.

PS Example 4; Fig 64; 151pp; English.

XX The present invention describes protease inhibitors that are analogues of  
 CC the Kunitz protease inhibitor (KPI) domain of the amyloid precursor  
 CC protein. The protease inhibitors can be used to treat or prevent  
 CC disorders associated with increased activity of serine proteases,  
 CC specifically blood loss during surgery (particularly cardiopulmonary  
 CC bypass surgery where plasma proteases are activated by contact with  
 CC surfaces in the heart-lung machine), but also other conditions such as  
 CC pancreatitis; deep vein thrombosis; rheumatoid arthritis; psoriasis;  
 CC myocardial infarction; and transplant rejection. They are also for organ  
 CC preservation and to promote wound healing. In vitro the protease  
 CC inhibitors may be used to inhibit serine proteases during preparation of  
 CC cell extracts. The protease inhibitors are based on a human peptide

CC sequence so are unlikely to be immunogenic, and can be produced at high  
 CC levels in recombinant expression systems, and can inhibit a wide range of  
 CC serine proteases. They are more potent or specific than known inhibitors.  
 CC The present sequence represents a KPI variant which is given in an  
 CC example from the present invention

XX Sequence 61 AA;

Query Match 98.9%; Score 347; DB 3; Length 61;  
 Best Local Similarity 98.4%; Pred. No. 3e-31;

Matches 60; Conservative 1; Mismatches 0; Indels 0; Gaps 0;

QY 1 EVREVCSEQAEFGPCRAAIYHWYFDVTEGKAPFFYGGCGGNRNNDTEEYCMAVCGSA 60  
 DB 1 EVREVCSEQAEFGPCRAAIYHWYFDVTEGKAPFFYGGCGGNRNNDTEEYCMAVCGSA 60

QY 61 I 61  
 DB 61 I 61

RESULT 5  
 AAY68175 standard; protein; 61 AA.

XX AAY68175;

DT 13-APR-2000 (first entry)

DE Kunitz protease inhibitor variant BG026.

XX Kunitz protease inhibitor; KPI; serine protease; kallikrein; plasmin;  
 KW amyloid precursor protein; coagulation factor; blood loss; cardiant;  
 KW cardiopulmonary bypass surgery; anticoagulant; anti-inflammatory;  
 KW anti-arthritic; thrombolytic; antirheumatic; antipsoriatic;  
 KW immunosuppressant; pancreatitis; deep vein thrombosis; psoriasis;  
 KW rheumatoid arthritis; myocardial infarction; transplant rejection.

OS Homo sapiens.  
 OS Synthetic.

PN W09963090-A2.

PD 09-DEC-1999.

PF 03-JUN-1999; 99MO-US012276.

PR 03-JUN-1998; 98US-0087885P.

PA (SCIO-) SCIOS INC.

PI White RT, Damm D, Lesikar DD, Mcfadden K, Garrick BL, Lucas AB;  
 PI Pollitt NS, Lam AO;

DR WPI; 2000-105699/09.

PT Novel enzyme inhibitors especially used to reduce postoperative bleeding.

PS Example 4; Fig 64; 151pp; English.

XX The present invention describes protease inhibitors that are analogues of  
 CC the Kunitz protease inhibitor (KPI) domain of the amyloid precursor  
 CC protein. The protease inhibitors can be used to treat or prevent  
 CC disorders associated with increased activity of serine proteases,  
 CC specifically blood loss during surgery (particularly cardiopulmonary  
 CC bypass surgery where plasma proteases are activated by contact with  
 CC surfaces in the heart-lung machine), but also other conditions such as  
 CC pancreatitis; deep vein thrombosis; rheumatoid arthritis; psoriasis;  
 CC myocardial infarction; and transplant rejection. They are also for organ  
 CC preservation and to promote wound healing. In vitro the protease  
 CC inhibitors may be used to inhibit serine proteases during preparation of  
 CC cell extracts. The protease inhibitors are based on a human peptide  
 CC sequence so are unlikely to be immunogenic, and can be produced at high

CC levels in recombinant expression systems, and can inhibit a wide range of  
 CC serine proteases. They are more potent or specific than known inhibitors.  
 CC The present sequence represents a KPI variant which is given in an  
 CC example from the present invention  
 CC  
 CC Sequence 61 AA;

Query Match 98.9%; Score 347; DB 3; Length 61;  
 Best Local Similarity 98.4%; Pred. No. 3e-31;  
 Matches 60; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 1 EVVREVCSEQATGCGRAIYHWYFDVTEGKCAPFFYGCGGNNRNPTEBYCMAVCGSA 60  
 DB 1 EVVREVCSEQATGCGRAIYHWYFDVTEGKCAPFFYGCGGNNRNPTEBYCMAVCGSA 60

QY 61 I 61  
 DB 61 I 61

RESULT 6  
 ID AAU09329 standard; protein; 61 AA.

AC AAU09329;  
 DT 03-JAN-2002 (first entry)

DE Human KPI variant, BG034.

KW Human; serine protease inhibitor; Kunitz Protease Inhibitor; KPI;  
 KW amyloid precursor protein; kallikrein; plasmin; coagulation factor;  
 KW blood loss; surgery; respiratory disorder; deep vein thrombosis;  
 KW inflammatory bowel disease; cardiovascular disorder; haemostatic; mutant;  
 KW mucin; variant.

OS Homo sapiens.  
 OS Synthetic.

PN US2001020003-A1.

PD 06-SEP-2001.

PF 21-JAN-1999; 99US-00234874.

PR 21-JAN-1999; 99US-00234874.

PA (WHIT/) WHITE R T.

PA (DAMM/) DAMM D.

PA (LESI/) LESIKAR D D.

PA (MCFR/) MCFADDEN K.

PA (GAR/) GARRICK B L.

PI White RT, Damm D, Lesikar DD, Mcfadden K, Garrick BL;

DR WPI; 2001-570185/64.

PT New serine protease inhibitors useful in ameliorating, treating or  
 PT preventing clinical conditions associated with increased activity of  
 PT serine proteases e.g. pulmonary injury, pancreatitis, deep vein  
 PT thrombosis, wound healing.

PS Example 4; Fig 46; 74pp; English.

CC The present invention relates to serine protease inhibitor peptides.  
 CC These peptides which are analogues of the Kunitz Protease Inhibitor (KPI)  
 CC domain of amyloid precursor protein bind and inhibit the activity of  
 CC serine proteases such as kallikrein, plasmin, and coagulation factors  
 CC (e.g. factors VIIa, IXa, XIa, and XIIa). The protease inhibitors of  
 CC the invention are useful for treating blood loss during surgery. The  
 CC protease inhibitors may also be used in ameliorating, treating or  
 CC preventing clinical conditions associated with increased activity of  
 CC serine proteases, in reducing tissue damage caused by activation of the

CC proteases of the contact pathway of the blood during surgical procedures  
 CC such as cardiopulmonary bypass, or reducing serine protease-associated  
 CC peri-operative and post-operative blood loss. Examples of other clinical  
 CC conditions associated with increased serine protease activity for which  
 CC the peptides may be used as treatment include pulmonary injury,  
 CC pancreatitis, allergy-induced protease release, deep vein thrombosis,  
 CC thrombocytopenia, rheumatoid arthritis, adult respiratory distress  
 CC syndrome, chronic inflammatory bowel disease, psoriasis,  
 CC hyperfibrinolytic haemorrhage, organ preservation, wound healing and  
 CC myocardial infarction. AAU09329-AAU09339 represent human KPI variants of  
 CC the present invention

QY Sequence 61 AA;

Query Match 98.9%; Score 347; DB 4; Length 61;  
 Best Local Similarity 98.4%; Pred. No. 3e-31;  
 Matches 60; Conservative 1; Mismatches 0; Indels 0; Gaps 0;

QY 1 EVVREVCSEQATGCGRAIYHWYFDVTEGKCAPFFYGCGGNNRNPTEBYCMAVCGSA 60  
 DB 1 EVVREVCSEQATGCGRAIYHWYFDVTEGKCAPFFYGCGGNNRNPTEBYCMAVCGSA 60

QY 61 I 61  
 DB 61 I 61

RESULT 7  
 ID AAU09335 standard; protein; 61 AA.

AC AAU09335;

DT 03-JAN-2002 (first entry)

DE Human KPI variant, BG026.

KW Human; serine protease inhibitor; Kunitz Protease Inhibitor; KPI;  
 KW amyloid precursor protein; kallikrein; plasmin; coagulation factor;  
 KW blood loss; surgery; respiratory disorder; deep vein thrombosis;  
 KW inflammatory bowel disease; cardiovascular disorder; haemostatic; mutant;  
 KW mucin; variant.

OS Homo sapiens.  
 OS Synthetic.

PN US2001020003-A1.

PD 06-SEP-2001.

PF 21-JAN-1999; 99US-00234874.

PR 21-JAN-1999; 99US-00234874.

PA (WHIT/) WHITE R T.

PA (DAMM/) DAMM D.

PA (LESI/) LESIKAR D D.

PA (MCFR/) MCFADDEN K.

PA (GAR/) GARRICK B L.

PI White RT, Damm D, Lesikar DD, Mcfadden K, Garrick BL;

DR WPI; 2001-570185/64.

PT New serine protease inhibitors useful in ameliorating, treating or  
 PT preventing clinical conditions associated with increased activity of  
 PT serine proteases e.g. pulmonary injury, pancreatitis, deep vein  
 PT thrombosis, wound healing.

PS Example 4; Fig 46; 74pp; English.

CC The present invention relates to serine protease inhibitor peptides.  
 CC These peptides which are analogues of the Kunitz Protease Inhibitor (KPI)

CC domain of amyloid precursor protein bind and inhibit the activity of  
CC serine proteases such as kallikrein, plasmin, and coagulation factors of  
CC (e.g., factors VIIa, IXa, Xa, XIa, and XIIa). The protease inhibitors of  
CC the invention are useful for treating blood loss during surgery. The  
CC protease inhibitors may also be used in ameliorating, treating or  
CC preventing clinical conditions associated with increased activity of  
CC serine proteases, in reducing tissue damage caused by activation of the  
CC proteases of the contract pathway of the blood during surgical procedures  
CC such as cardiopulmonary bypass, or reducing serine protease-associated  
CC peri-operative and post-operative blood loss. Examples of other clinical  
CC conditions associated with increased serine protease activity for which  
CC the peptides may be used as treatment includes pulmonary injury,  
CC pancreatitis, allergy-induced protease release, deep vein thrombosis,  
CC thrombocytopenia, rheumatoid arthritis, adult respiratory distress  
CC syndrome, chronic inflammatory bowel disease, psoriasis,  
CC hyperfibrinolytic haemorrhage, organ preservation, wound healing and  
CC myocardial infarction. AAU09229-AAU09339 represent human KPI variants of  
CC the present invention

XX Sequence 61 AA;

Query Match 98.9%; Score 347; DB 4; Length 61;  
Best Local Similarity 98.4%; Pred. No. 3e-31;  
Matches 60; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 1 EVWREVCSEQAEFGPCRAAIYHWYFDYTEGKCAPFFYGGCGGNRNPDTEECMAVCGSA 60  
DB 1 EVWREVCSEQAEFGPCRAAIYHWYFDYTEGKCAPFFYGGCGGNRNPDTEECMAVCGSA 60

QY 61 I 61  
DB 61 I 61

## RESULT 8

ID AAY68058 standard; protein; 61 AA.

XX AAY68058;

DT 13-APR-2000 (first entry)

DE Kunitz protease inhibitor analogue protein sequence Fig 41.

XX Kunitz protease inhibitor; KPI; serine protease; kallikrein; plasmin;  
XX amyloid precursor protein; coagulation factor; blood loss; cardiant;  
XX cardiopulmonary bypass surgery; anticoagulant; anti-inflammatory;  
XX anti-arthritic; thrombolytic; antirheumatic; antipsoriatic;  
XX immunosuppressant; pancreatitis; deep vein thrombosis; psoriasis;  
XX rheumatoid arthritis; myocardial infarction; transplant rejection.

OS Homo sapiens.  
OS Synthetic.

XX WO963090-A2.

XX PD 09-DEC-1999.

XX PF 03-JUN-1999; 99WO-US012276.

XX PR 03-JUN-1998; 98US-0087885P.

XX PA (SCIO-) SCIOS INC.

XX PI White RT, Damm D, Lesikar DD, Mcfadden K, Garrick BL, Lucas AB;

XX DR Politt NS, Lam AO;

XX WPI; 2000-105699/09.

XX Novel enzyme inhibitors especially used to reduce postoperative bleeding.  
XX Example 3; Fig 41; 15IPP; English.

CC The present invention describes protease inhibitors that are analogues of  
CC the kunitz protease inhibitor (KPI) domain of the amyloid precursor  
CC protein. The protease inhibitors can be used used to treat or prevent  
CC disorders associated with increased activity of serine proteases,  
CC specifically blood loss during surgery (particularly cardiopulmonary  
CC bypass surgery where plasma proteases are activated by contact with  
CC surfaces in the heart-lung machine), but also other conditions such as  
CC pancreatitis; deep vein thrombosis; rheumatoid arthritis; psoriasis;  
CC myocardial infarction; and transplant rejection. They are also for organ  
CC preservation and to promote wound healing. In vitro the protease  
CC inhibitors may be used to inhibit serine proteases during preparation of  
CC cell extracts. The protease inhibitors are based on a human peptide  
CC sequence so are unlikely to be immunogenic, and can inhibit a wide range of  
CC serine proteases. They are more potent or specific than known inhibitors.  
CC The present sequence is given in an example from the present invention

XX Sequence 61 AA;

Query Match 98.6%; Score 346; DB 3; Length 61;  
Best Local Similarity 98.4%; Pred. No. 3.9e-31;  
Matches 60; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 1 EVWREVCSEQAEFGPCRAAIYHWYFDYTEGKCAPFFYGGCGGNRNPDTEECMAVCGSA 60  
DB 1 EVWREVCSEQAEFGPCRAAIYHWYFDYTEGKCAPFFYGGCGGNRNPDTEECMAVCGSA 60

QY 61 I 61  
DB 61 I 61

## RESULT 9

ID AAY68050 standard; protein; 61 AA.

XX AAY68050;

DT 13-APR-2000 (first entry)

DE Kunitz protease inhibitor analogue protein sequence Fig 37.

XX Kunitz protease inhibitor; KPI; serine protease; kallikrein; plasmin;  
XX amyloid precursor protein; coagulation factor; blood loss; cardiant;  
XX cardiopulmonary bypass surgery; anticoagulant; anti-inflammatory;  
XX anti-arthritic; thrombolytic; antirheumatic; antipsoriatic;  
XX immunosuppressant; pancreatitis; deep vein thrombosis; psoriasis;  
XX rheumatoid arthritis; myocardial infarction; transplant rejection.

OS Homo sapiens.  
OS Synthetic.

XX WO963090-A2.

XX PD 09-DEC-1999.

XX PF 03-JUN-1999; 99WO-US012276.

XX PR 03-JUN-1998; 98US-0087885P.

XX PA (SCIO-) SCIOS INC.

XX PI White RT, Damm D, Lesikar DD, Mcfadden K, Garrick BL, Lucas AB;

XX DR Politt NS, Lam AO;

XX WPI; 2000-105699/09.

XX Novel enzyme inhibitors especially used to reduce postoperative bleeding.  
XX Example 3; Fig 37; 15IPP; English.

XX The present invention describes protease inhibitors that are analogues of  
XX the kunitz protease inhibitor (KPI) domain of the amyloid precursor

CC protein. The protease inhibitors can be used used to treat or prevent  
CC disorders associated with increased activity of serine proteases,  
CC specifically blood loss during surgery (particularly cardiopulmonary  
CC bypass surgery where plasma proteases are activated by contact with  
CC surfaces in the heart-lung machine), but also other conditions such as  
CC pancreatitis, deep vein thrombosis, rheumatoid arthritis, psoriasis,  
CC myocardial infarction, and transplant rejection. They are also for organ  
CC preservation and to promote wound healing. In vitro the protease  
CC inhibitors may be used to inhibit serine proteases during preparation of  
CC cell extracts. The protease inhibitors are based on a human peptide  
CC sequence so are unlikely to be immunogenic, can be produced at high  
CC levels in recombinant expression systems, and can inhibit a wide range of  
CC serine proteases. They are more potent or specific than known inhibitors.  
CC The present sequence is given in an example from the present invention  
XX

SO Sequence 61 AA;  
Query Match 98.6%; Score 346; DB 3; Length 61;  
Best Local Similarity 98.4%; Pred. No. 3.9e-31;  
Matches 60; Conservative 1; Mismatches 0; Indels 0; Gaps 0;

QY 1 EVREVCSEQATGFCRAIYHWYFDVTEGKCAFFYGGCGGNRNNFTDEEYCAVCGSA 60  
DB 1 EVREVCSEQATGFCRAIYHWYFDVTEGKCAFFYGGCGGNRNNFTDEEYCAVCGSA 60

QY 61 I 61  
DB 61 I 61

RESULT 10  
AA68157  
ID AA68157 standard; protein; 61 AA.  
XX  
AC AA68157;  
XX  
DT 13-APR-2000 (first entry)  
XX  
DE Kunitz protease inhibitor variant BG015.

XX Kunitz protease inhibitor; KPI; serine protease; kallikrein; plasmin;  
XX amyloid precursor protein; coagulation factor; blood loss; cardiac;  
XX cardiopulmonary bypass surgery; anticoagulant; anti-inflammatory;  
XX anti-atheritic; thrombolytic; antirheumatic; antipsoriatic;  
XX immunosuppressant; pancreatitis; deep vein thrombosis; psoriasis;  
XX rheumatoid arthritis; myocardial infarction; transplant rejection.  
XX  
OS Homo sapiens.  
OS Synthetic.

XX WO9963090-A2.  
XX 09-DEC-1999.  
XX 03-JUN-1999; 99WO-US012276.  
XX PF 03-JUN-1999; 99WO-US012276.  
XX PR 03-JUN-1998; 98US-0087885P.  
XX PA (SCIO-) SCIOS INC.

XX White RT, Damm D, Lesikar DD, Mcfadden K, Garrick BL, Lucas AB;  
XX PI Politt NS, Lam AO;  
XX DR WPI; 2000-105699/09.

XX Novel enzyme inhibitors especially used to reduce postoperative bleeding.  
XX Example 4; Fig 64; 151p; English.

XX The present invention describes protease inhibitors that are analogues of  
CC the Kunitz protease inhibitor (KPI) domain of the amyloid precursor  
CC protein. The protease inhibitors can be used used to treat or prevent  
CC disorders associated with increased activity of serine proteases,

CC specifically blood loss during surgery (particularly cardiopulmonary  
CC bypass surgery where plasma proteases are activated by contact with  
CC surfaces in the heart-lung machine), but also other conditions such as  
CC pancreatitis, deep vein thrombosis, rheumatoid arthritis, psoriasis,  
CC myocardial infarction, and transplant rejection. They are also for organ  
CC preservation and to promote wound healing. In vitro the protease  
CC inhibitors may be used to inhibit serine proteases during preparation of  
CC cell extracts. The protease inhibitors are based on a human peptide  
CC sequence so are unlikely to be immunogenic, can be produced at high  
CC levels in recombinant expression systems, and can inhibit a wide range of  
CC serine proteases. They are more potent or specific than known inhibitors.  
CC The present sequence represents a KPI variant which is given in an  
XX example from the present invention

SO Sequence 61 AA;  
Query Match 98.6%; Score 346; DB 3; Length 61;  
Best Local Similarity 98.4%; Pred. No. 3.9e-31;  
Matches 60; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 1 EVREVCSEQATGFCRAIYHWYFDVTEGKCAFFYGGCGGNRNNFTDEEYCAVCGSA 60  
DB 1 EVREVCSEQATGFCRAIYHWYFDVTEGKCAFFYGGCGGNRNNFTDEEYCAVCGSA 60

QY 61 I 61  
DB 61 I 61

RESULT 11  
AA68168  
ID AA68168 standard; protein; 61 AA.  
XX  
AC AA68168;  
XX  
DT 13-APR-2000 (first entry)  
XX  
DE Kunitz protease inhibitor variant BG033.

XX Kunitz protease inhibitor; KPI; serine protease; kallikrein; plasmin;  
XX amyloid precursor protein; coagulation factor; blood loss; cardiac;  
XX cardiopulmonary bypass surgery; anticoagulant; anti-inflammatory;  
XX anti-atheritic; thrombolytic; antirheumatic; antipsoriatic;  
XX immunosuppressant; pancreatitis; deep vein thrombosis; psoriasis;  
XX rheumatoid arthritis; myocardial infarction; transplant rejection.  
XX  
OS Homo sapiens.  
OS Synthetic.

XX WO9963090-A2.  
XX 09-DEC-1999.  
XX 03-JUN-1999; 99WO-US012276.  
XX PF 03-JUN-1999; 99WO-US012276.  
XX PR 03-JUN-1998; 98US-0087885P.  
XX PA (SCIO-) SCIOS INC.

XX White RT, Damm D, Lesikar DD, Mcfadden K, Garrick BL, Lucas AB;  
XX PI Politt NS, Lam AO;  
XX DR WPI; 2000-105699/09.

XX Novel enzyme inhibitors especially used to reduce postoperative bleeding.  
XX Example 4; Fig 64; 151p; English.

XX The present invention describes protease inhibitors that are analogues of  
CC the Kunitz protease inhibitor (KPI) domain of the amyloid precursor  
CC protein. The protease inhibitors can be used used to treat or prevent  
CC disorders associated with increased activity of serine proteases,  
CC specifically blood loss during surgery (particularly cardiopulmonary

CC bypass surgery where plasma proteases are activated by contact with  
CC surfaces in the heart-lung machine), but also other conditions such as  
CC pancreatitis, deep vein thrombosis, rheumatoid arthritis, psoriasis;  
CC myocardial infarction, and transplant rejection. They are also for organ  
CC preservation and to promote wound healing. In vitro the protease  
CC inhibitors may be used to inhibit serine proteases during preparation of  
CC cell extracts. The protease inhibitors are based on a human peptide  
CC sequence so are unlikely to be immunogenic, can be produced at high  
CC levels in recombinant expression systems, and can inhibit a wide range of  
CC serine proteases. They are more potent or specific than known inhibitors.  
CC The present sequence represents a KPI variant which is given in an  
CC example from the present invention  
CC  
SQ Sequence 61 AA;

Query Match 98.6%; Score 346; DB 3; Length 61;  
Best Local Similarity 98.4%; Pred. No. 3.9e-31;  
Matches 60; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 1 EVREVCSEQAETGPCRAAIYHWFVDTGKCAPFFYGGCGGNRNNDTEHCMAVCGSA 60  
DB 1 EVREVCSEQAETGPCRAAIYHWFVDTGKCAPFFYGGCGGNRNNDTEHCMAVCGSA 60  
QY 61 I 61  
DB 61 I 61

RESULT 12  
AAU09319  
ID AAU09319 standard; protein; 61 AA.  
AC AAU09319;  
XX  
DT 03-JAN-2002 (first entry)  
XX  
DE Human KPI variant, BG022.

XX Human; serine protease inhibitor; Kunitz Protease Inhibitor; KPI;  
KW amyloid precursor protein; kallikrein; plasmin; coagulation factor;  
KW blood loss; surgery; respiratory disorder; deep vein thrombosis;  
KW inflammatory bowel disease; cardiovascular disorder; haemostatic; mutant;  
muten; variant.  
XX  
OS Homo sapiens.  
OS Synthetic.  
OS  
XX  
PN US2001020003-A1.  
XX  
PD 06-SEP-2001.

PF 21-JAN-1999; 99US-00234874.  
XX  
XX  
PR 21-JAN-1999; 99US-00234874.  
XX  
XX

PA (WHIT/) WHITE R T.  
PA (DAMM/) DAMM D.  
PA (LESI/) LESIKAR D D.  
PA (MCFR/) MCFADDEN K.  
PA (GARR/) GARRICK B L.

PI White RT, Damm D, Lesikar DD, Mcfadden K, Garrick BL,  
XX  
XX  
DR WPI; 2001-570185/64.  
XX  
XX

PT New serine protease inhibitors useful in ameliorating, treating or  
PT preventing clinical conditions associated with increased activity of  
PT serine proteases e.g. pulmonary injury, pancreatitis, deep vein  
PT thrombosis, wound healing.  
XX  
XX  
PS Example 4; Fig 46; 74pp; English.  
XX  
CC

The present invention relates to serine protease inhibitor peptides.

CC These peptides which are analogues of the Kunitz Protease Inhibitor (KPI)  
CC domain of amyloid precursor protein bind and inhibit the activity of  
CC serine proteases such as kallikrein, plasmin, and coagulation factors  
CC (e.g. factors VIIa, IXa, Xa, XIa, and XIIa). The protease inhibitors of  
CC the invention are useful for treating blood loss during surgery. The  
CC protease inhibitors may also be used in ameliorating, treating or  
CC preventing clinical conditions associated with increased activity of  
CC serine proteases, in reducing tissue damage caused by activation of the  
CC proteases of the contact pathway of the blood during surgical procedures  
CC such as cardiopulmonary bypass, or reducing serine protease-associated  
CC peri-operative and post-operative blood loss. Examples of other clinical  
CC conditions associated with increased serine protease activity for which  
CC the peptides may be used as treatment include pulmonary injury,  
CC pancreatitis, allergy-induced protease release, deep vein thrombosis,  
CC thrombocytopenia, rheumatoid arthritis, adult respiratory distress  
CC syndrome, chronic inflammatory bowel disease, psoriasis,  
CC hyperfibrinolytic haemorrhage, organ preservation, wound healing and  
CC myocardial infarction. AAU09229-AAU09339 represent human KPI variants of  
CC the present invention  
CC  
SQ Sequence 61 AA;

Query Match 98.6%; Score 346; DB 4; Length 61;  
Best Local Similarity 98.4%; Pred. No. 3.9e-31;  
Matches 60; Conservative 1; Mismatches 0; Indels 0; Gaps 0;

QY 1 EVREVCSEQAETGPCRAAIYHWFVDTGKCAPFFYGGCGGNRNNDTEHCMAVCGSA 60  
DB 1 EVREVCSEQAETGPCRAAIYHWFVDTGKCAPFFYGGCGGNRNNDTEHCMAVCGSA 60  
QY 61 I 61  
DB 61 I 61

RESULT 13  
AAU09317  
ID AAU09317 standard; protein; 61 AA.  
AC AAU09317;  
XX  
DT 03-JAN-2002 (first entry)  
XX  
DE Human KPI variant, BG015.

XX Human; serine protease inhibitor; Kunitz Protease Inhibitor; KPI;  
KW amyloid precursor protein; kallikrein; plasmin; coagulation factor;  
KW blood loss; surgery; respiratory disorder; deep vein thrombosis;  
KW inflammatory bowel disease; cardiovascular disorder; haemostatic; mutant;  
muten; variant.  
XX  
OS Homo sapiens.  
OS Synthetic.  
OS  
XX  
PN US2001020003-A1.  
XX  
PD 06-SEP-2001.

PF 21-JAN-1999; 99US-00234874.  
XX  
XX  
PR 21-JAN-1999; 99US-00234874.  
XX  
XX

PA (WHIT/) WHITE R T.  
PA (DAMM/) DAMM D.  
PA (LESI/) LESIKAR D D.  
PA (MCFR/) MCFADDEN K.  
PA (GARR/) GARRICK B L.

PI White RT, Damm D, Lesikar DD, Mcfadden K, Garrick BL,  
XX  
XX  
DR WPI; 2001-570185/64.  
XX  
XX

New serine protease inhibitors useful in ameliorating, treating or



PT Preventing clinical conditions associated with increased activity of  
 PT serine proteases e.g. pulmonary injury, pancreatitis, deep vein  
 PT thrombosis, wound healing.

PS Example 4; Fig 46; 74pp; English.

CC The present invention relates to serine protease inhibitor peptides.  
 CC These peptides which are analogues of the Kunitz protease inhibitor (KPI)  
 CC domain of amyloid precursor protein bind and inhibit the activity of  
 CC serine proteases such as kallikrein, plasmin, and coagulation factors  
 CC (e.g. factors VIIa, IXa, Xa, XIa, and XIIa). The protease inhibitors of  
 CC the invention are useful for treating blood loss during surgery. The  
 CC protease inhibitors may also be used in ameliorating, treating or  
 CC preventing clinical conditions associated with increased activity of  
 CC serine proteases, in reducing tissue damage caused by activation of the  
 CC proteases of the contact pathway of the blood during surgical procedures  
 CC such as cardiopulmonary bypass, or reducing serine protease-associated  
 CC conditions associated with increased serine protease activity for which  
 CC the peptides may be used as treatment includes pulmonary injury,  
 CC pancreatitis, allergy-induced protease release, deep vein thrombosis,  
 CC thrombocytopenia, rheumatoid arthritis, adult respiratory distress  
 CC syndrome, chronic inflammatory bowel disease, psoriasis,  
 CC hyperfibrinolytic haemorrhage, organ preservation, wound healing and  
 CC myocardial infarction. AA09229-AA09339 represent human KPI variants of  
 CC the present invention.

XX Sequence 61 AA;

Query Match 98.6%; Score 346; DB 4; Length 61;  
 Best Local Similarity 98.4%; Pred. No. 3,9e-31;  
 Matches 60; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 1 EVNREVCSQAETGPCRAAIYHWYFDTEGKCAFFYGGCGGNRNPDTREYCAVCGSA 60  
 DB 1 EVNREVCSQAETGPCRAAIYHWYFDTEGKCAFFYGGCGGNRNPDTREYCAVCGSA 60

QY 61 I 61  
 DB 61 I 61

RESULT 14  
 ID AAY68049  
 AA68049 standard; protein; 146 AA.

XX AAY68049;

DT 13-APR-2000 (first entry)

DE Yeast mating-factor-KPI(-4-57) fusion protein sequence Fig 20.

KW Kunitz protease inhibitor; KPI; serine protease; kallikrein; plasmin;  
 KW amyloid precursor protein; coagulation factor; blood loss; cardiac;  
 KW cardiopulmonary bypass surgery; anticoagulant; anti-inflammatory;  
 KW anti-arthritic; thrombolytic; antineumatic; antipsoriatic;  
 KW immunosuppressant; pancreatitis; deep vein thrombosis; psoriasis;  
 KW rheumatoid arthritis; myocardial infarction; transplant rejection.

OS Homo sapiens.  
 OS Saccharomyces cerevisiae.  
 OS Synthetic.

PN MO9963090-A2.

PD 09-DEC-1999.

PF 03-JUN-1999; 99WO-US012276.

PR 03-JUN-1998; 98US-0087885P.

XX (SCIO-) SCIOS INC.

PT White RT, Damm D, Lesikar DD, Mcfadde K, Garrick BL, Lucas AB;  
 PT Pollitt NS, Lam AO;  
 DR MPI; 2000-105699/09.  
 DR N-PSDB; AA257535.

PT Novel enzyme inhibitors especially used to reduce postoperative bleeding.  
 PS Example 3; Fig 20; 151pp; English.

CC The present invention describes protease inhibitors that are analogues of  
 CC the Kunitz protease inhibitor (KPI) domain of the amyloid precursor  
 CC protein. The protease inhibitors can be used used to treat or prevent  
 CC disorders associated with increased activity of serine proteases,  
 CC specifically blood loss during surgery (particularly cardiopulmonary  
 CC bypass surgery where plasma proteases are activated by contact with  
 CC surfaces in the heart-lung machine), but also other conditions such as  
 CC pancreatitis; deep vein thrombosis; rheumatoid arthritis; psoriasis;  
 CC myocardial infarction; and transplant rejection. They are also for organ  
 CC preservation and to promote wound healing. In vitro the protease  
 CC inhibitors may be used to inhibit serine proteases during preparation of  
 CC cell extracts. The protease inhibitors are based on a human peptide  
 CC sequence so are unlikely to be immunogenic, and can be produced at high  
 CC levels in recombinant expression systems, and can inhibit a wide range of  
 CC serine proteases. They are more potent or specific than known inhibitors.  
 CC The present sequence is given in an example from the present invention

XX Sequence 146 AA;

Query Match 98.6%; Score 346; DB 3; Length 146;  
 Best Local Similarity 98.4%; Pred. No. 9.4e-31;  
 Matches 60; Conservative 1; Mismatches 0; Indels 0; Gaps 0;

QY 1 EVNREVCSQAETGPCRAAIYHWYFDTEGKCAFFYGGCGGNRNPDTREYCAVCGSA 60  
 DB 86 EVNREVCSQAETGPCRAAIYHWYFDTEGKCAFFYGGCGGNRNPDTREYCAVCGSA 145

QY 61 I 61  
 DB 146 I 146

RESULT 15  
 ID AAY68057  
 AA68057 standard; protein; 146 AA.

XX AAY68057;

DT 13-APR-2000 (first entry)

DE Yeast mating-factor-KPI(-4-57) fusion protein sequence Fig 24.

KW Kunitz protease inhibitor; KPI; serine protease; kallikrein; plasmin;  
 KW amyloid precursor protein; coagulation factor; blood loss; cardiac;  
 KW cardiopulmonary bypass surgery; anticoagulant; anti-inflammatory;  
 KW anti-arthritic; thrombolytic; antineumatic; antipsoriatic;  
 KW immunosuppressant; pancreatitis; deep vein thrombosis; psoriasis;  
 KW rheumatoid arthritis; myocardial infarction; transplant rejection.

OS Homo sapiens.  
 OS Saccharomyces cerevisiae.  
 OS Synthetic.

PN MO9963090-A2.

PD 09-DEC-1999.

PF 03-JUN-1999; 99WO-US012276.

PR 03-JUN-1998; 98US-0087885P.

XX (SCIO-) SCIOS INC.

PI White RT, Damm D, Iesikar DD, Mcfadden K, Garrick BL, Lucas AB;  
PI Pollitt NS, Lam AO;  
XX  
DR WPI: 2000-105699/09.  
DR N-PSDB; AA257539.  
XX

PT Novel enzyme inhibitors especially used to reduce postoperative bleeding.  
XX

PS Example 3; Fig 24; 151pp; English.  
XX

CC The present invention describes protease inhibitors that are analogues of  
CC the Kunitz protease inhibitor (KPI) domain of the amyloid precursor  
CC protein. The protease inhibitors can be used to treat or prevent  
CC disorders associated with increased activity of serine proteases,  
CC specifically blood loss during surgery (particularly cardiopulmonary  
CC bypass surgery where plasma proteases are activated by contact with  
CC surfaces in the heart-lung machine), but also other conditions such as  
CC pancreatitis; deep vein thrombosis; rheumatoid arthritis; psoriasis;  
CC myocardial infarction; and transplant rejection. They are also for organ  
CC preservation and to promote wound healing. In vitro the protease  
CC inhibitors may be used to inhibit serine proteases during preparation of  
CC cell extracts. The protease inhibitors are based on a human peptide  
CC sequence so are unlikely to be immunogenic, can be produced at high  
CC levels in recombinant expression systems, and can inhibit a wide range of  
CC serine proteases. They are more potent or specific than known inhibitors.  
CC The present sequence is given in an example from the present invention  
XX

SQ Sequence 146 AA;

Query Match 98.6%; Score 346; DB 3; Length 146;  
Best Local Similarity 98.4%; Pred. No. 9, 4e-31;

Matches 60; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 1 EVVREVCSEQAEITGPCRAIYHMYFDVTEGKCAPFYGGCGGNNRNFTEECMAVCGSA 60  
DB 86 EVVREVCSEQAEITGPCRAIYHMYFDVTEGKCAPFYGGCGGNNRNFTEECMAVCGSA 145

QY 61 I 61

DB 146 I 146

Search completed: April 8, 2004, 09:33:20  
Job time : 55 secs

GenCore version 5.1.6  
Copyright (c) 1993 - 2004 CompuGen Ltd.

OM protein - protein search, using sw model

Run on: April 8, 2004, 09:26:35 ; Search time 23 seconds

(without alignments)  
136,921 Million cell updates/sec

Title: US-10-076-604-208

Perfect score: 351

Sequence: 1 EVREYVCSQEAETGFCRAI.....GNRNNPDEBYCMAYCGSAI 61

Scoring table:

BLOSUM62  
Gapop 10.0 , Gapext 0.5

Searched: 389414 seqs, 51625971 residues

Total number of hits satisfying chosen parameters: 389414

Minimum DB seq length: 0

Maximum DB seq length: 2000000000

Post-processing: Minimum Match 0%  
Maximum Match 100%  
Listing first 45 summaries

Database: Issued Patents AA.\*

- 1: /cgn2\_6/prodata/2/1aa/5A.COMB.pep:\*
- 2: /cgn2\_6/prodata/2/1aa/5B.COMB.pep:\*
- 3: /cgn2\_6/prodata/2/1aa/6A.COMB.pep:\*
- 4: /cgn2\_6/prodata/2/1aa/6B.COMB.pep:\*
- 5: /cgn2\_6/prodata/2/1aa/6C.COMB.pep:\*
- 6: /cgn2\_6/prodata/2/1aa/backfltest1.pep:\*

Pred. No. is the number of results predicted by chance to have a score greater than or equal to the score of the result being printed, and is derived by analysis of the total score distribution.

# SUMMARIES

Result No.	Score	Query Match	Length	ID	Description
1	351	100.0	61	2	US-08-829-876-208
2	351	100.0	61	4	US-09-234-873A-216
3	351	100.0	61	4	US-09-234-873A-223
4	347	98.9	61	2	US-08-829-876-208
5	347	98.9	61	2	US-08-829-876-218
6	347	98.9	61	2	US-09-234-874A-218
7	347	98.9	61	4	US-09-234-874A-218
8	347	98.9	61	4	US-09-234-874A-224
9	347	98.9	61	4	US-09-234-873A-218
10	346	98.6	61	2	US-09-234-873A-224
11	346	98.6	61	2	US-08-829-876-206
12	346	98.6	61	2	US-08-829-876-217
13	346	98.6	61	4	US-09-234-874A-206
14	346	98.6	61	4	US-09-234-874A-217
15	346	98.6	61	4	US-09-234-873A-206
16	343	97.7	61	2	US-09-234-873A-217
17	343	97.7	61	2	US-08-829-876-173
18	343	97.7	61	2	US-08-829-876-211
19	343	97.7	61	4	US-09-234-874A-173
20	343	97.7	61	4	US-09-234-874A-211
21	343	97.7	61	4	US-09-234-873A-173
22	343	97.7	146	2	US-09-234-873A-211
23	343	97.7	146	2	US-08-829-876-85
24	343	97.7	146	4	US-09-234-874A-85
25	342	97.4	61	2	US-08-829-876-216
26	342	97.4	61	2	US-08-829-876-223
27	342	97.4	61	4	US-09-234-874A-216

28	342	97.4	61	4	US-09-234-874A-223	Sequence 223, App
29	342	97.4	61	4	US-09-234-873A-216	Sequence 216, App
30	342	97.4	61	4	US-09-234-873A-223	Sequence 223, App
31	341	97.2	61	2	US-08-829-876-204	Sequence 204, App
32	341	97.2	61	2	US-08-829-876-215	Sequence 215, App
33	341	97.2	61	4	US-09-234-874A-204	Sequence 204, App
34	341	97.2	61	4	US-09-234-874A-215	Sequence 215, App
35	341	97.2	61	4	US-09-234-873A-204	Sequence 204, App
36	341	97.2	61	4	US-09-234-873A-215	Sequence 215, App
37	340	96.9	61	2	US-08-829-876-219	Sequence 219, App
38	340	96.9	61	4	US-09-234-874A-219	Sequence 219, App
39	340	96.9	61	2	US-08-829-876-171	Sequence 171, App
40	339	96.6	61	2	US-08-829-876-178	Sequence 178, App
41	339	96.6	61	2	US-08-829-876-178	Sequence 178, App
42	339	96.6	61	4	US-09-234-874A-171	Sequence 171, App
43	339	96.6	61	4	US-09-234-874A-178	Sequence 178, App
44	339	96.6	61	4	US-09-234-874A-178	Sequence 178, App
45	339	96.6	61	4	US-09-234-874A-220	Sequence 220, App

## ALIGNMENTS

RESULT 1  
US-08-829-876-208

Sequence 208, Application US/08829876

Patent No. 5962266

GENERAL INFORMATION:

APPLICANT: White, Tyler R.

APPLICANT: Damm, Deborah

APPLICANT: Lesikar, David D.

APPLICANT: McFadden, Kathleen

APPLICANT: Garrick, Brett L.

TITLE OF INVENTION: PROTEASE INHIBITOR PEPTIDES

NUMBER OF SEQUENCES: 228

CORRESPONDENCE ADDRESS:

ADDRESSEE: Foley & Lardner

STREET: 3000 K Street, N.W., Suite 500

CITY: Washington

STATE: D.C.

COUNTRY: USA

ZIP: 20007-5109

COMPUTER READABLE FORM:

MEDIUM TYPE: Floppy disk

COMPUTER: IBM PC compatible

OPERATING SYSTEM: PC-DOS/MS-DOS

SOFTWARE: Patentin Release #1.0, Version #1.30

CURRENT APPLICATION DATA:

APPLICATION NUMBER: US/08/829,876

FILING DATE:

CLASSIFICATION:

PRIOR APPLICATION DATA:

APPLICATION NUMBER: US 08/436,555

FILING DATE: 08-MAY-1995

ATTORNEY/AGENT INFORMATION:

NAME: Pelto, Don J.

REGISTRATION NUMBER: 33,754

REFERENCE/DOCKET NUMBER: 56324/106/SCNO

TELECOMMUNICATION INFORMATION:

TELEPHONE: (202)672-5300

TELEFAX: (202)672-5399

TELEX: 904136

INFORMATION FOR SEQ ID NO: 208:

SEQUENCE CHARACTERISTICS:

LENGTH: 61 amino acids

TYPE: amino acid

STRANDEDNESS: single

TOPOLOGY: linear

MOLECULE TYPE: protein

US-08-829-876-208

Query Match 100.0%; Score 351; DB 2; Length 61;  
Best Local Similarity 100.0%; Pred. No. 8.4e-34;

Matches	61; Conservative	0; Mismatches	0; Indels	0; Gaps	0
Qy	1	EVVREVCSEDAEAGPCRAIHYHYEDYEGKCAPFEYGGCGGNRNNDTEECYMGCSA	60		
Db	1	EVVREVCSEDAEAGPCRAIHYHYEDYEGKCAPFEYGGCGGNRNNDTEECYMGCSA	60		
Qy	61	I	61		
Db	61	I	61		

```

1      RESULT 2
2      US-09-234-874A-208
3      Sequence 208, Application US/09234874A
4      Patent No. 6376648
5      GENERAL INFORMATION:
6      APPLICANT: White, Tyler R.
7      Damu, Deborah
8      Lesikar, David D.
9      McFadden, Kathleen
10     Garrick, Brett L.
11     TITLE OF INVENTION: PROTEASE INHIBITOR PEPTIDES
12     NUMBER OF SEQUENCES: 228
13     CORRESPONDENCE ADDRESS:
14     ADDRESSEE: Foley & Lardner
15     STREET: 3000 K Street, N.W., Suite 500
16     CITY: Washington
17     STATE: D.C.
18     COUNTRY: USA
19     ZIP: 20007-5109
20     COMPUTER READABLE FORM:
21     MEDIUM TYPE: Floppy disk
22     COMPUTER: IBM PC compatible
23     OPERATING SYSTEM: PC-DOS/MS-DOS
24     SOFTWARE: Patentin Release #1.0, Version #1.300A
25     CURRENT APPLICATION DATA:
26     APPLICATION NUMBER: US/09/234,874A
27     FILING DATE: 11-Jun-2001
28     PRIOR APPLICATION DATA:
29     APPLICATION NUMBER: 08/436,555
30     FILING DATE: 08-MAY-1995
31     ATTORNEY/AGENT INFORMATION:
32     NAME: Bent, Stephen
33     REGISTRATION NUMBER: 29,768
34     REFERENCE/DOCKET NUMBER: 056324/0106
35     TELECOMMUNICATION INFORMATION:
36     TELEPHONE: (202) 672-5300
37     TELEFAX: (202) 672-5399
38     TELEEX: 904136
39     INFORMATION FOR SEQ ID NO: 208:
40     SEQUENCE CHARACTERISTICS:
41     LENGTH: 61 amino acids
42     TYPE: amino acid
43     STRANDEDNESS: single
44     TOPOLOGY: linear
45     MOLECULE TYPE: protein
46     SEQUENCE DESCRIPTION: SEQ ID NO: 208:
47     US-09-234-874A-208

```

```

Query Match      100.0%; Score 351, DB 4; Length 61;
Best Local Similarity 100.0%; Pred. NO. 8.4e-34;
Matches 61; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 EVVREVCSEQAEITGFCRAAIYHWYFDVTEGKCAFFYGGCGGGRNNFTDEEYCAVCGSA 60
   |||||
Db 1 EVVREVCSEQAEITGFCRAAIYHWYFDVTEGKCAFFYGGCGGGRNNFTDEEYCAVCGSA 60
   |||||

QY 61 I 61
   |
Db 61 I 61

```

```

US-09-234-873A-208
1  Sequence 208, Application US/09234873A
2  Patent No. 5613850
3  GENERAL INFORMATION:
4  APPLICANT: White, Tyler R.
5  Damm, Deborah
6  Lesikar, David D.
7  McFadden, Brett Leen
8  Garrick, Brett L.
9  TITLE OF INVENTION: PROTEASE INHIBITOR PEPTIDES
10 NUMBER OF SEQUENCES: 228
11 CORRESPONDENCE ADDRESS:
12 ADDRESSEE: Foley & Lardner
13 STREET: 3000 K Street, N.W., Suite 500
14 City: Washington
15 STATE: D.C.
16 COUNTRY: USA
17 ZIP: 20007-5109
18 COMPUTER READABLE FORM:
19 MEDIUM TYPE: Floppy disk
20 COMPUTER: IBM PC compatible
21 OPERATING SYSTEM: PC-DOS/MS-DOS
22 SOFTWARE: Patent In Release #1.0, Version #1.30
23 CURRENT APPLICATION DATA:
24 APPLICATION NUMBER: US/09/234,873A
25 FILING DATE: 21-Jan-1999
26 PRIORITY APPLICATION DATA:
27 APPLICATION NUMBER: 08/829,676
28 FILING DATE: 02-Apr-1997
29 APPLICATION NUMBER: 08/436,555
30 FILING DATE: 08-MAY-1995
31 ATTORNEY/AGENT INFORMATION:
32 NAME: Bent, Stephen
33 REGISTRATION NUMBER: 29,768
34 REFERENCE/DOCKET NUMBER: 056324/0116
35 TELECOMMUNICATION INFORMATION:
36 TELEPHONE: (202)672-5300
37 TELEFAX: (202)672-5399
38 TELETYPE: 904136
39 INFORMATION FOR SEQ ID NO: 208:
40 SEQUENCE CHARACTERISTICS:
41 LENGTH: 61 amino acids
42 TYPE: amino acid
43 STRANDEDNESS: single
44 TOPOLOGY: linear
45 MOLECULE TYPE: protein
46 SEQUENCE DESCRIPTION: SEQ ID NO: 208:
47 IS-09-234-873A-208

```

```

Query Match Similarity      100.0%; Score 351; DB 4; Length 61;
Best Local Similarity      100.0%; Pred. NO.8,4e-34;
Matches      61; Conservative      0; Mismatches      0; Indels      0; Gaps      0;

QY      1 EVVREVCSEQAEPTGFCRAAIYHWYFDVTEGKCAPFYGGGGGNRNFTDEYCMACVCSA 60
      |||
Db      1 EVVREVCSEQAEPTGFCRAAIYHWYFDVTEGKCAPFYGGGGGNRNFTDEYCMACVCSA 60
QY      61 I 61
Db      61 I 61

RESULT 4
US-08-829-876-218
; Sequence 218, Application US/08829876
; Patent No. 5962266
; GENERAL INFORMATION:
; APPLICANT: White, Tyler R.
; APPLICANT: Damm, Deborah
; APPLICANT: Lesikar, David D.
; APPLICANT: McFadden, Kathleen
; APPLICANT: Garrick, Bret L.
; TITLE OF INVENTION: PROTEASE INHIBITOR PEPTIDES

```

NUMBER OF SEQUENCES: 228  
CORRESPONDENCE ADDRESS:  
ADDRESSEE: Foley & Lardner  
STREET: 3000 K Street, N.W., Suite 500  
CITY: Washington  
STATE: D.C.  
COUNTRY: USA  
ZIP: 20007-5109  
COMPUTER READABLE FORM:  
MEDIUM TYPE: Floppy disk  
COMPUTER: IBM PC compatible  
OPERATING SYSTEM: PC-DOS/MS-DOS  
SOFTWARE: Patent Release #1.0, Version #1.30  
CURRENT APPLICATION DATA:  
APPLICATION NUMBER: US/08/829,876  
FILING DATE:  
CLASSIFICATION:  
PRIOR APPLICATION DATA:  
APPLICATION NUMBER: US 08/436,555  
FILING DATE: 08-MAY-1995  
ATTORNEY/AGENT INFORMATION:  
NAME: Pelto, Don J.  
REGISTRATION NUMBER: 33,754  
REFERENCE/DOCKET NUMBER: 56324/106/SCNO  
TELECOMMUNICATION INFORMATION:  
TELEPHONE: (202)672-5300  
TELEFAX: (202)672-5399  
INFORMATION FOR SEQ ID NO: 218:  
SEQUENCE CHARACTERISTICS:  
LENGTH: 61 amino acids  
TYPE: amino acid  
STRANDEDNESS: single  
TOPOLOGY: linear  
MOLECULE TYPE: protein  
US-08-829-876-218

Query Match 98.9%; Score 347; DB 2; Length 61;  
Best Local Similarity 98.4%; Pred. No. 2,4e-33;  
Matches 60; Conservative 1; Mismatches 0; Indels 0; Gaps 0;

QY 1 EVVREVCSEQAEFGPCRAAIYHWYFDVTEGKCAPFFYGGCGGNRNPFTEECMAVCGSA 60  
DB 1 EVVREVCSEQAEFGPCRAAIYHWYFDVTEGKCAPFFYGGCGGNRNPFTEECMAVCGSA 60  
QY 61 I 61  
DB 61 I 61

RESULT 5  
US-08-829-876-224  
Sequence 224, Application US/08829876  
Patent No. 5962266  
GENERAL INFORMATION:  
APPLICANT: White, Tyler R.  
APPLICANT: Damm, Deborah  
APPLICANT: Lesikar, David D.  
APPLICANT: McFadden, Kathleen  
APPLICANT: Garrick, Brett L.  
TITLE OF INVENTION: PROTEASE INHIBITOR PEPTIDES  
NUMBER OF SEQUENCES: 228  
CORRESPONDENCE ADDRESS:  
ADDRESSEE: Foley & Lardner  
STREET: 3000 K Street, N.W., Suite 500  
CITY: Washington  
STATE: D.C.  
COUNTRY: USA  
ZIP: 20007-5109  
COMPUTER READABLE FORM:  
MEDIUM TYPE: Floppy disk  
COMPUTER: IBM PC compatible  
OPERATING SYSTEM: PC-DOS/MS-DOS

SOFTWARE: Patent Release #1.0, Version #1.30  
CURRENT APPLICATION DATA:  
APPLICATION NUMBER: US/08/829,876  
FILING DATE:  
CLASSIFICATION:  
PRIOR APPLICATION DATA:  
APPLICATION NUMBER: US 08/436,555  
FILING DATE: 08-MAY-1995  
ATTORNEY/AGENT INFORMATION:  
NAME: Pelto, Don J.  
REGISTRATION NUMBER: 33,754  
REFERENCE/DOCKET NUMBER: 56324/106/SCNO  
TELECOMMUNICATION INFORMATION:  
TELEPHONE: (202)672-5300  
TELEFAX: (202)672-5399  
INFORMATION FOR SEQ ID NO: 224:  
SEQUENCE CHARACTERISTICS:  
LENGTH: 61 amino acids  
TYPE: amino acid  
STRANDEDNESS: single  
TOPOLOGY: linear  
MOLECULE TYPE: protein  
US-08-829-876-224

Query Match 98.9%; Score 347; DB 2; Length 61;  
Best Local Similarity 98.4%; Pred. No. 2,4e-33;  
Matches 60; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 1 EVVREVCSEQAEFGPCRAAIYHWYFDVTEGKCAPFFYGGCGGNRNPFTEECMAVCGSA 60  
DB 1 EVVREVCSEQAEFGPCRAAIYHWYFDVTEGKCAPFFYGGCGGNRNPFTEECMAVCGSA 60  
QY 61 I 61  
DB 61 I 61

RESULT 5  
US-09-234-874A-218  
Sequence 218, Application US/09234874A  
Patent No. 6376648  
GENERAL INFORMATION:  
APPLICANT: White, Tyler R.  
APPLICANT: Damm, Deborah  
APPLICANT: Lesikar, David D.  
APPLICANT: McFadden, Kathleen  
APPLICANT: Garrick, Brett L.  
TITLE OF INVENTION: PROTEASE INHIBITOR PEPTIDES  
NUMBER OF SEQUENCES: 228  
CORRESPONDENCE ADDRESS:  
ADDRESSEE: Foley & Lardner  
STREET: 3000 K Street, N.W., Suite 500  
CITY: Washington  
STATE: D.C.  
COUNTRY: USA  
ZIP: 20007-5109  
COMPUTER READABLE FORM:  
MEDIUM TYPE: Floppy disk  
COMPUTER: IBM PC compatible  
OPERATING SYSTEM: PC-DOS/MS-DOS  
SOFTWARE: Patent Release #1.0, Version #1.30  
CURRENT APPLICATION DATA:  
APPLICATION NUMBER: US/09/234,874A  
FILING DATE: 11-Jun-2001  
PRIOR APPLICATION DATA:  
APPLICATION NUMBER: US/08/436,555  
FILING DATE: 08-MAY-1995  
ATTORNEY/AGENT INFORMATION:  
NAME: Bent, Stephen  
REGISTRATION NUMBER: 29,768  
REFERENCE/DOCKET NUMBER: 056324/0106  
TELECOMMUNICATION INFORMATION:

TELEPHONE: (202)672-5300  
TELEFAX: (202)672-5399  
TELEX: 904136  
INFORMATION FOR SEQ ID NO: 218:  
SEQUENCE CHARACTERISTICS:  
LENGTH: 61 amino acids  
TYPE: amino acid  
STRANDEDNESS: single  
TOPOLOGY: linear  
MOLECULE TYPE: protein  
SEQUENCE DESCRIPTION: SEQ ID NO: 218:  
US-09-234-874A-218

Query Match 98.9%; Score 347; DB 4; Length 61;  
Best Local Similarity 98.4%; Pred. No. 2,4e-33;  
Matches 60; Conservative 1; Mismatches 0; Indels 0; Gaps 0;

QY 1 EVREVCSEQAEITGPCCRAIYHWYFDVTEGKCAFFYGGCGGNRNNDTEYCMAVCGSA 60  
DB 1 EVREVCSEQAEITGPCCRAIYHWYFDVTEGKCAFFYGGCGGNRNNDTEYCMAVCGSA 60

QY 61 I 61  
DB 61 I 61

RESULT 7  
US-09-234-874A-224  
Sequence 224, Application US/09234874A  
Patent No. 6376648  
GENERAL INFORMATION:  
APPLICANT: White, Tyler R.  
Lesikar, David D.  
Damm, Deborah  
McFadden, Kathleen  
Garrick, Brett L.  
TITLE OF INVENTION: PROTEASE INHIBITOR PEPTIDES  
NUMBER OF SEQUENCES: 228  
CORRESPONDENCE ADDRESS:  
ADDRESSEE: Foley & Lardner  
STREET: 3000 K Street, N.W., Suite 500  
CITY: Washington  
STATE: D.C.  
COUNTRY: USA  
ZIP: 20007-5109  
COMPUTER READABLE FORM:  
MEDIUM TYPE: Floppy disk  
COMPUTER: IBM PC compatible  
OPERATING SYSTEM: PC-DOS/MS-DOS  
SOFTWARE: Patentin Release #1.0, Version #1.30  
CURRENT APPLICATION DATA:  
APPLICATION NUMBER: US/09/234,874A  
FILING DATE: 11-Jun-2001  
PRIORITY APPLICATION DATA:  
APPLICATION NUMBER: 08/436,555  
FILING DATE: 08-MAY-1995  
ATTORNEY/AGENT INFORMATION:  
NAME: Bent, Stephen  
REGISTRATION NUMBER: 29,768  
REFERENCE/DOCKET NUMBER: 056324/0106  
TELECOMMUNICATION INFORMATION:  
TELEPHONE: (202)672-5300  
TELEFAX: (202)672-5399  
TELEX: 904136  
INFORMATION FOR SEQ ID NO: 224:  
SEQUENCE CHARACTERISTICS:  
LENGTH: 61 amino acids  
TYPE: amino acid  
STRANDEDNESS: single  
TOPOLOGY: linear  
MOLECULE TYPE: protein  
SEQUENCE DESCRIPTION: SEQ ID NO: 224:  
US-09-234-874A-224

Query Match 98.9%; Score 347; DB 4; Length 61;  
Best Local Similarity 98.4%; Pred. No. 2,4e-33;  
Matches 60; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 1 EVREVCSEQAEITGPCCRAIYHWYFDVTEGKCAFFYGGCGGNRNNDTEYCMAVCGSA 60  
DB 1 EVREVCSEQAEITGPCCRAIYHWYFDVTEGKCAFFYGGCGGNRNNDTEYCMAVCGSA 60

QY 61 I 61  
DB 61 I 61

RESULT 8  
US-09-234-873A-218  
Sequence 218, Application US/09234873A  
Patent No. 6613890  
GENERAL INFORMATION:  
APPLICANT: White, Tyler R.  
Damm, Deborah  
Lesikar, David D.  
McFadden, Kathleen  
Garrick, Brett L.

TITLE OF INVENTION: PROTEASE INHIBITOR PEPTIDES  
NUMBER OF SEQUENCES: 228  
CORRESPONDENCE ADDRESS:  
ADDRESSEE: Foley & Lardner  
STREET: 3000 K Street, N.W., Suite 500  
CITY: Washington  
STATE: D.C.  
COUNTRY: USA  
ZIP: 20007-5109

COMPUTER READABLE FORM:  
MEDIUM TYPE: Floppy disk  
COMPUTER: IBM PC compatible  
OPERATING SYSTEM: PC-DOS/MS-DOS  
SOFTWARE: Patentin Release #1.0, Version #1.30  
CURRENT APPLICATION DATA:  
APPLICATION NUMBER: US/09/234,873A  
FILING DATE: 21-Jan-1999  
PRIORITY APPLICATION DATA:  
APPLICATION NUMBER: 08/829,876  
FILING DATE: 02-APR-1997  
APPLICATION NUMBER: 08/436,555  
FILING DATE: 08-MAY-1995  
ATTORNEY/AGENT INFORMATION:  
NAME: Bent, Stephen  
REGISTRATION NUMBER: 29,768  
REFERENCE/DOCKET NUMBER: 056324/0116  
TELECOMMUNICATION INFORMATION:  
TELEPHONE: (202)672-5300  
TELEFAX: (202)672-5399  
TELEX: 904136  
INFORMATION FOR SEQ ID NO: 218:  
SEQUENCE CHARACTERISTICS:  
LENGTH: 61 amino acids  
TYPE: amino acid  
STRANDEDNESS: single  
TOPOLOGY: linear  
MOLECULE TYPE: protein  
SEQUENCE DESCRIPTION: SEQ ID NO: 218:  
US-09-234-873A-218

Query Match 98.9%; Score 347; DB 4; Length 61;  
Best Local Similarity 98.4%; Pred. No. 2,4e-33;  
Matches 60; Conservative 1; Mismatches 0; Indels 0; Gaps 0;

QY 1 EVREVCSEQAEITGPCCRAIYHWYFDVTEGKCAFFYGGCGGNRNNDTEYCMAVCGSA 60  
DB 1 EVREVCSEQAEITGPCCRAIYHWYFDVTEGKCAFFYGGCGGNRNNDTEYCMAVCGSA 60

QY 61 I 61

Db 61 I 61

RESULT 9  
US-09-234-873A-224  
; Sequence 224, Application US/09234873A  
; Patent No. 6613890  
; GENERAL INFORMATION:  
; APPLICANT: White, Tyler R.  
; Damm, Deborah  
; Lesikar, David D.  
; McFadden, Kathleen  
; Garrick, Brett L.  
; TITLE OF INVENTION: PROTEASE INHIBITOR PEPTIDES  
; NUMBER OF SEQUENCES: 228  
; CORRESPONDENCE ADDRESS:  
; ADDRESSEE: Foley & Lardner  
; STREET: 3000 K Street, N.W., Suite 500  
; CITY: Washington  
; STATE: D.C.  
; COUNTRY: USA  
; ZIP: 20007-5109  
; COMPUTER READABLE FORM:  
; MEDIUM TYPE: Floppy disk  
; COMPUTER: IBM PC compatible  
; OPERATING SYSTEM: PC-DOS/MS-DOS  
; SOFTWARE: Patent In Release #1.0, Version #1.30  
; CURRENT APPLICATION DATA:  
; APPLICATION NUMBER: US/09/234,873A  
; FILING DATE: 21-Jan-1999  
; PRIOR APPLICATION DATA:  
; APPLICATION NUMBER: 08/829,876  
; FILING DATE: 02-Apr-1997  
; APPLICATION NUMBER: 08/436,555  
; FILING DATE: 08-May-1995  
; ATTORNEY/AGENT INFORMATION:  
; NAME: Bent, Stephen  
; REGISTRATION NUMBER: 29,768  
; REFERENCE/DOCKET NUMBER: 056324/0116  
; TELECOMMUNICATION INFORMATION:  
; TELEPHONE: (202)672-5300  
; TELEFAX: (202)672-5399  
; TELEX: 904136  
; INFORMATION FOR SEQ ID NO: 224:  
; SEQUENCE CHARACTERISTICS:  
; LENGTH: 61 amino acids  
; TYPE: amino acid  
; STRANDEDNESS: single  
; TOPOLOGY: linear  
; MOLECULE TYPE: protein  
; SEQUENCE DESCRIPTION: SEQ ID NO: 224:  
US-09-234-873A-224

Query Match 98.9%; Score 347; DB 4; Length 61;  
Best Local Similarity 98.4%; Pred. No. 2.4e-33;  
Matches 60; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 1 EVVREVCSEQAEETGCPRAIYHWYFDVTEGKCAPFFYGGCGGNRNPFTEYCAVCGSA 60  
DB 1 EVVREVCSEQAEETGCPRAIYHWYFDVTEGKCAPFFYGGCGGNRNPFTEYCAVCGSA 60

QY 61 I 61  
DB 61 I 61

RESULT 10  
US-08-829-876-206  
; Sequence 206, Application US/08829876  
; Patent No. 5962266  
; GENERAL INFORMATION:  
; APPLICANT: White, Tyler R.

APPLICANT: Damm, Deborah  
; APPLICANT: Lesikar, David D.  
; APPLICANT: McFadden, Kathleen  
; APPLICANT: Garrick, Brett L.  
; TITLE OF INVENTION: PROTEASE INHIBITOR PEPTIDES  
; NUMBER OF SEQUENCES: 228  
; CORRESPONDENCE ADDRESS:  
; ADDRESSEE: Foley & Lardner  
; STREET: 3000 K Street, N.W., Suite 500  
; CITY: Washington  
; STATE: D.C.  
; COUNTRY: USA  
; ZIP: 20007-5109  
; COMPUTER READABLE FORM:  
; MEDIUM TYPE: Floppy disk  
; COMPUTER: IBM PC compatible  
; OPERATING SYSTEM: PC-DOS/MS-DOS  
; SOFTWARE: Patent In Release #1.0, Version #1.30  
; CURRENT APPLICATION DATA:  
; APPLICATION NUMBER: US/08/829,876  
; FILING DATE:  
; CLASSIFICATION:  
; PRIOR APPLICATION DATA:  
; APPLICATION NUMBER: US 08/436,555  
; FILING DATE: 08-May-1995  
; ATTORNEY/AGENT INFORMATION:  
; NAME: Peltio, Don J.  
; REGISTRATION NUMBER: 33,754  
; REFERENCE/DOCKET NUMBER: 56324/106/SCNO  
; TELECOMMUNICATION INFORMATION:  
; TELEPHONE: (202)672-5300  
; TELEFAX: (202)672-5399  
; TELEX: 904136  
; INFORMATION FOR SEQ ID NO: 206:  
; SEQUENCE CHARACTERISTICS:  
; LENGTH: 61 amino acids  
; TYPE: amino acid  
; STRANDEDNESS: single  
; TOPOLOGY: linear  
; MOLECULE TYPE: protein  
US-08-829-876-206

Query Match 98.6%; Score 346; DB 2; Length 61;  
Best Local Similarity 98.4%; Pred. No. 3.2e-33;  
Matches 60; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 1 EVVREVCSEQAEETGCPRAIYHWYFDVTEGKCAPFFYGGCGGNRNPFTEYCAVCGSA 60  
DB 1 EVVREVCSEQAEETGCPRAIYHWYFDVTEGKCAPFFYGGCGGNRNPFTEYCAVCGSA 60

QY 61 I 61  
DB 61 I 61

RESULT 11  
US-08-829-876-217  
; Sequence 217, Application US/08829876  
; Patent No. 5962266  
; GENERAL INFORMATION:  
; APPLICANT: White, Tyler R.  
; Damm, Deborah  
; Lesikar, David D.  
; McFadden, Kathleen  
; Garrick, Brett L.  
; TITLE OF INVENTION: PROTEASE INHIBITOR PEPTIDES  
; NUMBER OF SEQUENCES: 228  
; CORRESPONDENCE ADDRESS:  
; ADDRESSEE: Foley & Lardner  
; STREET: 3000 K Street, N.W., Suite 500  
; CITY: Washington  
; STATE: D.C.  
; COUNTRY: USA

ZIP: 20007-5109  
COMPUTER READABLE FORM:  
MEDIUM TYPE: floppy disk  
COMPUTER: IBM PC compatible  
OPERATING SYSTEM: PC-DOS/MS-DOS  
SOFTWARE: Patentin Release #1.0, Version #1.30  
CURRENT APPLICATION DATA:  
APPLICATION NUMBER: US/08/829,876  
FILING DATE:  
CLASSIFICATION:  
PRIOR APPLICATION DATA:  
APPLICATION NUMBER: US 08/436,555  
FILING DATE: 08-MAY-1995  
ATTORNEY/AGENT INFORMATION:  
NAME: Pelto, Don J.  
REGISTRATION NUMBER: 33,754  
REFERENCE/DOCKET NUMBER: 56324/106/SCNO  
TELECOMMUNICATION INFORMATION:  
TELEPHONE: (202)672-5300  
TELEFAX: (202)672-5399  
TELEX: 904136  
INFORMATION FOR SEQ ID NO: 217:  
SEQUENCE CHARACTERISTICS:  
LENGTH: 61 amino acids  
TYPE: amino acid  
STRANDEDNESS: single  
TOPOLOGY: linear  
MOLECULE TYPE: protein  
US-08-829-876-217

Query Match 98.6%; Score 346; DB 2; Length 61;  
Best Local Similarity 98.4%; Pred. No. 3.2e-33;  
Matches 60; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 1 EVREVCSEQAEFTGCRRAIYHWYFDVTEGKCAFFYGGCGGNRNPFTEECMAVCGSA 60  
DB 1 EVREVCSEQAEVGPCCRAIYHWYFDVTEGKCAFFYGGCGGNRNPFTEECMAVCGSA 60

QY 61 I 61  
DB 61 I 61

RESULT 12  
US-09-234-874A-206  
Sequence 206, Application US/09234874A  
Patent No. 6376648  
GENERAL INFORMATION:  
APPLICANT: White, Tyler R.  
Damir, Deborah  
Lesikar, David D.  
McFadden, Kathleen  
Garrick, Brett L.  
TITLE OF INVENTION: PROTEASE INHIBITOR PEPTIDES  
NUMBER OF SEQUENCES: 228  
CORRESPONDENCE ADDRESS:  
ADDRESSEE: Foley & Lardner  
STREET: 3000 K Street, N.W., Suite 500  
CITY: Washington  
STATE: D.C.  
COUNTRY: USA  
ZIP: 20007-5109  
COMPUTER READABLE FORM:  
MEDIUM TYPE: floppy disk  
COMPUTER: IBM PC compatible  
OPERATING SYSTEM: PC-DOS/MS-DOS  
SOFTWARE: Patentin Release #1.0, Version #1.30  
CURRENT APPLICATION DATA:  
APPLICATION NUMBER: US/09/234,874A  
FILING DATE: 11-Jun-2001  
PRIOR APPLICATION DATA:  
APPLICATION NUMBER: 08/436,555  
FILING DATE: 08-MAY-1995

ATTORNEY/AGENT INFORMATION:  
NAME: Bent, Stephen  
REGISTRATION NUMBER: 29,768  
REFERENCE/DOCKET NUMBER: 056324/0106  
TELECOMMUNICATION INFORMATION:  
TELEPHONE: (202)672-5500  
TELEFAX: (202)672-5399  
TELEX: 904136  
INFORMATION FOR SEQ ID NO: 206:  
SEQUENCE CHARACTERISTICS:  
LENGTH: 61 amino acids  
TYPE: amino acid  
STRANDEDNESS: single  
TOPOLOGY: linear  
MOLECULE TYPE: protein  
SEQUENCE DESCRIPTION: SEQ ID NO: 206:  
US-09-234-874A-206

Query Match 98.6%; Score 346; DB 4; Length 61;  
Best Local Similarity 98.4%; Pred. No. 3.2e-33;  
Matches 60; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 1 EVREVCSEQAEFTGCRRAIYHWYFDVTEGKCAFFYGGCGGNRNPFTEECMAVCGSA 60  
DB 1 EVREVCSEQAEFTGCRRAIYHWYFDVTEGKCAFFYGGCGGNRNPFTEECMAVCGSA 60

QY 61 I 61  
DB 61 I 61

RESULT 13  
US-09-234-874A-217  
Sequence 217, Application US/09234874A  
Patent No. 6376648  
GENERAL INFORMATION:  
APPLICANT: White, Tyler R.  
Damir, Deborah  
Lesikar, David D.  
McFadden, Kathleen  
Garrick, Brett L.  
TITLE OF INVENTION: PROTEASE INHIBITOR PEPTIDES  
NUMBER OF SEQUENCES: 228  
CORRESPONDENCE ADDRESS:  
ADDRESSEE: Foley & Lardner  
STREET: 3000 K Street, N.W., Suite 500  
CITY: Washington  
STATE: D.C.  
COUNTRY: USA  
ZIP: 20007-5109  
COMPUTER READABLE FORM:  
MEDIUM TYPE: floppy disk  
COMPUTER: IBM PC compatible  
OPERATING SYSTEM: PC-DOS/MS-DOS  
SOFTWARE: Patentin Release #1.0, Version #1.30  
CURRENT APPLICATION DATA:  
APPLICATION NUMBER: US/09/234,874A  
FILING DATE: 11-Jun-2001  
PRIOR APPLICATION DATA:  
APPLICATION NUMBER: 08/436,555  
FILING DATE: 08-MAY-1995  
ATTORNEY/AGENT INFORMATION:  
NAME: Bent, Stephen  
REGISTRATION NUMBER: 29,768  
REFERENCE/DOCKET NUMBER: 056324/0106  
TELECOMMUNICATION INFORMATION:  
TELEPHONE: (202)672-5300  
TELEFAX: (202)672-5399  
TELEX: 904136  
INFORMATION FOR SEQ ID NO: 217:  
SEQUENCE CHARACTERISTICS:  
LENGTH: 61 amino acids  
TYPE: amino acid



STRANDEDNESS: single  
TOPOLOGY: linear  
MOLECULE TYPE: protein  
SEQUENCE DESCRIPTION: SEQ ID NO: 217:  
US-09-234-873A-217

Query Match 98.6%; Score 346; DB 4; Length 61;  
Best Local Similarity 98.4%; Pred. No. 3.2e-33;  
Matches 60; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 1 EVVREVCSEQAEFGPCRAIYHWYFDVTEGKCAPFFYGGCGGNRNNDTEEYCMAYCGSA 60  
DB 1 EVVREVCSEQAEFGPCRAIYHWYFDVTEGKCAPFFYGGCGGNRNNDTEEYCMAYCGSA 60

QY 61 I 61  
DB 61 I 61

## RESULT 14

US-09-234-873A-206  
Sequence 206, Application US/09234873A  
Patent No. 6613890

GENERAL INFORMATION:  
APPLICANT: White, Tyler R.

Damm, Deborah  
Lesikar, David D.  
McFadden, Kathleen  
Garrick, Brett L.

TITLE OF INVENTION: PROTEASE INHIBITOR PEPTIDES  
NUMBER OF SEQUENCES: 228  
CORRESPONDENCE ADDRESS:  
ADDRESSEE: Foley & Lardner  
STREET: 3000 K Street, N.W., Suite 500  
CITY: Washington  
STATE: D.C.

COUNTRY: USA  
ZIP: 20007-5109  
COMPUTER READABLE FORM:  
MEDIUM TYPE: floppy disk  
COMPUTER: IBM PC compatible  
OPERATING SYSTEM: PC-DOS/MS-DOS  
SOFTWARE: Patentin Release #1.0, Version #1.30

CURRENT APPLICATION DATA:  
APPLICATION NUMBER: US/09/234,873A  
FILING DATE: 21-Jan-1999

PRIOR APPLICATION DATA:  
APPLICATION NUMBER: 08/829,876  
FILING DATE: 02-APR-1997  
APPLICATION NUMBER: 08/436,555  
FILING DATE: 08-MAY-1995

ATTORNEY/AGENT INFORMATION:  
NAME: Bent, Stephen  
REGISTRATION NUMBER: 29 768  
REFERENCE/DOCKET NUMBER: 056324/0116

TELECOMMUNICATION INFORMATION:  
TELEPHONE: (202)672-5300  
TELEFAX: (202)672-5399  
TELEX: 904136

INFORMATION FOR SEQ ID NO: 206:  
SEQUENCE CHARACTERISTICS:  
LENGTH: 61 amino acids  
TYPE: amino acid  
STRANDEDNESS: single  
TOPOLOGY: linear

MOLECULE TYPE: protein  
SEQUENCE DESCRIPTION: SEQ ID NO: 206:  
US-09-234-873A-206

Query Match 98.6%; Score 346; DB 4; Length 61;  
Best Local Similarity 98.4%; Pred. No. 3.2e-33;  
Matches 60; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 98.6%; Score 346; DB 4; Length 61;  
DB 98.4%; Pred. No. 3.2e-33;  
Matches 60; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 98.6%; Score 346; DB 4; Length 61;  
DB 98.4%; Pred. No. 3.2e-33;  
Matches 60; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 1 EVVREVCSEQAEFGPCRAIYHWYFDVTEGKCAPFFYGGCGGNRNNDTEEYCMAYCGSA 60  
DB 1 EVVREVCSEQAEFGPCRAIYHWYFDVTEGKCAPFFYGGCGGNRNNDTEEYCMAYCGSA 60

QY 61 I 61  
DB 61 I 61

## RESULT 15

US-09-234-873A-217  
Sequence 217, Application US/09234873A  
Patent No. 6613890

GENERAL INFORMATION:  
APPLICANT: White, Tyler R.

Damm, Deborah  
Lesikar, David D.  
McFadden, Kathleen  
Garrick, Brett L.

TITLE OF INVENTION: PROTEASE INHIBITOR PEPTIDES  
NUMBER OF SEQUENCES: 228  
CORRESPONDENCE ADDRESS:  
ADDRESSEE: Foley & Lardner  
STREET: 3000 K Street, N.W., Suite 500  
CITY: Washington  
STATE: D.C.

COUNTRY: USA  
ZIP: 20007-5109  
COMPUTER READABLE FORM:  
MEDIUM TYPE: floppy disk  
COMPUTER: IBM PC compatible  
OPERATING SYSTEM: PC-DOS/MS-DOS  
SOFTWARE: Patentin Release #1.0, Version #1.30

CURRENT APPLICATION DATA:  
APPLICATION NUMBER: US/09/234,873A  
FILING DATE: 21-Jan-1999

PRIOR APPLICATION DATA:  
APPLICATION NUMBER: 08/829,876  
FILING DATE: 02-APR-1997  
APPLICATION NUMBER: 08/436,555  
FILING DATE: 08-MAY-1995

ATTORNEY/AGENT INFORMATION:  
NAME: Bent, Stephen  
REGISTRATION NUMBER: 29 768  
REFERENCE/DOCKET NUMBER: 056324/0116

TELECOMMUNICATION INFORMATION:  
TELEPHONE: (202)672-5300  
TELEFAX: (202)672-5399  
TELEX: 904136

INFORMATION FOR SEQ ID NO: 217:  
SEQUENCE CHARACTERISTICS:  
LENGTH: 61 amino acids  
TYPE: amino acid  
STRANDEDNESS: single  
TOPOLOGY: linear

MOLECULE TYPE: protein  
SEQUENCE DESCRIPTION: SEQ ID NO: 217:  
US-09-234-873A-217

Query Match 98.6%; Score 346; DB 4; Length 61;  
Best Local Similarity 98.4%; Pred. No. 3.2e-33;  
Matches 60; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 98.6%; Score 346; DB 4; Length 61;  
DB 98.4%; Pred. No. 3.2e-33;  
Matches 60; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 98.6%; Score 346; DB 4; Length 61;  
DB 98.4%; Pred. No. 3.2e-33;  
Matches 60; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 98.6%; Score 346; DB 4; Length 61;  
DB 98.4%; Pred. No. 3.2e-33;  
Matches 60; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 98.6%; Score 346; DB 4; Length 61;  
DB 98.4%; Pred. No. 3.2e-33;  
Matches 60; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Search completed: April 8, 2004, 09:27:12

Thu Apr 8 09:47:14 2004

Job time : 23 secs

us-10-076-604-208.ra1

---

GenCore version 5.1.6  
Copyright (c) 1993 - 2004 Compugen Ltd.

OM protein - protein search, using sw model

Run on: April 8, 2004, 09:26:36 ; Search time 40 Seconds  
(without alignments)  
400.980 Million cell updates/sec

Title: US-10-076-604-208  
Perfect score: 351  
Sequence: 1 EVAREVCESEAEETPCRAAI.....GKNNFTETRYCAVCGSAI 61

Scoring table: BLOSUM62  
Gapop 10.0 , Gapext 0.5

Searched: 1073127 seqs, 262937947 residues

Total number of hits satisfying chosen parameters: 1073127

Minimum DB seq length: 0  
Maximum DB seq length: 2000000000

Post-processing: Minimum Match 0%  
Maximum Match 100%  
Listing first 45 summaries

Database :  
1: /cgnt2\_6/ptodata/1/pubppa/US07\_PUBCOMB.pep:\*  
2: /cgnt2\_6/ptodata/1/pubppa/PCR\_NEW\_PUB.pep:\*  
3: /cgnt2\_6/ptodata/1/pubppa/US06\_NEW\_PUB.pep:\*  
4: /cgnt2\_6/ptodata/1/pubppa/US06\_PUBCOMB.pep:\*  
5: /cgnt2\_6/ptodata/1/pubppa/US07\_PUBCOMB.pep:\*  
6: /cgnt2\_6/ptodata/1/pubppa/US07\_PUB.pep:\*  
7: /cgnt2\_6/ptodata/1/pubppa/US08\_PUBCOMB.pep:\*  
8: /cgnt2\_6/ptodata/1/pubppa/US08\_NEW\_PUB.pep:\*  
9: /cgnt2\_6/ptodata/1/pubppa/US09\_PUBCOMB.pep:\*  
10: /cgnt2\_6/ptodata/1/pubppa/US09\_PUBCOMB.pep:\*  
11: /cgnt2\_6/ptodata/1/pubppa/US09\_PUBCOMB.pep:\*  
12: /cgnt2\_6/ptodata/1/pubppa/US09\_PUBCOMB.pep:\*  
13: /cgnt2\_6/ptodata/1/pubppa/US10\_PUBCOMB.pep:\*  
14: /cgnt2\_6/ptodata/1/pubppa/US10\_PUBCOMB.pep:\*  
15: /cgnt2\_6/ptodata/1/pubppa/US10\_PUBCOMB.pep:\*  
16: /cgnt2\_6/ptodata/1/pubppa/US10\_PUBCOMB.pep:\*  
17: /cgnt2\_6/ptodata/1/pubppa/US10\_PUBCOMB.pep:\*  
18: /cgnt2\_6/ptodata/1/pubppa/US60\_PUBCOMB.pep:\*

Pred. No. is the number of results predicted by chance to have a score greater than or equal to the score of the result being printed, and is derived by analysis of the total score distribution.

# SUMMARIES

Result No.	Score	Query Match	Length	DB ID	Description
1	351	100.0	61	14	US-10-076-604-208
2	347	98.9	61	14	US-10-076-604-218
3	347	98.9	61	14	US-10-076-604-224
4	346	98.6	61	14	US-10-076-604-206
5	346	98.6	61	14	US-10-076-604-217
6	343	97.7	61	14	US-10-076-604-173
7	343	97.7	61	14	US-10-076-604-211
8	342	97.4	61	14	US-10-076-604-85
9	342	97.4	61	14	US-10-076-604-216
10	341	97.2	61	14	US-10-076-604-223
11	341	97.2	61	14	US-10-076-604-204
12	340	96.9	61	14	US-10-076-604-215
13	340	96.6	61	14	US-10-076-604-219
14	339	96.6	61	14	US-10-076-604-171
15	339	96.6	61	14	US-10-076-604-178

16	339	96.6	61	14	US-10-076-604-220	Sequence 220, App
17	339	96.6	146	14	US-10-076-604-107	Sequence 107, App
18	338	96.3	61	14	US-10-076-604-131	Sequence 131, App
19	338	96.3	61	14	US-10-076-604-172	Sequence 172, App
20	338	96.3	61	14	US-10-076-604-174	Sequence 174, App
21	338	96.3	61	14	US-10-076-604-209	Sequence 209, App
22	338	96.3	61	14	US-10-076-604-221	Sequence 221, App
23	338	96.3	146	14	US-10-076-604-83	Sequence 83, App
24	338	96.3	146	14	US-10-076-604-89	Sequence 89, App
25	337	96.0	61	14	US-10-076-604-139	Sequence 139, App
26	337	96.0	61	14	US-10-076-604-198	Sequence 198, App
27	337	96.0	61	14	US-10-076-604-207	Sequence 207, App
28	337	96.0	61	14	US-10-076-604-210	Sequence 210, App
29	335	95.4	61	14	US-10-076-604-222	Sequence 222, App
30	334	95.2	61	14	US-10-076-604-117	Sequence 117, App
31	334	95.2	61	14	US-10-076-604-130	Sequence 130, App
32	334	95.2	61	14	US-10-076-604-177	Sequence 177, App
33	334	95.2	61	14	US-10-076-604-179	Sequence 179, App
34	334	95.2	146	14	US-10-076-604-175	Sequence 175, App
35	333	94.9	61	14	US-10-076-604-132	Sequence 132, App
36	333	94.9	61	14	US-10-076-604-134	Sequence 134, App
37	332	94.6	61	14	US-10-076-604-181	Sequence 181, App
38	332	94.6	61	14	US-10-076-604-196	Sequence 196, App
39	332	94.6	61	14	US-10-076-604-205	Sequence 205, App
40	331	94.3	61	14	US-10-076-604-120	Sequence 120, App
41	331	94.3	61	14	US-10-076-604-186	Sequence 186, App
42	331	94.3	61	14	US-10-076-604-188	Sequence 188, App
43	331	94.3	61	14	US-10-076-604-212	Sequence 212, App
44	331	94.3	146	14	US-10-076-604-93	Sequence 93, App
45	330	94.0	61	14	US-10-076-604-121	Sequence 121, App

## ALIGNMENTS

RESULT 1  
US-10-076-604-208  
Sequence 208, Application US/10076604  
Publication No. US20030114372A1  
GENERAL INFORMATION:  
APPLICANT: White, Tyler R.  
Inventor: Damu, Deborah  
Lesikar, David D.  
McFadden, Kathleen  
Garlick, Brett L.  
TITLE OF INVENTION: PROTEASE INHIBITOR PEPTIDES  
NUMBER OF SEQUENCES: 228  
CORRESPONDENCE ADDRESS:  
ADDRESSEE: Foley & Lardner  
STREET: 3000 K Street, N.W., Suite 500  
CITY: Washington  
STATE: D.C.  
COUNTRY: USA  
ZIP: 20007-5109  
COMPUTER READABLE FORM:  
MEDIUM TYPE: Floppy disk  
COMPUTER: IBM PC compatible  
OPERATING SYSTEM: PC-DOS/MS-DOS  
SOFTWARE: Patent Release #1.0, Version #1.30  
CURRENT APPLICATION DATA:  
APPLICATION NUMBER: US/10/076,604  
FILING DATE: 19-Feb-2002  
PRIOR APPLICATION DATA:  
APPLICATION NUMBER: US/09/201,715  
FILING DATE: 01-Dec-1998  
APPLICATION NUMBER: US 08/436,555  
FILING DATE: 08-MAY-1995  
ATTORNEY/AGENT INFORMATION:  
NAME: Felto, Don J.  
REGISTRATION NUMBER: 33,754  
REFERENCE/DOCKET NUMBER: 56324/117  
TELECOMMUNICATION INFORMATION:  
TELEPHONE: (202) 672-5300

TELEFAX: (202) 672-5399  
INFORMATION FOR SEQ ID NO: 208:  
SEQUENCE CHARACTERISTICS:  
LENGTH: 61 amino acids  
TYPE: amino acid  
STRANDEDNESS: single  
TOPOLOGY: linear  
MOLECULE TYPE: protein  
SEQUENCE DESCRIPTION: SEQ ID NO: 208:  
US-10-076-604-208

Query Match  
Best Local Similarity 100.0%; Score 351; DB 14; Length 61;  
Matches 61; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 EVREVCSQAEATGRCRAIYHWYFDVTEGKCAPFFYGGCGGNRNPFTEYCMAYCGSA 60  
DB 1 EVREVCSQAEATGRCRAIYHWYFDVTEGKCAPFFYGGCGGNRNPFTEYCMAYCGSA 60

QY 61 I 61  
DB 61 I 61

RESULT 2  
US-10-076-604-218  
Sequence 218, Application US/10076604  
Publication No. US20030114372A1  
GENERAL INFORMATION:  
APPLICANT: White, Tyler R.  
Damm, Deborah  
Lesikar, David D.  
McFadden, Kathleen  
Garrick, Brett L.  
TITLE OF INVENTION: PROTEASE INHIBITOR PEPTIDES  
NUMBER OF SEQUENCES: 228  
CORRESPONDENCE ADDRESS:  
ADDRESSEE: Foley & Lardner  
STREET: 3000 K Street, N.W., Suite 500  
CITY: Washington  
STATE: D.C.  
COUNTRY: USA  
ZIP: 20007-5109  
COMPUTER READABLE FORM:  
MEDIUM TYPE: floppy disk  
COMPUTER: IBM PC compatible  
OPERATING SYSTEM: PC-DOS/MS-DOS  
SOFTWARE: Patentin Release #1.0, Version #1.30  
CURRENT APPLICATION DATA:  
APPLICATION NUMBER: US/10/076,604  
FILING DATE: 19-Feb-2002  
PRIOR APPLICATION DATA:  
APPLICATION NUMBER: US/09/201,715  
FILING DATE: 01-Dec-1998  
APPLICATION NUMBER: US 08/436,555  
FILING DATE: 08-MAY-1995  
ATTORNEY/AGENT INFORMATION:  
NAME: Pelto, Don J.  
REGISTRATION NUMBER: 33,754  
REFERENCE/DOCKET NUMBER: 56324/117  
TELECOMMUNICATION INFORMATION:  
TELEPHONE: (202) 672-5300  
TELEFAX: (202) 672-5399  
INFORMATION FOR SEQ ID NO: 218:  
SEQUENCE CHARACTERISTICS:  
LENGTH: 61 amino acids  
TYPE: amino acid  
STRANDEDNESS: single  
TOPOLOGY: linear  
MOLECULE TYPE: protein  
SEQUENCE DESCRIPTION: SEQ ID NO: 218:

US-10-076-604-218

Query Match  
Best Local Similarity 98.4%; Score 347; DB 14; Length 61;  
Matches 60; Conservative 1; Mismatches 0; Indels 0; Gaps 0;

QY 1 EVREVCSQAEATGRCRAIYHWYFDVTEGKCAPFFYGGCGGNRNPFTEYCMAYCGSA 60  
DB 1 EVREVCSQAEATGRCRAIYHWYFDVTEGKCAPFFYGGCGGNRNPFTEYCMAYCGSA 60

QY 61 I 61  
DB 61 I 61

RESULT 3  
US-10-076-604-224  
Sequence 224, Application US/10076604  
Publication No. US20030114372A1  
GENERAL INFORMATION:  
APPLICANT: White, Tyler R.  
Damm, Deborah  
Lesikar, David D.  
McFadden, Kathleen  
Garrick, Brett L.  
TITLE OF INVENTION: PROTEASE INHIBITOR PEPTIDES  
NUMBER OF SEQUENCES: 228  
CORRESPONDENCE ADDRESS:  
ADDRESSEE: Foley & Lardner  
STREET: 3000 K Street, N.W., Suite 500  
CITY: Washington  
STATE: D.C.  
COUNTRY: USA  
ZIP: 20007-5109  
COMPUTER READABLE FORM:  
MEDIUM TYPE: floppy disk  
COMPUTER: IBM PC compatible  
OPERATING SYSTEM: PC-DOS/MS-DOS  
SOFTWARE: Patentin Release #1.0, Version #1.30  
CURRENT APPLICATION DATA:  
APPLICATION NUMBER: US/10/076,604  
FILING DATE: 19-Feb-2002  
PRIOR APPLICATION DATA:  
APPLICATION NUMBER: US/09/201,715  
FILING DATE: 01-Dec-1998  
APPLICATION NUMBER: US 08/436,555  
FILING DATE: 08-MAY-1995  
ATTORNEY/AGENT INFORMATION:  
NAME: Pelto, Don J.  
REGISTRATION NUMBER: 33,754  
REFERENCE/DOCKET NUMBER: 56324/117  
TELECOMMUNICATION INFORMATION:  
TELEPHONE: (202) 672-5300  
TELEFAX: (202) 672-5399  
INFORMATION FOR SEQ ID NO: 224:  
SEQUENCE CHARACTERISTICS:  
LENGTH: 61 amino acids  
TYPE: amino acid  
STRANDEDNESS: single  
TOPOLOGY: linear  
MOLECULE TYPE: protein  
SEQUENCE DESCRIPTION: SEQ ID NO: 224:  
US-10-076-604-224

Query Match  
Best Local Similarity 98.9%; Score 347; DB 14; Length 61;  
Matches 60; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 1 EVREVCSQAEATGRCRAIYHWYFDVTEGKCAPFFYGGCGGNRNPFTEYCMAYCGSA 60  
DB 1 EVREVCSQAEATGRCRAIYHWYFDVTEGKCAPFFYGGCGGNRNPFTEYCMAYCGSA 60

OY 61 I 61  
Db 61 I 61

## RESULT 4

US-10-076-604-206  
Sequence 206, Application US/10076604  
Publication No. US20030114372A1  
GENERAL INFORMATION:  
APPLICANT: White, Tyler R.  
Lesikar, David D.  
McFadden, Kathleen  
Garrick, Brett L.  
TITLE OF INVENTION: PROTEASE INHIBITOR PEPTIDES  
NUMBER OF SEQUENCES: 228  
CORRESPONDENCE ADDRESS:  
ADDRESSEE: Foley & Lardner  
STREET: 3000 K Street, N.W., Suite 500  
CITY: Washington  
STATE: D.C.  
COUNTRY: USA  
ZIP: 20007-5109  
COMPUTER READABLE FORM:  
MEDIUM TYPE: Floppy disk  
COMPUTER: IBM PC compatible  
OPERATING SYSTEM: PC-DOS/MS-DOS  
SOFTWARE: Patentin Release #1.0, Version #1.30  
CURRENT APPLICATION DATA:  
APPLICATION NUMBER: US/10/076,604  
FILING DATE: 19-Feb-2002  
PRIOR APPLICATION DATA:  
APPLICATION NUMBER: US/09/201,715  
FILING DATE: 01-Dec-1998  
APPLICATION NUMBER: US 08/436,555  
FILING DATE: 08-MAY-1995  
ATTORNEY/AGENT INFORMATION:  
NAME: Pelco, Don J.  
REGISTRATION NUMBER: 33,754  
REFERENCE/DOCKET NUMBER: 56324/117  
TELECOMMUNICATION INFORMATION:  
TELEPHONE: (202)672-5300  
TELEFAX: (202)672-5399  
TELEX: 904136  
INFORMATION FOR SEQ ID NO: 206:  
SEQUENCE CHARACTERISTICS:  
LENGTH: 61 amino acids  
TYPE: amino acid  
STRANDEDNESS: single  
TOPOLOGY: linear  
MOLECULE TYPE: protein  
SEQUENCE DESCRIPTION: SEQ ID NO: 206:  
US-10-076-604-206

Query Match 98.6%; Score 346; DB 14; Length 61;  
Best Local Similarity 98.4%; Pred. No. 4.8e-35;  
Matches 60; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

OY 1 EVYREVCSQAEETGPGRAIYHYFPDVTGKCAPFYGGCGGNRNPFDEYCMAYCGSA 60  
|||  
Db 1 EVYREVCSQAEETGPGRAIYHYFPDVTGKCAPFYGGCGGNRNPFDEYCMAYCGSA 60  
|||  
OY 61 I 61  
Db 61 I 61

## RESULT 5

US-10-076-604-217  
Sequence 217, Application US/10076604  
Publication No. US20030114372A1  
GENERAL INFORMATION:

APPLICANT: White, Tyler R.

Damm, Deborah  
Lesikar, David D.  
McFadden, Kathleen  
Garrick, Brett L.

TITLE OF INVENTION: PROTEASE INHIBITOR PEPTIDES

NUMBER OF SEQUENCES: 228

CORRESPONDENCE ADDRESS:

ADDRESSEE: Foley & Lardner

STREET: 3000 K Street, N.W., Suite 500

CITY: Washington

STATE: D.C.

COUNTRY: USA

ZIP: 20007-5109

COMPUTER READABLE FORM:

MEDIUM TYPE: Floppy disk

COMPUTER: IBM PC compatible

OPERATING SYSTEM: PC-DOS/MS-DOS

SOFTWARE: Patentin Release #1.0, Version #1.30

CURRENT APPLICATION DATA:

APPLICATION NUMBER: US/10/076,604

FILING DATE: 19-Feb-2002

PRIOR APPLICATION DATA:

APPLICATION NUMBER: US/09/201,715

FILING DATE: 01-Dec-1998

APPLICATION NUMBER: US 08/436,555

FILING DATE: 08-MAY-1995

ATTORNEY/AGENT INFORMATION:

NAME: Pelco, Don J.

REGISTRATION NUMBER: 33,754

REFERENCE/DOCKET NUMBER: 56324/117

TELECOMMUNICATION INFORMATION:

TELEPHONE: (202)672-5300

TELEFAX: (202)672-5399

TELEX: 904136

INFORMATION FOR SEQ ID NO: 217:

SEQUENCE CHARACTERISTICS:

LENGTH: 61 amino acids

TYPE: amino acid

STRANDEDNESS: single

TOPOLOGY: linear

MOLECULE TYPE: protein

SEQUENCE DESCRIPTION: SEQ ID NO: 217:  
US-10-076-604-217

Query Match 98.6%; Score 346; DB 14; Length 61;  
Best Local Similarity 98.4%; Pred. No. 4.8e-35;  
Matches 60; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

OY 1 EVYREVCSQAEETGPGRAIYHYFPDVTGKCAPFYGGCGGNRNPFDEYCMAYCGSA 60  
|||  
Db 1 EVYREVCSQAEETGPGRAIYHYFPDVTGKCAPFYGGCGGNRNPFDEYCMAYCGSA 60  
|||  
OY 61 I 61  
Db 61 I 61

## RESULT 6

US-10-076-604-173  
Sequence 173, Application US/10076604  
Publication No. US20030114372A1  
GENERAL INFORMATION:  
APPLICANT: White, Tyler R.  
Damm, Deborah  
Lesikar, David D.  
McFadden, Kathleen  
Garrick, Brett L.  
TITLE OF INVENTION: PROTEASE INHIBITOR PEPTIDES  
NUMBER OF SEQUENCES: 228  
CORRESPONDENCE ADDRESS:  
ADDRESSEE: Foley & Lardner  
STREET: 3000 K Street, N.W., Suite 500

CITY: Washington  
STATE: D.C.  
COUNTRY: USA  
ZIP: 20007-5109  
COMPUTER READABLE FORM:  
MEDIUM TYPE: floppy disk  
COMPUTER: IBM PC compatible  
OPERATING SYSTEM: PC-DOS/MS-DOS  
SOFTWARE: Patent Release #1.0, Version #1.30  
CURRENT APPLICATION DATA:  
APPLICATION NUMBER: US/10/076,604  
FILING DATE: 19-Feb-2002  
PRIOR APPLICATION DATA:  
APPLICATION NUMBER: US/09/201,715  
FILING DATE: 01-Dec-1998  
APPLICATION NUMBER: US 08/436,555  
FILING DATE: 08-MAY-1995  
ATTORNEY/AGENT INFORMATION:  
NAME: Felto, Don J.  
REGISTRATION NUMBER: 33,754  
REFERENCE/DOCKET NUMBER: 56324/117  
TELECOMMUNICATION INFORMATION:  
TELEPHONE: (202)672-5300  
TELEFAX: (202)672-5399  
TELEX: 904136  
INFORMATION FOR SEQ ID NO: 173:  
SEQUENCE CHARACTERISTICS:  
LENGTH: 61 amino acids  
TYPE: amino acid  
STRANDEDNESS: single  
TOPOLOGY: linear  
MOLECULE TYPE: protein  
SEQUENCE DESCRIPTION: SEQ ID NO: 173:  
US-10-076-604-173

Query Match 97.7%; Score 343; DB 14; Length 61;  
Best Local Similarity 98.4%; Pred. No. 1.1e-34;  
Matches 60; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 1 EVREVCSEQAETGPCRAIYHWYFDVTEGKCAFFYGGCGGNRNNFDTTEYCMAVCGSA 60  
DB 1 EVREVCSEQAETGPCRAIYHWYFDVTEGKCAFFYGGCGGNRNNFDTTEYCMAVCGSA 60

QY 61 I 61  
DB 61 I 61

RESULT 7  
US-10-076-604-211  
Sequence 211, Application US/10076604  
Publication No. US20030114372A1  
GENERAL INFORMATION:  
APPLICANT: White, Tyler R.  
Damm, Deborah  
Lesikar, David D.  
McFadden, Kathleen  
Garrick, Brett L.  
TITLE OF INVENTION: PROTEASE INHIBITOR PEPTIDES  
NUMBER OF SEQUENCES: 228  
CORRESPONDENCE ADDRESSES:  
ADDRESSEE: Foley & Lardner  
STREET: 3000 K Street, N.W., Suite 500  
CITY: Washington  
STATE: D.C.  
COUNTRY: USA  
ZIP: 20007-5109  
COMPUTER READABLE FORM:  
MEDIUM TYPE: floppy disk  
COMPUTER: IBM PC compatible  
OPERATING SYSTEM: PC-DOS/MS-DOS  
SOFTWARE: Patent Release #1.0, Version #1.30  
CURRENT APPLICATION DATA:

APPLICATION NUMBER: US/10/076,604  
FILING DATE: 19-Feb-2002  
PRIOR APPLICATION DATA:  
APPLICATION NUMBER: US/09/201,715  
FILING DATE: 01-Dec-1998  
APPLICATION NUMBER: US 08/436,555  
FILING DATE: 08-MAY-1995  
ATTORNEY/AGENT INFORMATION:  
NAME: Felto, Don J.  
REGISTRATION NUMBER: 33,754  
REFERENCE/DOCKET NUMBER: 56324/117  
TELECOMMUNICATION INFORMATION:  
TELEPHONE: (202)672-5300  
TELEFAX: (202)672-5399  
TELEX: 904136  
INFORMATION FOR SEQ ID NO: 211:  
SEQUENCE CHARACTERISTICS:  
LENGTH: 61 amino acids  
TYPE: amino acid  
STRANDEDNESS: single  
TOPOLOGY: linear  
MOLECULE TYPE: protein  
SEQUENCE DESCRIPTION: SEQ ID NO: 211:  
US-10-076-604-211

Query Match 97.7%; Score 343; DB 14; Length 61;  
Best Local Similarity 98.4%; Pred. No. 1.1e-34;  
Matches 60; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 1 EVREVCSEQAETGPCRAIYHWYFDVTEGKCAFFYGGCGGNRNNFDTTEYCMAVCGSA 60  
DB 1 EVREVCSEQAETGPCRAIYHWYFDVTEGKCAFFYGGCGGNRNNFDTTEYCMAVCGSA 60

QY 61 I 61  
DB 61 I 61

RESULT 8  
US-10-076-604-85  
Sequence 85, Application US/10076604  
Publication No. US20030114372A1  
GENERAL INFORMATION:  
APPLICANT: White, Tyler R.  
Damm, Deborah  
Lesikar, David D.  
McFadden, Kathleen  
Garrick, Brett L.  
TITLE OF INVENTION: PROTEASE INHIBITOR PEPTIDES  
NUMBER OF SEQUENCES: 228  
CORRESPONDENCE ADDRESSES:  
ADDRESSEE: Foley & Lardner  
STREET: 3000 K Street, N.W., Suite 500  
CITY: Washington  
STATE: D.C.  
COUNTRY: USA  
ZIP: 20007-5109  
COMPUTER READABLE FORM:  
MEDIUM TYPE: floppy disk  
COMPUTER: IBM PC compatible  
OPERATING SYSTEM: PC-DOS/MS-DOS  
SOFTWARE: Patent Release #1.0, Version #1.30  
CURRENT APPLICATION DATA:  
APPLICATION NUMBER: US/10/076,604  
FILING DATE: 19-Feb-2002  
PRIOR APPLICATION DATA:  
APPLICATION NUMBER: US/09/201,715  
FILING DATE: 01-Dec-1998  
APPLICATION NUMBER: US 08/436,555  
FILING DATE: 08-MAY-1995  
ATTORNEY/AGENT INFORMATION:  
NAME: Felto, Don J.  
REGISTRATION NUMBER: 33,754

REFERENCE/DOCKET NUMBER: 56324/117  
TELECOMMUNICATION INFORMATION:  
TELEPHONE: (202) 672-5300  
TELEFAX: (202) 672-5399  
TELEX: 904136  
INFORMATION FOR SEQ ID NO: 85:  
SEQUENCE CHARACTERISTICS:  
LENGTH: 146 amino acids  
TYPE: amino acid  
TOPOLOGY: linear  
MOLECULE TYPE: protein  
SEQUENCE DESCRIPTION: SEQ ID NO: 85:  
US-10-076-604-85

Query Match 97.7%; Score 343; DB 14; Length 146;  
Best Local Similarity 98.4%; Pred. No. 2.8e-34;  
Matches 60; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 1 EVVREVCSEQAETGCPRAIYHWYFDVTEGKCAPFFYGGCGGNRRNFDTEECMAVCGSA 60  
DB 86 EVVREVCSEQAETGCPRAIYHWYFDVTEGKCAPFFYGGCGGNRRNFDTEECMAVCGSA 145

QY 61 I 61  
DB 146 I 146

RESULT 9  
US-10-076-604-216  
Sequence 216, Application US/10076604  
Publication No. US20030114372A1  
GENERAL INFORMATION:  
APPLICANT: White, Tyler R.  
Lesikar, David D.  
McFadden, Kathleen  
Garrick, Brett L.  
TITLE OF INVENTION: PROTEASE INHIBITOR PEPTIDES  
NUMBER OF SEQUENCES: 228  
CORRESPONDENCE ADDRESS:  
ADDRESSEE: Foley & Lardner  
STREET: 3000 K Street, N.W., Suite 500  
CITY: Washington  
STATE: D.C.  
COUNTRY: USA  
ZIP: 20007-5109  
COMPUTER READABLE FORM:  
MEDIUM TYPE: floppy disk  
COMPUTER: IBM PC compatible  
OPERATING SYSTEM: PC-DOS/MS-DOS  
SOFTWARE: Patentin Release #1.0, Version #1.30  
CURRENT APPLICATION DATA:  
APPLICATION NUMBER: US/10/076,604  
FILING DATE: 19-Feb-2002  
PRIOR APPLICATION DATA:  
APPLICATION NUMBER: US/09/201,715  
FILING DATE: 01-Dec-1998  
APPLICATION NUMBER: US 08/436,555  
FILING DATE: 08-MAY-1995  
ATTORNEY/AGENT INFORMATION:  
NAME: Pelto, Don J.  
REGISTRATION NUMBER: 33,754  
REFERENCE/DOCKET NUMBER: 56324/117  
TELECOMMUNICATION INFORMATION:  
TELEPHONE: (202) 672-5300  
TELEFAX: (202) 672-5399  
TELEX: 904136  
INFORMATION FOR SEQ ID NO: 216:  
SEQUENCE CHARACTERISTICS:  
LENGTH: 61 amino acids  
TYPE: amino acid  
STRANDEDNESS: single  
TOPOLOGY: linear

MOLECULE TYPE: protein  
SEQUENCE DESCRIPTION: SEQ ID NO: 216:  
US-10-076-604-216

Query Match 97.4%; Score 342; DB 14; Length 61;  
Best Local Similarity 96.7%; Pred. No. 1.5e-34;  
Matches 59; Conservative 1; Mismatches 1; Indels 0; Gaps 0;

QY 1 EVVREVCSEQAETGCPRAIYHWYFDVTEGKCAPFFYGGCGGNRRNFDTEECMAVCGSA 60  
DB 1 EVVREVCSEQAETGCPRAIYHWYFDVTEGKCAPFFYGGCGGNRRNFDTEECMAVCGSA 60

QY 61 I 61  
DB 61 I 61

RESULT 10  
US-10-076-604-223  
Sequence 223, Application US/10076604  
Publication No. US20030114372A1  
GENERAL INFORMATION:  
APPLICANT: White, Tyler R.  
Dam, Deborah  
Lesikar, David D.  
McFadden, Kathleen  
Garrick, Brett L.  
TITLE OF INVENTION: PROTEASE INHIBITOR PEPTIDES  
NUMBER OF SEQUENCES: 228  
CORRESPONDENCE ADDRESS:  
ADDRESSEE: Foley & Lardner  
STREET: 3000 K Street, N.W., Suite 500  
CITY: Washington  
STATE: D.C.  
COUNTRY: USA  
ZIP: 20007-5109  
COMPUTER READABLE FORM:  
MEDIUM TYPE: floppy disk  
COMPUTER: IBM PC compatible  
OPERATING SYSTEM: PC-DOS/MS-DOS  
SOFTWARE: Patentin Release #1.0, Version #1.30  
CURRENT APPLICATION DATA:  
APPLICATION NUMBER: US/10/076,604  
FILING DATE: 19-Feb-2002  
PRIOR APPLICATION DATA:  
APPLICATION NUMBER: US/09/201,715  
FILING DATE: 01-Dec-1998  
APPLICATION NUMBER: US 08/436,555  
FILING DATE: 08-MAY-1995  
ATTORNEY/AGENT INFORMATION:  
NAME: Pelto, Don J.  
REGISTRATION NUMBER: 33,754  
REFERENCE/DOCKET NUMBER: 56324/117  
TELECOMMUNICATION INFORMATION:  
TELEPHONE: (202) 672-5300  
TELEFAX: (202) 672-5399  
TELEX: 904136  
INFORMATION FOR SEQ ID NO: 223:  
SEQUENCE CHARACTERISTICS:  
LENGTH: 61 amino acids  
TYPE: amino acid  
STRANDEDNESS: single  
TOPOLOGY: linear  
MOLECULE TYPE: protein  
SEQUENCE DESCRIPTION: SEQ ID NO: 223:  
US-10-076-604-223

Query Match 97.4%; Score 342; DB 14; Length 61;  
Best Local Similarity 96.7%; Pred. No. 1.5e-34;  
Matches 59; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1 EVVREVCSEQAETGCPRAIYHWYFDVTEGKCAPFFYGGCGGNRRNFDTEECMAVCGSA 60

Db 1 EVREVCSEQAETGPCRLIYHWFDYTEGKCAPFFYGGCGGNRNNFTDEYCMAYCGSA 60  
QY 61 I 61  
Db 61 I 61

## RESULT 11

US-10-076-604-204  
; Sequence 204, Application US/10076604  
; Publication No. US20030114372A1  
; GENERAL INFORMATION:  
; APPLICANT: White, Tyler R.  
; Damu, Deborah  
; Lesikar, David D.  
; McFadden, Kathleen  
; Garrick, Brett L.  
; TITLE OF INVENTION: PROTEASE INHIBITOR PEPTIDES  
; NUMBER OF SEQUENCES: 228  
; CORRESPONDENCE ADDRESS:  
; ADDRESSEE: Foley & Lardner  
; STREET: 3000 K Street, N.W., Suite 500  
; CITY: Washington  
; STATE: D.C.  
; COUNTRY: USA  
; ZIP: 20007-5109  
; COMPUTER READABLE FORM:  
; MEDIUM TYPE: Floppy disk  
; COMPUTER: IBM PC compatible  
; OPERATING SYSTEM: PC-DOS/MS-DOS  
; SOFTWARE: Patent in Release #1.0, Version #1.30  
; CURRENT APPLICATION DATA:  
; APPLICATION NUMBER: US/10/076.604  
; FILING DATE: 19-Feb-2002  
; PRIOR APPLICATION DATA:  
; APPLICATION NUMBER: US/09/201.715  
; FILING DATE: 01-Dec-1998  
; APPLICATION NUMBER: US 08/436,555  
; FILING DATE: 08-MAY-1995  
; ATTORNEY/AGENT INFORMATION:  
; NAME: Pelto, Don J.  
; REGISTRATION NUMBER: 33,754  
; REFERENCE/DOCKET NUMBER: 56324/117  
; TELECOMMUNICATION INFORMATION:  
; TELEPHONE: (202) 672-5300  
; TELEFAX: (202) 672-5399  
; TELEX: 904136  
; INFORMATION FOR SEQ ID NO: 204:  
; SEQUENCE CHARACTERISTICS:  
; LENGTH: 61 amino acids  
; TYPE: amino acid  
; STRANDEDNESS: single  
; TOPOLOGY: linear  
; MOLECULE TYPE: protein  
; SEQUENCE DESCRIPTION: SEQ ID NO: 204:  
US-10-076-604-204

Query Match 97.2%; Score 341; DB 14; Length 61;  
Best Local Similarity 96.7%; Pred. No. 2e-34;  
Matches 59; Conservative 1; Mismatches 1; Indels 0; Gaps 0;  
QY 1 EVREVCSEQAETGPCRAIYHWFDYTEGKCAPFFYGGCGGNRNNFTDEYCMAYCGSA 60  
Db 1 EVREVCSEQAETGPCRLIYHWFDYTEGKCAPFFYGGCGGNRNNFTDEYCMAYCGSA 60  
QY 61 I 61  
Db 61 I 61

RESULT 12  
US-10-076-604-215  
; Sequence 215, Application US/10076604

; Publication No. US20030114372A1

; GENERAL INFORMATION:

; APPLICANT: White, Tyler R.

; Damu, Deborah

; Lesikar, David D.

; McFadden, Kathleen

; Garrick, Brett L.

; TITLE OF INVENTION: PROTEASE INHIBITOR PEPTIDES

; NUMBER OF SEQUENCES: 228

; CORRESPONDENCE ADDRESS:

; ADDRESSEE: Foley & Lardner

; STREET: 3000 K Street, N.W., Suite 500

; CITY: Washington

; STATE: D.C.

; COUNTRY: USA

; ZIP: 20007-5109

; COMPUTER READABLE FORM:

; MEDIUM TYPE: Floppy disk

; COMPUTER: IBM PC compatible

; OPERATING SYSTEM: PC-DOS/MS-DOS

; SOFTWARE: Patent in Release #1.0, Version #1.30

; CURRENT APPLICATION DATA:

; APPLICATION NUMBER: US/10/076.604

; FILING DATE: 19-Feb-2002

; PRIOR APPLICATION DATA:

; APPLICATION NUMBER: US/09/201.715

; FILING DATE: 01-Dec-1998

; APPLICATION NUMBER: US 08/436,555

; FILING DATE: 08-MAY-1995

; ATTORNEY/AGENT INFORMATION:

; NAME: Pelto, Don J.

; REGISTRATION NUMBER: 33,754

; REFERENCE/DOCKET NUMBER: 56324/117

; TELECOMMUNICATION INFORMATION:

; TELEPHONE: (202) 672-5300

; TELEFAX: (202) 672-5399

; TELEX: 904136

; INFORMATION FOR SEQ ID NO: 215:

; SEQUENCE CHARACTERISTICS:

; LENGTH: 61 amino acids

; TYPE: amino acid

; STRANDEDNESS: single

; TOPOLOGY: linear

; MOLECULE TYPE: protein

; SEQUENCE DESCRIPTION: SEQ ID NO: 215:

US-10-076-604-215

Query Match 97.2%; Score 341; DB 14; Length 61;  
Best Local Similarity 96.7%; Pred. No. 2e-34;  
Matches 59; Conservative 0; Mismatches 2; Indels 0; Gaps 0;  
QY 1 EVREVCSEQAETGPCRAIYHWFDYTEGKCAPFFYGGCGGNRNNFTDEYCMAYCGSA 60  
Db 1 EVREVCSEQAETGPCRLIYHWFDYTEGKCAPFFYGGCGGNRNNFTDEYCMAYCGSA 60  
QY 61 I 61  
Db 61 I 61

## RESULT 13

US-10-076-604-219

; Sequence 219, Application US/10076604

; Publication No. US20030114372A1

; GENERAL INFORMATION:

; APPLICANT: White, Tyler R.

; Damu, Deborah

; Lesikar, David D.

; McFadden, Kathleen

; Garrick, Brett L.

; TITLE OF INVENTION: PROTEASE INHIBITOR PEPTIDES

; NUMBER OF SEQUENCES: 228

; CORRESPONDENCE ADDRESS:



ADDRESSEE: Foley & Lardner  
STREET: 3000 K Street, N.W., Suite 500  
CITY: Washington  
STATE: D.C.  
COUNTRY: USA  
ZIP: 20007-5109  
COMPUTER READABLE FORM:  
MEDIUM TYPE: Floppy disk  
COMPUTER: IBM PC compatible  
OPERATING SYSTEM: PC-DOS/MS-DOS  
SOFTWARE: Patentin Release #1.0, Version #1.30  
CURRENT APPLICATION DATA:  
APPLICATION NUMBER: US/10/076,604  
FILING DATE: 19-Feb-2002  
PRIOR APPLICATION DATA:  
APPLICATION NUMBER: US/09/201,715  
FILING DATE: 01-Dec-1998  
APPLICATION NUMBER: US 08/436,555  
FILING DATE: 08-MAY-1995  
ATTORNEY/AGENT INFORMATION:  
NAME: Pelco, Don J.  
REGISTRATION NUMBER: 33,754  
REFERENCE/DOCKET NUMBER: 56324/117  
TELECOMMUNICATION INFORMATION:  
TELEPHONE: (202) 672-5300  
TELEFAX: (202) 672-5399  
TELEX: 904136  
INFORMATION FOR SEQ ID NO: 219:  
SEQUENCE CHARACTERISTICS:  
LENGTH: 61 amino acids  
TYPE: amino acid  
STRANDEDNESS: single  
TOPOLOGY: linear  
MOLECULE TYPE: protein  
SEQUENCE DESCRIPTION: SEQ ID NO: 219:  
US-10-076-604-219  
Query Match 96.9%; Score 340; DB 14; Length 61;  
Best Local Similarity 96.7%; Pred. No. 2,6e-34;  
Matches 59; Conservative 0; Mismatches 2; Indels 0; Gaps 0;  
QY 1 EVVRVCSQAETGPGRAIYHWYFDVTEGKCAFFYGGCGGNRNFTDEEYCAVCGSA 60  
DB 1 EVVRVCSQAETGPGRAIYHWYFDVTEGKCAFFYGGCGGNRNFTDEEYCAVCGSA 60  
QY 61 I 61  
DB 61 I 61  
RESULT 14  
US-10-076-604-171  
Sequence 171, Application US/10076604  
Publication No. US20030114372A1  
GENERAL INFORMATION:  
APPLICANT: White, Tyler R.  
Damm, Deborah  
Lesikar, David D.  
McFadden, Kathleen  
Garrick, Brett L.  
TITLE OF INVENTION: PROTEASE INHIBITOR PEPTIDES  
NUMBER OF SEQUENCES: 228  
CORRESPONDENCE ADDRESS:  
ADDRESSEE: Foley & Lardner  
STREET: 3000 K Street, N.W., Suite 500  
CITY: Washington  
STATE: D.C.  
COUNTRY: USA  
ZIP: 20007-5109  
COMPUTER READABLE FORM:  
MEDIUM TYPE: Floppy disk  
COMPUTER: IBM PC compatible  
OPERATING SYSTEM: PC-DOS/MS-DOS  
SOFTWARE: Patentin Release #1.0, Version #1.30  
CURRENT APPLICATION DATA:  
APPLICATION NUMBER: US/10/076,604  
FILING DATE: 19-Feb-2002  
PRIOR APPLICATION DATA:  
APPLICATION NUMBER: US/09/201,715  
FILING DATE: 01-Dec-1998  
APPLICATION NUMBER: US 08/436,555  
FILING DATE: 08-MAY-1995  
ATTORNEY/AGENT INFORMATION:  
NAME: Pelco, Don J.  
REGISTRATION NUMBER: 33,754  
REFERENCE/DOCKET NUMBER: 56324/117  
TELECOMMUNICATION INFORMATION:  
TELEPHONE: (202) 672-5300  
TELEFAX: (202) 672-5399  
TELEX: 904136  
INFORMATION FOR SEQ ID NO: 171:  
SEQUENCE CHARACTERISTICS:  
LENGTH: 61 amino acids  
TYPE: amino acid  
STRANDEDNESS: single  
TOPOLOGY: linear  
MOLECULE TYPE: protein  
SEQUENCE DESCRIPTION: SEQ ID NO: 171:  
US-10-076-604-171

SOFTWARE: Patentin Release #1.0, Version #1.30  
CURRENT APPLICATION DATA:  
APPLICATION NUMBER: US/10/076,604  
FILING DATE: 19-Feb-2002  
PRIOR APPLICATION DATA:  
APPLICATION NUMBER: US/09/201,715  
FILING DATE: 01-Dec-1998  
APPLICATION NUMBER: US 08/436,555  
FILING DATE: 08-MAY-1995  
ATTORNEY/AGENT INFORMATION:  
NAME: Pelco, Don J.  
REGISTRATION NUMBER: 33,754  
REFERENCE/DOCKET NUMBER: 56324/117  
TELECOMMUNICATION INFORMATION:  
TELEPHONE: (202) 672-5300  
TELEFAX: (202) 672-5399  
TELEX: 904136  
INFORMATION FOR SEQ ID NO: 171:  
SEQUENCE CHARACTERISTICS:  
LENGTH: 61 amino acids  
TYPE: amino acid  
STRANDEDNESS: single  
TOPOLOGY: linear  
MOLECULE TYPE: protein  
SEQUENCE DESCRIPTION: SEQ ID NO: 171:  
US-10-076-604-171  
Query Match 96.6%; Score 339; DB 14; Length 61;  
Best Local Similarity 96.7%; Pred. No. 3,5e-34;  
Matches 59; Conservative 1; Mismatches 1; Indels 0; Gaps 0;  
QY 1 EVVRVCSQAETGPGRAIYHWYFDVTEGKCAFFYGGCGGNRNFTDEEYCAVCGSA 60  
DB 1 EVVRVCSQAETGPGRAIYHWYFDVTEGKCAFFYGGCGGNRNFTDEEYCAVCGSA 60  
QY 61 I 61  
DB 61 I 61  
RESULT 15  
US-10-076-604-178  
Sequence 178, Application US/10076604  
Publication No. US20030114372A1  
GENERAL INFORMATION:  
APPLICANT: White, Tyler R.  
Damm, Deborah  
Lesikar, David D.  
McFadden, Kathleen  
Garrick, Brett L.  
TITLE OF INVENTION: PROTEASE INHIBITOR PEPTIDES  
NUMBER OF SEQUENCES: 228  
CORRESPONDENCE ADDRESS:  
ADDRESSEE: Foley & Lardner  
STREET: 3000 K Street, N.W., Suite 500  
CITY: Washington  
STATE: D.C.  
COUNTRY: USA  
ZIP: 20007-5109  
COMPUTER READABLE FORM:  
MEDIUM TYPE: Floppy disk  
COMPUTER: IBM PC compatible  
OPERATING SYSTEM: PC-DOS/MS-DOS  
SOFTWARE: Patentin Release #1.0, Version #1.30  
CURRENT APPLICATION DATA:  
APPLICATION NUMBER: US/10/076,604  
FILING DATE: 19-Feb-2002  
PRIOR APPLICATION DATA:  
APPLICATION NUMBER: US/09/201,715  
FILING DATE: 01-Dec-1998  
APPLICATION NUMBER: US 08/436,555  
FILING DATE: 08-MAY-1995  
ATTORNEY/AGENT INFORMATION:

NAME: Peltó, Don J.  
 REGISTRATION NUMBER: 33,754  
 REFERENCE/DOCKET NUMBER: 56324/117  
 TELECOMMUNICATION INFORMATION:  
 TELEPHONE: (202)672-5300  
 TELEFAX: (202)672-5399  
 TELEX: 904136  
 INFORMATION FOR SEQ ID NO: 178:  
 SEQUENCE CHARACTERISTICS:  
 LENGTH: 61 amino acids  
 TYPE: amino acid  
 STRANDEDNESS: single  
 TOPOLOGY: linear  
 MOLECULE TYPE: protein  
 SEQUENCE DESCRIPTION: SEQ ID NO: 178:  
 US-10-076-604-178

Query Match 96.6%; Score 339; DB 14; Length 61;  
 Best Local Similarity 96.7%; Pred. No. 3.5e-34;  
 Matches 59; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1 EVREAVCSQAETPCRAIYHWYFDVTEGKCAPFFYGGCGGNRNPFTEYCMAYCGSA 60  
 DB 1 EVREAVCSQAETPCRAIYHWYFDVTEGKCAPFFYGGCGGNRNPFTEYCMAYCGSA 60  
 QY 61 I 61  
 DB 61 I 61

Search completed: April 8, 2004, 09:31:21  
 Job time : 40 secs

GenCore version 5.1.6  
Copyright (c) 1993 - 2004 CompuGen Ltd.

OM protein - protein search, using sw model

Run on: April 8, 2004, 09:31:26 ; Search time 21 Seconds

(without alignments)  
279.413 Million cell updates/sec

Title: US-10-076-604-208

Perfect score: 351

Sequence: 1 EVREVCSEQAETGPCRAI.....GNRNNFTEYCAVCGSAI 61

Scoring table: BLOSUM62

Gapop 10.0 , Gapext 0.5

Searched: 283366 segs, 96191526 residues

Total number of hits satisfying chosen parameters: 283366

Minimum DB seq length: 0

Maximum DB seq length: 2000000000

Post-processing: Minimum Match 0%

Maximum Match 100%

Listing first 45 summaries

Database :

1: PIR.78:\*

2: PIR.78:\*

3: PIR.78:\*

4: PIR.78:\*

Pred. No. is the number of results predicted by chance to have a score greater than or equal to the score of the result being printed, and is derived by analysis of the total score distribution.

#### SUMMARIES

Result No.	Score	Query Match	Length	DB ID	Description
1	329	93.7	484	4 A32761	hypothetical Alzhe
2	326	92.9	770	1 ORHUA4	Alzheimer's disease
3	317	90.3	100	2 A32282	Alzheimer's disease
4	304	86.6	76	2 S06778	Alzheimer's disease
5	303	85.2	76	2 S03607	Alzheimer's disease
6	299	85.2	76	2 S04855	Alzheimer's disease
7	288	82.1	747	2 JH0773	Alzheimer's disease
8	238	67.8	751	2 A49974	beta-amyloid precu
9	238	67.8	763	2 A49321	amyloid beta (A4)
10	238	67.8	765	2 S42880	amyloid precursor
11	236	67.2	111	2 S41082	amyloid precursor
12	168	47.9	55	2 S30332	proteinase inhibit
13	161	45.9	252	2 JG0185	hepatocyte growth
14	160	45.6	2225	2 T26063	hypothetical prote
15	158	45.0	58	1 TIRHAK	isochlorin K (BP
16	157	44.7	1558	2 C89114	protein C37C3.6a
17	157	44.7	2167	2 T34395	hypothetical prote
18	155	44.2	3137	2 A37797	collagen alpha 3(V
19	145	43.9	57	2 S10063	isoprotein G2 -
20	133	43.6	68	2 TIRBOC	trypsin inhibitor,
21	153	43.6	100	1 TIRBO	basic proteinase i
22	153	43.6	302	1 TIRTKG	tissue factor path
23	151	43.0	1965	2 T33216	hypothetical prote
24	150	42.7	60	1 TIRVU2	venom basic protei
25	150	42.7	123	2 A28652	inter-alpha-trypsi
26	148	42.2	59	2 S00371	isoprotein G1 -
27	148	42.2	352	1 TIRBOI	alpha-1-microglobu
28	147	41.9	337	1 TIRGBI	alpha-1-microglobu
29	147	41.9	349	2 S35708	alpha-1-microglobu

30	146	41.6	62	2 S07451	proteinase inhibit
31	145	41.5	3176	2 C8H3A	collagen alpha 3(V
32	145	41.3	64	2 S41399	kunitz-type protei
33	144	41.0	60	1 TIRBOR	serum basic protei
34	143	40.7	349	2 S21089	alpha-1-microglobu
35	143	40.7	352	1 HCHU	alpha-1-microglobu
36	142	40.5	100	1 TIRBOP	spleen basic prote
37	142	40.5	125	1 TIRBOI	alpha-1-microglobu
38	142	40.5	304	1 JG2264	tissue factor path
39	142	40.5	1743	2 T26859	hypothetical prote
40	140	39.9	249	2 T26060	hypothetical prote
41	139	39.6	396	2 S53325	tissue factor path
42	138	39.3	61	1 TIRVIT1	venom basic protei
43	138	39.3	304	1 TIRHUK	tissue factor path
44	137	39.0	2150	2 T32497	hypothetical prote
45	136	38.7	110	1 TITTOR	basic proteinase i

#### ALIGNMENTS

RESULT 1  
A32761  
hypothetical Alzheimer's disease amyloid beta protein, Alu-containing clone - human (fr  
C:Species: Homo sapiens (man)  
C:Date: 29-Jan-1990 #sequence\_revision 10-Apr-1996 #text\_change 10-Apr-1996  
C:Accession: A32761  
Ride Sauvage, F.; Octave, J.N.  
Science 245, 651-653, 1989  
A>Title: A novel mRNA of the A4 amyloid precursor gene coding for a possibly secreted f  
A:Reference number: A32761; MUID:89346754; PMID:2569763  
A:Accession: A32761  
A:Molecule type: mRNA  
A:Residues: 1-484 <DB>  
A:Cross-references: GB:M28373  
A:Note: the authors translated the codon ATG for residue 433 as Leu  
C:Comment: This is the hypothetical translation of a sequence believed to contain cloni  
C:Keywords: cloning artifact

Query Match 93.7%; Score 329; DB 4; Length 484;  
Best Local Similarity 95.1%; Pred. No. 1,7e-30;  
Matches 58; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 1 EVREVCSEQAETGPCRAIYHYFDTGKCAPEFYGGGNNRNNFTEYCAVCGSA 60  
DB 206 EVREVCSEQAETGPCRAIYHYFDTGKCAPEFYGGGNNRNNFTEYCAVCGSA 265

QY 61 I 61  
DB 266 I 266

#### RESULT 2

Q8HUA4  
Alzheimer's disease amyloid beta protein precursor [validated] - human  
N:Alternate names: Alzheimer's disease amyloid A4 protein; coagulation factor XIIa inhib  
N:Contents: amyloid beta protein long; plaque form; amyloid beta protein short; vascula  
protein precursor splice form APP(770)  
C:Species: Homo sapiens (man)  
C:Date: 30-Jun-1987 #sequence\_revision 28-Jul-1995 #text\_change 15-Sep-2000  
C:Accession: S02260; S05194; A32277; A32601; A35486; I39452; I39451; I39453; I59562; A4  
4681; A28583; A29302; A60805; S06121; A60355; A59011; A38364; S29076; S38252; S  
N:Lemmaire, H.G.; Salbaum, J.M.; Multaup, G.; Kang, J.; Bayney, R.M.; Unterbeck, A.; Be  
Nucleic Acids Res. 17, 517-522, 1989  
A>Title: The Pread(695) precursor protein of Alzheimer's disease A4 amyloid is encoded  
A:Reference number: S02260; MUID:89128427; PMID:2783775  
A:Accession: S02260  
A:Molecule type: DNA  
A:Residues: 1-288; V, 365-770 <LEMI>  
A:Cross-references: EMBL:X13466  
A:Note: alternative splice form APP(695)  
R:Lemmaire, H.G.  
submitted to the EMBL Data Library, November 1988

A/Reference number: S05194  
A/Accession: S05194  
A/Molecule type: DNA  
A/Residues: 1-14, 'V', 17-288, 'V', 365-770 <LEN2>  
A/Cross-references: EMBL:X13466; NID:G35598; PIDN:CAA31830.1; PID:G871360  
A/Note: alternative splice form APP(695)  
A/Rita Fauci, G.J. Lahiri, D.K. Salton, S.R.J. Robak, N.K.  
Biochem. Biophys. Res. Commun. 159, 297-304, 1989  
A/Title: Characterization of the 5' end region and the first two exons of the beta-protein  
A/Reference number: A32277; MUID:8916870; PMID:2538123  
A/Accession: A32277  
A/Molecule type: DNA  
A/Residues: 1-75 <IAF>  
A/Cross-references: GB:M2546; GB:M2547; NID:G341202; PIDN:AA31654.1; PID:G516074  
A/Johnson, E.M.; Chaney, M.O.; Moore, R.E.; Ward, K.E.; Norris, F.H.; Little, S.P.  
Biochem. Biophys. Res. Commun. 163, 1248-1255, 1989  
A/Title: Alzheimer's disease amyloid peptide is encoded by two exons and shows similarity  
A/Reference number: A32860; MUID:89392030; PMID:2675837  
A/Accession: A32860  
A/Molecule type: DNA  
A/Residues: 656-737 <JOH>  
A/Cross-references: GB:M29270; NID:G178863; PIDN:AA51768.1; PID:G178865  
A/Pirelli, F.; Levy, E.; Van Duijn, S.G.; Bots, G.T.A.M.; Luyendijk, W.; Frangione, B.  
Biochem. Biophys. Res. Commun. 170, 301-307, 1990  
A/Title: Expression of a normal and variant Alzheimer's beta-protein gene in amyloid of  
A/Reference number: A35486; MUID:90321244; PMID:2156878  
A/Accession: A35486  
A/Molecule type: DNA  
A/Residues: 672-710 <PREL>  
A/Note: 693-Gln was found in DNA isolated from HCHWA-D patients  
A/Yoshikaki, S.I.; Sasaki, H.; Doh-ura, K.; Furuya, H.; Sasaki, Y.  
Gene 87, 257-263, 1990  
A/Title: Genomic organization of the human amyloid beta-protein precursor gene.  
A/Reference number: I39451; MUID:90236318; PMID:2110105  
A/Accession: I39451  
A/Status: nucleic acid sequence not shown; translation not shown; translated from GB/EMBL  
A/Molecule type: DNA  
A/Residues: 1-770 <YOS1>  
A/Cross-references: GB:M33112; NID:G178613; PIDN:AA55502.1; PID:G178616  
A/Accession: I39451  
A/Status: nucleic acid sequence not shown; translation not shown; translated from GB/EMBL  
A/Molecule type: DNA  
A/Residues: 1-530, 'QW', MPV1PAFWKAVGR, <YOS2>  
A/Cross-references: GB:M34875; NID:G178608; PIDN:AA55501.1; PID:G178615  
A/Yoshikaki, S.I.; Sasaki, H.; Doh-ura, K.; Furuya, H.; Sasaki, Y.  
Gene 102, 291-292, 1991  
A/Reference number: A59020; MUID:91340168; PMID:1908403  
A/Contents: annotation; extratum  
A/Note: revised physical map for reference I39451  
A/Riley, E.; Caman, M.D.; Fernandez-Madrid, I.J.; Power, M.D.; Lieberburg, I.; van Duijn  
Science 248, 1124-1126, 1990  
A/Title: Mutation of the Alzheimer's disease amyloid gene in hereditary cerebral hemorrhage  
A/Reference number: I39453; MUID:90260665; PMID:2111584  
A/Accession: I39453  
A/Status: translated from GB/EMBL/DBJ  
A/Molecule type: DNA  
A/Residues: 656-737 <LEV>  
A/Cross-references: GB:M37896; NID:G178618; PIDN:AA51727.1; PID:G178620  
A/Note: a mutation with 693-Gln is presented  
A/Murrell, J.; Farlow, M.; Chetti, B.; Benson, M.D.  
Science 254, 97-99, 1991  
A/Title: A mutation in the amyloid precursor protein associated with hereditary Alzheimer  
A/Reference number: I59562; MUID:92022553; PMID:1925564  
A/Accession: I59562  
A/Status: translated from GB/EMBL/DBJ  
A/Molecule type: DNA  
A/Residues: 689-716, 'F', 718-737 <MUR>  
A/Cross-references: GB:S57665; NID:G236720; PIDN:AA31999.1; PID:G236721  
A/Kimino, K.; Orr, H.T.; Beyam, S.; Wiseman, E.M.; Alonso, M.E.; Fuld, S.M.; Anderson,  
A/Stratton, S.E.; Korzenberg, J.R.; Sharma, V.; Kukull, W.; Larson, E.; Heaton, L.L.; Martin,  
A/Hum. Genet. 51, 998-1014, 1992  
A/Title: Linkage and mutational analysis of familial Alzheimer disease kindreds for the  
A/Reference number: A44017; MUID:93053537; PMID:1415269

A/Accession: A44017  
A/Molecule type: DNA  
A/Residues: 687-692, 'G', 694-718 <KAM1>  
A/Cross-references: GB:S45135; NID:G257377; PIDN:AA32645.1; PID:G257378  
A/Experimental source: familial Alzheimer disease family GB  
A/Note: sequence extracted from NCBI backbone (NCBI:115374)  
A/Accession: B44017  
A/Molecule type: DNA  
A/Residues: 687-718 <KAM2>  
A/Cross-references: GB:S45136; NID:G257379; PIDN:AA32646.1; PID:G257380  
A/Experimental source: familial Alzheimer disease family IT  
A/Note: sequence extracted from NCBI backbone (NCBI:115376)  
A/Rang, U.; Lemstra, H.G.; Unterbeck, A.; Salbaum, J.M.; Masters, C.L.; Grzeschik, K.H.  
Nature 325, 733-736, 1987  
A/Title: The precursor of Alzheimer's disease amyloid A4 protein resembles a cell-surf.  
A/Reference number: A03134; MUID:87144572; PMID:2881207  
A/Accession: A03134  
A/Molecule type: mRNA  
A/Residues: 1-288, 'V', 365-770 <KAN>  
A/Cross-references: GB:Y00264; NID:G28525; PIDN:CAA68374.1; PID:G28526  
A/Note: alternative splice form APP(695)  
A/Robak, N.K.; Ramakrishna, N.; Wolfe, G.; Wisniewski, H.M.  
Proc. Natl. Acad. Sci. U.S.A. 84, 4190-4194, 1987  
A/Title: Molecular cloning and characterization of a cDNA encoding the cerebrovascular  
A/Reference number: A29030; MUID:87231971; PMID:3035574  
A/Accession: A29030  
A/Molecule type: mRNA  
A/Residues: 284-288, 'V', 365-646, 'E', 648-770 <ROB>  
A/Cross-references: GB:M6765; NID:G178539; PIDN:AA51722.1; PID:G178540  
A/Note: the authors translated the codon GAG for residue 647 as Asp  
A/Goldgaber, D.; Lerman, M.I.; McBride, O.W.; Saffioti, U.; Gajdusek, D.C.  
Science 235, 877-880, 1987  
A/Title: Characterization and chromosomal localization of a cDNA encoding brain amyloid  
A/Reference number: A47584; MUID:87120328; PMID:3810169  
A/Accession: A47584  
A/Molecule type: mRNA  
A/Residues: 674-756, 'S', 758-770 <GOL>  
A/Cross-references: GB:M15533; NID:G178706; PIDN:AA5540.1; PID:G178707  
A/Experimental source: brain  
A/Ranzi, R.E.; Gusella, J.F.; Watkins, P.C.; Bruns, G.A.P.; St George-Hyslop, P.; Van  
Science 235, 880-884, 1987  
A/Title: Amyloid beta protein gene: cDNA, mRNA distribution, and genetic linkage near  
A/Reference number: A47585; MUID:87120329; PMID:2949367  
A/Accession: A47585  
A/Molecule type: mRNA  
A/Residues: 674-703 <TAN1>  
A/Cross-references: GB:M15532; NID:G177957; PIDN:AA51564.1; PID:G177958  
A/Experimental source: brain  
A/Ranzi, R.E.; Weidemann, A.; Multhaup, G.; Salbaum, J.M.; Lemstra, H.G.; Kang, J.; Muel  
EMBO J. 7, 949-957, 1988  
A/Title: Identification, transmembrane orientation and biogenesis of the amyloid A4 pre  
A/Reference number: S02638; MUID:88296437; PMID:2900137  
A/Accession: S02638  
A/Molecule type: mRNA  
A/Residues: 672-678 <DYR>  
A/Ranzi, R.E.; McClatchey, A.I.; Lampert, E.D.; Valla-Komarov, L.; Gusella, J.F.; Ne  
Nature 331, 528-530, 1988  
A/Title: Protease inhibitor domain encoded by an amyloid protein precursor mRNA associ  
A/Reference number: S00707; MUID:88122640; PMID:2853290  
A/Accession: S00707  
A/Molecule type: mRNA  
A/Residues: 286-344, 'I', 365-366 <TAN2>  
A/Cross-references: EMBL:X06982; NID:G28817; PIDN:CAA30042.1; PID:G929612  
A/Experimental source: promyelocytic leukemia cell line HL60  
A/Note: alternative splice form APP(751)  
A/Ponte, P.; Gonzalez-Dehert, P.; Schilling, J.; Miller, J.; Heu, D.; Greenberg, B.; I  
Nature 331, 525-527, 1988  
A/Title: A new A4 amyloid mRNA contains a domain homologous to serine proteinase inhibi  
A/Reference number: S00925; MUID:88122639; PMID:2853289  
A/Accession: S00925  
A/Molecule type: mRNA  
A/Residues: 1-344, 'I', 365-770 <PO2>  
A/Cross-references: GB:X06989; EMBL:Y00297; NID:G28720; PIDN:CAA30050.1; PID:G28721

A/Note: alternative splice form APP(751)  
 R:Kitsaguchi, N.; Takahashi, Y.; Tokushima, Y.; Shiojiri, S.; Ito, H.  
 Nature 331, 530-532, 1988  
 A/Title: Novel precursor of Alzheimer's disease amyloid protein shows protease inhibitor  
 A/Reference number: A38949; MUID:88122641; PMID:2893291  
 A/Accession: A38949  
 A/Molecule type: mRNA  
 A/Residues: 287-367 <KIT>  
 A/Cross-references: GB:X06981; NID:928916; PIDN:CAA30041.1; PID:9329611  
 A/Experimental source: glioblastoma cell line  
 A/Note: Alternative splice form APP(770)  
 R:Vitek, M.P.; Rasool, C.G.; de Sauvage, F.; Vitek, S.M.; Bartus, R.T.; Beer, B.; Ashor  
 Brain Res. Mol. Brain Res. 4, 121-131, 1988  
 A/Title: Absence of mutation in the beta-amyloid CDNs cloned from the brains of three F  
 A/Reference number: A30320  
 A/Accession: A30320  
 A/Molecule type: not compared with conceptual translation  
 A/Status: not compared with conceptual translation  
 A/Molecule type: mRNA  
 A/Residues: 284-288, 'V', 365-770 <VIT1>  
 A/Accession: B30320  
 A/Status: not compared with conceptual translation  
 A/Molecule type: mRNA  
 A/Residues: 122-288, 'V', 365-770 <VIT2>  
 A/Accession: C30320  
 A/Status: not compared with conceptual translation  
 A/Molecule type: mRNA  
 A/Residues: 606-770 <VIT3>  
 A/Accession: A31087  
 A/Title: Molecular cloning of amyloid cDNA derived from mRNA of the Alzheimer disease br  
 A/Reference number: A31087; MUID:88124954; PMID:2893379  
 A/Accession: A31087  
 A/Molecule type: mRNA  
 A/Residues: 507-770 <ZAI>  
 A/Cross-references: GB:M18734; NID:9178572; PIDN:AAA1176.1; PID:9178573  
 A/Note: the authors translated the codon GAA for residue 599 as Gly, ACC for residue 603  
 as Val, GTG for residue 609 as Asn, AAT for residue 610 as Gly, and GGT for residue 65  
 A/Note: the cited Genbank accession number, J03594, is not in release 101.0  
 R:Waters, C.L.; Multhaup, G.; Simms, G.; Potgiesser, J.; Martins, R.N.; Beyreuther, K.  
 Query Match 92.9%; Score 326; DB 1; Length 770;  
 Best Local Similarity 93.4%; Pred. No. 5.7e-30;  
 Matches 57; Conservative 1; Mismatches 3; Indels 0; Gaps 0;  
 QY 1 EVREVCSQAEITGPCRAAIYHWYFDVTEGKCAFFYGGCGGGRNNPDTBEYCAVCGSA 60  
 DB 285 EVREVCSQAEITGPCRAAIYHWYFDVTEGKCAFFYGGCGGGRNNPDTBEYCAVCGSA 344  
 QY 61 I 61  
 DB 345 M 345  
 RESULT 3  
 A32282  
 Alzheimer's disease amyloid beta protein precursor - mouse (fragment)  
 C/Species: Mus musculus (house mouse)  
 C/Date: 17-Aug-1989 #sequence\_revision 17-Aug-1989 #text\_change 13-Aug-1999  
 C/Accession: A32282  
 R:Yamada, T.; Sasaki, H.; Dohura, K.; Goto, I.; Sakaki, Y.  
 Biochem. Biophys. Res. Commun. 158, 906-912, 1989  
 A/Title: Structure and expression of the alternatively-spliced forms of mRNA for the mu  
 A/Reference number: A32282; MUID:89149813; PMID:2493250  
 A/Accession: A32282  
 A/Status: preliminary  
 A/Molecule type: mRNA  
 A/Residues: 1-100 <YAM>  
 A/Cross-references: GB:MA2397; NID:9200350; PIDN:AA33929.1; PID:9200351  
 C/Superfamily: Alzheimer's disease amyloid beta protein; animal Kunitz-type proteinase  
 C/Keywords: alternative splicing  
 F/1-61/Domain: animal Kunitz-type proteinase inhibitor homology <BPI>  
 Query Match 90.3%; Score 317; DB 2; Length 100;

Best Local Similarity 93.2%; Pred. No. 9.9e-30;  
 Matches 55; Conservative 0; Mismatches 4; Indels 0; Gaps 0;  
 QY 1 EVREVCSQAEITGPCRAAIYHWYFDVTEGKCAFFYGGCGGGRNNPDTBEYCAVCGS 59  
 DB 5 EVREVCSQAEITGPCRAAIYHWYFDVTEGKCAFFYGGCGGGRNNPDTBEYCAVCGS 63  
 RESULT 4  
 506678  
 Alzheimer's disease amyloid beta protein - rhesus macaque (fragment)  
 C/Species: Macaca mulatta (rhesus macaque)  
 C/Date: 28-Feb-1990 #sequence\_revision 28-Feb-1990 #text\_change 13-Aug-1999  
 C/Accession: S06678  
 R:Koo, E.H.; Sisodia, S.S.; Price, D.L.  
 submitted to the EMBL Data Library, July 1989  
 A/Reference number: S06678  
 A/Accession: S06678  
 A/Molecule type: mRNA  
 A/Residues: 1-76 <KOO>  
 A/Cross-references: EMBL:X15985; NID:938080; PIDN:CAA34116.1; PID:9380135  
 C/Superfamily: Alzheimer's disease amyloid beta protein; animal Kunitz-type proteinase  
 C/Keywords: alternative splicing; serine proteinase inhibitor  
 F/3-53/Domain: animal Kunitz-type proteinase inhibitor homology <BPI>  
 Query Match 86.6%; Score 304; DB 2; Length 76;  
 Best Local Similarity 91.2%; Pred. No. 2.5e-28;  
 Matches 52; Conservative 1; Mismatches 4; Indels 0; Gaps 0;  
 QY 5 EVCSQAEITGPCRAAIYHWYFDVTEGKCAFFYGGCGGGRNNPDTBEYCAVCGSAI 61  
 DB 1 EVCSQAEITGPCRAAIYHWYFDVTEGKCAFFYGGCGGGRNNPDTBEYCAVCGSAV 57  
 RESULT 5  
 503607  
 Alzheimer's disease amyloid A4 protein - rat (fragment)  
 C/Species: Rattus norvegicus (Norway rat)  
 C/Date: 07-Sep-1990 #sequence\_revision 07-Sep-1990 #text\_change 13-Aug-1999  
 C/Accession: S03607  
 R:Kang, U.; Mueller-Hill, B.  
 Nucleic Acids Res. 17, 2130, 1989  
 A/Title: The sequence of the two extra exons in rat pA4.  
 A/Reference number: S03607; MUID:89183625; PMID:2648331  
 A/Accession: S03607  
 A/Molecule type: mRNA  
 A/Residues: 1-76 <KAN>  
 A/Cross-references: EMBL:X14066; NID:956957; PIDN:CAA32229.1; PID:9530262  
 C/Superfamily: Alzheimer's disease amyloid beta protein; animal Kunitz-type proteinase  
 C/Keywords: alternative splicing; serine proteinase inhibitor; transmembrane protein  
 F/3-53/Domain: animal Kunitz-type proteinase inhibitor homology <BPI>  
 Query Match 86.3%; Score 303; DB 2; Length 76;  
 Best Local Similarity 94.5%; Pred. No. 3.2e-28;  
 Matches 52; Conservative 0; Mismatches 3; Indels 0; Gaps 0;  
 QY 5 EVCSQAEITGPCRAAIYHWYFDVTEGKCAFFYGGCGGGRNNPDTBEYCAVCGS 59  
 DB 1 EVCSQAEITGPCRAAIYHWYFDVTEGKCAFFYGGCGGGRNNPDTBEYCAVCGS 55  
 RESULT 6  
 S04855  
 Alzheimer's disease amyloid A4 protein - mouse (fragment)  
 C/Species: Mus musculus domesticus (western European house mouse)  
 C/Date: 28-Feb-1990 #sequence\_revision 28-Feb-1990 #text\_change 13-Aug-1999  
 C/Accession: S04855  
 R:Fukuchi, K.I.; Martin, G.M.; Deeb, S.S.  
 Nucleic Acids Res. 17, 5396, 1989  
 A/Title: Sequence of the protease inhibitor domain of the A4 amyloid protein precursor  
 A/Reference number: S04855; MUID:89345111; PMID:2569710  
 A/Accession: S04855  
 A/Molecule type: mRNA



A:Reference number: S47528, MUID:94368849, PMID:8086458  
 A:Accession: S47528  
 A:Status: preliminary  
 A:Molecule type: mRNA  
 A:Residues: 1-765 <SA2>  
 A:Cross-references: EMBL:X77934  
 C:Superfamily: Alzheimer's disease amyloid beta protein; animal Kunitz-type proteinase inhibitor  
 C:Keywords: alternative splicing  
 F:312-362/Domain: animal Kunitz-type proteinase inhibitor homology <BPI>

Query Match 67.8%; Score 238; DB 2; Length 765;  
 Best Local Similarity 64.4%; Pred. No. 8.9e-20;  
 Matches 38; Conservative 11; Mismatches 10; Indels 0; Gaps 0;

QY 3 VREVCSEQAEITGPPRAAIYHWYFDVTEGKCAPFFYGGCGGNRNNDTEBYCMAVC 61  
 DB 308 VKAVCSQEAHTGPPRAIYHWYFDVTEGKCAPFFYGGCGGNRNNDTEBYCMAVC 366

## RESULT 11

S41082  
 amyloid precursor protein homolog - human (fragment)  
 C:Species: Homo sapiens (man)  
 C:Date: 25-Dec-1994 #sequence\_revision 03-Aug-1995 #text\_change 29-Aug-1997  
 C:Accession: S41082  
 R:Peterson, L.C.; Bjorn, S.E.; Norris, F.; Norris, K.; Sprecher, C.; Foster, D.C.  
 FEBS Lett. 338, 53-57, 1994  
 A:Title: Expression, purification and characterization of a Kunitz-type protease inhibitor  
 A:Reference number: S41082, MUID:94139895, PMID:8307156  
 A:Accession: S41082  
 A:Status: preliminary  
 A:Molecule type: DNA  
 A:Residues: 1-111 <PRT>  
 C:Superfamily: animal Kunitz-type proteinase inhibitor homology  
 F:59-109/Domain: animal Kunitz-type proteinase inhibitor homology <BPI>

Query Match 67.2%; Score 236; DB 2; Length 111;  
 Best Local Similarity 67.3%; Pred. No. 2.6e-20;  
 Matches 37; Conservative 10; Mismatches 8; Indels 0; Gaps 0;

QY 3 VREVCSEQAEITGPPRAAIYHWYFDVTEGKCAPFFYGGCGGNRNNDTEBYCMAVC 57  
 DB 55 VKAVCSQEAHTGPPRAIYHWYFDVTEGKCAPFFYGGCGGNRNNDTEBYCMAVC 109

## RESULT 12

S30332  
 proteinase inhibitor (Kunitz-type) - sea anemone (Stichodactyla helianthus)  
 C:Species: Stichodactyla helianthus, Stichodactis helianthus (Caribbean sea anemone)  
 C:Date: 19-Mar-1997 #sequence\_revision 19-Mar-1997 #text\_change 16-Jul-1999  
 C:Accession: S30332  
 R:Antuch, W.; Berndt, K.D.; Chavez, M.A.; Delfin, J.; Wuehrich, K.  
 Eur. J. Biochem. 212, 675-684, 1993  
 A:Title: The NMR solution structure of a Kunitz-type proteinase inhibitor from the sea  
 A:Reference number: S30332, MUID:93215644, PMID:8462542  
 A:Accession: S30332  
 A:Status: preliminary  
 A:Molecule type: protein  
 A:Residues: 1-55 <ANT>  
 C:Superfamily: basic proteinase inhibitor; animal Kunitz-type proteinase inhibitor homology  
 F:3-53/Domain: animal Kunitz-type proteinase inhibitor homology <BPI>

Query Match 47.9%; Score 168; DB 2; Length 55;  
 Best Local Similarity 51.9%; Pred. No. 1.1e-12;  
 Matches 27; Conservative 6; Mismatches 19; Indels 0; Gaps 0;

QY 6 VCSQEAETGPPRAAIYHWYFDVTEGKCAPFFYGGCGGNRNNDTEBYCMAVC 57  
 DB 2 ICSEPKVGRCKGVPRFVFDSETGKCTPFYGGCGGNRNNDTEBYCMAVC 53

## RESULT 13

JG0185

hepatocyte growth factor activator inhibitor type 2 - mouse  
 C:Species: Mus musculus (house mouse)  
 C:Date: 23-Jul-1999 #sequence\_revision 23-Jul-1999 #text\_change 11-May-2000  
 C:Accession: JG0185  
 R:Itou, H.; Katsoka, H.; Hamasuna, R.; Kitamura, N.; Kono, M.  
 Biochem. Biophys. Res. Commun. 255, 740-748, 1999  
 A:Title: Hepatocyte growth factor activator inhibitor type 2 lacking the first kunitz-  
 A:Reference number: JG0185, MUID:99160423, PMID:10049781  
 A:Accession: JG0185  
 A:Status: preliminary  
 A:Molecule type: mRNA  
 A:Residues: 1-252 <ITO>  
 A:Cross-references: GB:AF099016  
 C:Superfamily: animal Kunitz-type proteinase inhibitor homology  
 F:133-183/Domain: animal Kunitz-type proteinase inhibitor homology <BPI>

Query Match 45.9%; Score 161; DB 2; Length 252;  
 Best Local Similarity 45.5%; Pred. No. 2.7e-11;  
 Matches 25; Conservative 10; Mismatches 20; Indels 0; Gaps 0;

QY 3 VREVCSEQAEITGPPRAAIYHWYFDVTEGKCAPFFYGGCGGNRNNDTEBYCMAVC 57  
 DB 34 VHSQGVKVKCKRASIPRWYNTDSCQPFYGGCGGNRNNDTEBYCMAVC 88

## RESULT 14

T26063  
 hypothetical protein W01F3.3 - Caenorhabditis elegans  
 C:Species: Caenorhabditis elegans  
 C:Date: 15-Oct-1999 #sequence\_revision 15-Oct-1999 #text\_change 15-Oct-1999  
 C:Accession: T26063  
 R:Cummings, P.  
 submitted to the EMBL Data Library, March 1997  
 A:Reference number: Z20145  
 A:Accession: T26063  
 A:Status: preliminary; translated from GB/EMBL/DBJ  
 A:Molecule type: DNA  
 A:Residues: 1-225 <WIL>  
 A:Cross-references: EMBL:T29815; PIDN:CA07294.1; GSPDB:GN00023; CESP:W01F3.3  
 A:Experimental source: clone W01F3  
 C:Genetics:  
 A:Gene: CESP:W01F3.3  
 A:Map position: 5  
 A:Introns: 33/1; 56/1; 100/1; 142/3; 271/3; 451/1; 525/3; 774/1; 1093/1; 1178/1; 1221/1;

Query Match 45.6%; Score 160; DB 2; Length 225;  
 Best Local Similarity 47.3%; Pred. No. 2.6e-10;  
 Matches 26; Conservative 8; Mismatches 21; Indels 0; Gaps 0;

QY 3 VREVCSEQAEITGPPRAAIYHWYFDVTEGKCAPFFYGGCGGNRNNDTEBYCMAVC 57  
 DB 1119 IEEXKLGVEBPGKXNFRADRYFVVDGTCHPFYGGCGGNRNNDTEBYCMAVC 1173

## RESULT 15

THA8K  
 isoform inhibitor K (BPI type) - Roman snail  
 C:Species: Helix pomatia (Roman snail)  
 C:Date: 23-Oct-1981 #sequence\_revision 23-Oct-1981 #text\_change 05-Aug-1994  
 C:Accession: A91232; A01225  
 R:Tschesche, H.; Dietl, T.  
 Eur. J. Biochem. 58, 439-451, 1975  
 A:Title: The amino-acid sequence of isoform inhibitor K from snails (Helix pomatia). A sequ  
 A:Reference number: A91232; MUID:76043680; PMID:1183446  
 A:Accession: A91232  
 A:Molecule type: protein  
 A:Residues: 1-58 <TSC>  
 R:Dietl, T.; Tschesche, H.  
 Hoppe-Seyler's Z. Physiol. Chem. 357, 139-145, 1976  
 A:Title: Die Disulfidbruecken des Trypsin-Kalikrein-Inhibitoren K aus Weinbergsechnecker  
 A:Reference number: A91666; MUID:76141310; PMID:34462  
 A:Contents: annotation; disulfide bonds  
 C:Comment: This is one of several isoform inhibitors of broad specificity that are secreted





GenCore version 5.1.6  
Copyright (c) 1993 - 2004 Compugen Ltd.

OM protein - protein search, using sw model

Run on: April 8, 2004, 09:26:36 ; Search time 11 Seconds

(Without alignments)  
288.753 Million cell updates/sec

Title: US-10-076-604-208  
Perfect score: 351  
Sequence: 1 EVVRVVCSEQAETGPCRAI.....GNNNPDTEYCMAYCGSAI 61

Scoring table: BIOSUM62  
Gapop 10.0, Gapext 0.5

Searched: 141681 seqs, 52070155 residues

Total number of hits satisfying chosen parameters: 141681

Minimum DB seq length: 0

Maximum DB seq length: 2000000000

Post-processing: Minimum Match 0%  
Maximum Match 100%

Listing first 45 summaries

Database : SwissProt.42.\*

Pred. No. is the number of results predicted by chance to have a score greater than or equal to the score of the result being printed, and is derived by analysis of the total score distribution.

## SUMMARIES

Result No.	Score	Query Match	Length	DB ID	Description
1	326	92.9	770	1 A4_HUMAN	P05067 h amyloid b
2	325	92.6	751	1 A4_SAISC	Q95241 s amyloid b
3	322	91.7	770	1 A4_MACFA	P53601 m amyloid b
4	322	91.7	770	1 A4_PIG	P79307 s amyloid b
5	321	91.5	770	1 A4_RAT	P08592 r amyloid b
6	319	90.9	770	1 A4_CAVPO	Q60495 c amyloid b
7	317	90.3	770	1 A4_MOUSE	P12023 m amyloid b
8	304	86.6	76	1 A4_MACM	P29316 macaca mula
9	238	67.8	765	1 APP2_HUMAN	Q06481 homo sapien
10	238	67.8	765	1 APP2_RAT	P15943 rattus norv
11	236	67.2	737	1 A4_FUGRU	O93379 fugu rubrip
12	195.5	55.7	780	1 A4_TETFL	O73683 tetradon f
13	169	48.1	252	1 SPT2_HUMAN	O43391 homo sapien
14	168	47.9	55	1 ISH1_STOHE	P31713 stochactis
15	161	45.9	252	1 SPT2_MOUSE	O94003 mus musculu
16	158	45.0	55	1 ISH2_STOHE	P81129 stochactis
17	158	45.0	55	1 ISH1_HELPO	O94003 mus musculu
18	158	45.0	133	1 EPP1_HUMAN	P00594 helix pomat
19	158	44.5	197	1 MCP1_MELCP	P82568 melithaea c
20	155	44.2	3137	1 CA36_CHICK	P15389 gallus gall
21	153	43.6	67	1 IBPC_BOVIN	P00974 bos taurus
22	153	43.6	67	1 BPT1_BOVIN	P00974 bos taurus
23	153	43.6	302	1 TFP1_RAT	Q02445 rattus norv
24	150	42.7	63	1 IVB2_DABRU	P00390 dabola rube
25	150	42.7	123	1 IATR_SHEEP	P13371 ovis aries
26	149	42.5	349	1 AMBP_MESAU	Q60559 mesocricetu
27	148	42.2	352	1 AMBP_BOVIN	P00578 bos taurus
28	147	41.9	133	1 EPP1_MACMU	Q9bdl1 macaca mula
29	147	41.9	337	1 AMBP_PIG	P04366 sus scrofa
30	147	41.9	349	1 AMBP_MOUSE	Q07456 mus musculu
31	146	41.6	62	1 IPS2_AREBU	P10580 anemonta su
32	146	41.6	230	1 TFP2_MOUSE	O35336 mus musculu
33	146	41.6	346	1 AMBP_MERUN	O62577 meriones un

34	146	41.6	3176	1 CA36_HUMAN	P12111 homo sapien
35	145	41.3	64	1 SPT3_HUMAN	P49223 homo sapien
36	145	41.3	83	1 ELAC_MACRU	O62845 macropus eu
37	144	41.0	60	1 IBPS_BOVIN	P00595 bos taurus
38	144	41.0	507	1 SPT1_MOUSE	Q97097 mus musculu
39	143	40.7	58	1 AXPI_ANTAR	P81547 antioleura
40	143	40.7	349	1 AMBP_RAT	Q64240 rattus norv
41	143	40.7	352	1 AMBP_HUMAN	P02760 homo sapien
42	142	40.5	100	1 BPT2_BOVIN	P04815 bos taurus
43	142	40.5	123	1 IATR_HORSE	P04365 equus caball
44	142	40.5	304	1 TFP1_MACMU	Q28864 macaca mula
45	141	40.2	306	1 TFP1_MOUSE	O54819 mus musculu

## ALIGNMENTS

RESULT 1  
ID A4\_HUMAN  
AC P05067; P09000; F78438; Q13764; Q13778; Q13793; Q16011; Q16014;  
AT Q16019; Q16020; Q9B738; Q9UCAS; Q9UCB6; Q9UCB8; Q9UCD1; Q9U058;  
DT 13-AUG-1987 (rel. 05, Created)  
DT 01-NOV-1991 (rel. 20, Last annotation update)  
DT 15-MAR-2004 (rel. 43, Last annotation update)  
DE Amyloid beta A4 protein precursor (APP) (ABPP) (Alzheimer's disease  
DE amyloid protein) (Cerebral vascular amyloid peptide) (CVAAP) (Protease  
DE nexin-II) (PN-II) (APP1) (preA4) [Contains: Soluble APP-alpha (S-APP-  
DE alpha); Soluble APP-beta (S-APP-beta); C99; Beta-amyloid protein 42  
DE (Beta-APP42); Beta-amyloid protein 40 (Beta-APP40); C83; P3(42);  
DE P3(40); Gamma-CRF(59) (Gamma-secretase C-terminal fragment 59)  
DE (Amyloid intracellular domain 59) (AID(59)); Gamma-CRF(57) (Gamma-  
DE secretase C-terminal fragment 57) (Amyloid intracellular domain 57)  
DE (AID(57)); Gamma-CRF(50) (Gamma-secretase C-terminal fragment 50)  
DE (Amyloid intracellular domain 50) (AID(50)); C31].  
OS Homo sapiens (Human).  
GN APP OR A4 OR AD1.  
OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;  
OC Mammalia; Eutheria; Primates; Catarrhini; Homnidae; Homo.  
OX NCBI\_TaxId=9606;  
RN [1]  
RP SEQUENCE FROM N.A. (ISOFORM APP695).  
RC TISSUE=Brain;  
RX MEDLINE=87144572; PubMed=2881207;  
RA Kang J., Lemire H.-G., Unterbeck A., Salbaum J.M., Masfres C.L.,  
RA Grzeschik K.-H., Multhaup G., Beyreuther K., Muller-Hill B.,  
RT "The precursor of Alzheimer's disease amyloid A4 protein resembles a  
RT cell-surface receptor."  
RL Nature 325:733-736 (1987).  
[2]  
RP SEQUENCE FROM N.A. (ISOFORM APP751).  
RC TISSUE=Brain;  
RX MEDLINE=88122639; PubMed=2893289;  
RA Lemire H.-G., Salbaum J.M., Multhaup G., Kang J., Bayney R.M.,  
RA Unterbeck A., Beyreuther K., Muller-Hill B.,  
RA "The PreA4 (695) precursor protein of Alzheimer's disease A4 amyloid  
RA is encoded by 16 exons."  
RL Nucleic Acids Res. 17:517-522 (1989).  
[3]  
RP SEQUENCE FROM N.A. (ISOFORM APP695).  
RC MEDLINE=89128427; PubMed=2783775;  
RA Lemire H.-G., Salbaum J.M., Multhaup G., Kang J., Bayney R.M.,  
RA Unterbeck A., Beyreuther K., Muller-Hill B.,  
RA "The PreA4 (695) precursor protein of Alzheimer's disease A4 amyloid  
RA is encoded by 16 exons."  
RL Nucleic Acids Res. 17:517-522 (1989).  
[4]  
RP SEQUENCE FROM N.A. (ISOFORM APP770).  
RC MEDLINE=90236318; PubMed=2110105;  
RA Yoshikaki S.-I., Sasaki H., Doh-Ura K., Furuya H., Sakaki Y.,  
RA "Genomic organization of the human amyloid beta-protein precursor  
RA gene.";

- RL Gene 87:257-263 (1990).  
 RN [5]  
 RP ERRATUM, AND REVISIONS.  
 RA Yoshikai S.-I., Sasaki H., Doh-ura K., Furuya H., Sasaki Y.,  
 RL Gene 102:291-292 (1991).  
 RN [6]  
 RP SEQUENCE FROM N.A. (ISOFORM L-APP733).  
 RC TISSUE=Leukocyte;  
 RX MEDLINE=92268136; PubMed=1587857;  
 RA Koenig G., Moening U., Czech C., Prior R., Banati R.,  
 RA Schreier-Gasser U., Bauer J., Masters C.L., Beyreuther K.;  
 RT "Identification and differential expression of a novel alternative  
 RT splice isoform of the beta A4 amyloid precursor protein (APP) mRNA in  
 RT leukocytes and brain microglial cells.";  
 RL J. Biol. Chem. 267:10804-10809 (1992).  
 RN [7]  
 RP SEQUENCE FROM N.A. (ISOFORM APP770).  
 RX MEDLINE=97263807; PubMed=9108164;  
 RA Hattori M., Tsukihara F., Furuhara Y., Tanahashi H., Hirose M.,  
 RA Saito M., Tsukuni S., Sakaki Y.;  
 RT "A novel method for making nested deletions and its application for  
 RT sequencing of a 300 kb region of human APP locus.";  
 RL Nucleic Acids Res. 25:1802-1808 (1997).  
 RN [8]  
 RP SEQUENCE FROM N.A. (ISOFORM APP639).  
 RC TISSUE=Brain;  
 RX MEDLINE=22744650; PubMed=12859342;  
 RA Tang K., Wang C., Shen C., Sheng S., Ravid R., Jing N.;  
 RT "Identification of a novel alternative splicing isoform of human  
 RT amyloid precursor protein gene, APP639.";  
 RL Eur. J. Neurosci. 18:102-108 (2003).  
 RN [9]  
 RP SEQUENCE FROM N.A. (ISOFORM APP305).  
 RC TISSUE=Pituitary;  
 RX MEDLINE=22388257; PubMed=12477932;  
 RA Strausberg R.L., Feingold E.A., Grouse L.H., Derge J.G.,  
 RA Klausner R.D., Collins F.S., Wagner L., Shenmen C.M., Schuler G.D.,  
 RA Altschul S.F., Zeeberg B., Buetow K.H., Schaefer C.F., Bhat N.K.,  
 RA Hopkins R.F., Jordan H., Moore T., Max S.I., Wang J., Hsieh F.,  
 RA Diatchenko L., Marusina B., Farmer A.A., Rubin G.M., Hong L.,  
 RA Stapleton M., Soares M.B., Bonaldo M.F., Casavant T.L., Scheetz T.E.,  
 RA Brownstein W.J., Ueda T.B., Tomihata S., Carninci P., Prange C.,  
 RA Rana S.S., Lochan N.A., Peters J., Abramson R.D., Mullen S.J.,  
 RA Bosak S.A., McKernan P.J., McKernan K.J., Malek J.A., Gunaratne P.H.,  
 RA Richards S., Morley K.C., Hale S., Garcia A.M., Gay L.J., Hulyk S.W.,  
 RA Villalón D.K., Muzny D.M., Sodergren E.J., Lu X., Gibbs R.A.,  
 RA Fahey J., Hellon E., Kettelman M., Madan A., Rodriguez S., Sanchez A.,  
 RA Whiting M., Madan A., Young A.C., Shevchenko Y., Bouffard G.G.,  
 RA Blakeley R.M., Touchman J.W., Green E.D., Dickson M.C.,  
 RA Rodriguez A.C., Grimwood J., Schmutz J., Myers R.M.,  
 RA Butlerfield Y.S.N., Krzywinski M.I., Skalska U., Small D.E.,  
 RA Schenck A., Schein J.E., Jones S.J.M., Marra M.A.;  
 RT "Generation and initial analysis of more than 15,000 full-length  
 RT human and mouse cDNA sequences.";  
 RL Proc. Natl. Acad. Sci. U.S.A. 99:16699-16903 (2002).  
 RN [10]  
 RP SEQUENCE OF 1-10 FROM N.A.  
 RC TISSUE=Liver;  
 RX MEDLINE=99016647; PubMed=1140222;  
 RA Schon E.A., Mita S., Sadlock J., Herbert J.;  
 RT "A cDNA specifying the human amyloid beta precursor protein (ABPP)  
 RT encodes a 95-kDa polypeptide.";  
 RL Nucleic Acids Res. 16:9351-9351 (1988).  
 RN [11]  
 RP ERRATUM, AND REVISIONS.  
 RA Mita S., Sadlock J., Herbert J., Schon E.A.;  
 RL Nucleic Acids Res. 16:11402-11402 (1988).  
 RN [12]  
 RP SEQUENCE OF 1-75 FROM N.A.  
 RX MEDLINE=89165870; PubMed=2539123;  
 RA La Ferla G., Lahiri D.K., Salton S.R., Robakis N.K.;  
 RT "Characterization of the 5' end region and the first two exons of the  
 RT beta-protein precursor gene.";  
 RL Biochem. Biophys. Res. Commun. 159:297-304 (1989).  
 RN [13]  
 RP SEQUENCE OF 18-50.  
 RC TISSUE=Fibroblast;  
 RX MEDLINE=87250462; PubMed=3597385;  
 RA van Nostrand W.E., Cunningham D.D.;  
 RT "Purification of protease nexin II from human fibroblasts.";  
 RL J. Biol. Chem. 262:8508-8514 (1987).  
 RN [14]  
 RP PARTIAL SEQUENCE FROM N.A. (ISOFORM APP751).  
 RC TISSUE=Brain;  
 RX MEDLINE=89346754; PubMed=2569763;  
 RA de Sauvage F., Octave J.N.;  
 RT "A novel mRNA of the A4 amyloid precursor gene coding for a possibly  
 RT secreted protein.";  
 RL Science 245:651-653 (1989).  
 RN [15]  
 RP PARTIAL SEQUENCE FROM N.A. (ISOFORM APP695).  
 RC TISSUE=Brain;  
 RX MEDLINE=87231971; PubMed=3035574;  
 RA Robakis N.K., Ramakrishna N., Wolfe G., Wisniewski H.M.;  
 RT "Molecular cloning and characterization of a cDNA encoding the  
 RT cerebrovascular and the neuritic plaque amyloid peptides.";  
 RL Proc. Natl. Acad. Sci. U.S.A. 84:4190-4194 (1987).  
 RN [16]  
 RP SEQUENCE OF 286-366 FROM N.A.  
 RX MEDLINE=88122640; PubMed=2893290;  
 RA Tanzi R.E., McClatchey A.I., Lamperti E.D., Villa-Komaroff L.,  
 RA Gusella J.F., Neve R.L.;  
 RT "Protease inhibitor domain encoded by an amyloid protein precursor  
 RT mRNA associated with Alzheimer's disease.";  
 RL Nature 331:528-530 (1988).  
 RN [17]  
 RP SEQUENCE OF 287-367 FROM N.A.  
 RX MEDLINE=88122641; PubMed=2893291;  
 RA Kitaguchi N., Takahashi Y., Tokushima Y., Shiojiri S., Ito H.;  
 RT "Novel precursor of Alzheimer's disease amyloid protein shows  
 RT protease inhibitory activity.";  
 RL Nature 331:530-532 (1988).  
 RN [18]  
 RP SEQUENCE OF 507-770 FROM N.A.  
 RC TISSUE=Brain cortex;  
 RX MEDLINE=88124954; PubMed=2893379;  
 RA Zain S.B., Salim M., Chou W.G., Sajdel-Sulkowska E.M., Majocha R.E.,  
 RA Marcotta C.A.;  
 RT "Molecular cloning of amyloid cDNA derived from mRNA of the Alzheimer  
 RT disease brain: coding and noncoding regions of the fetal precursor  
 RT mRNA are expressed in the cortex.";  
 RL Proc. Natl. Acad. Sci. U.S.A. 85:929-933 (1988).  
 RN [19]  
 RP SEQUENCE OF 523-555, AND COLLAGEN-BINDING DOMAIN.  
 RX MEDLINE=96139497; PubMed=8576160;  
 RA Behr D., Heese L., Masters C.L., Multhaup G.;  
 RT "Regulation of amyloid protein precursor (APP) binding to collagen and  
 RT mapping of the binding sites on APP and collagen type I.";  
 RL J. Biol. Chem. 271:1613-1620 (1996).  
 RN [20]  
 RP SEQUENCE OF 655-737 FROM N.A., AND VARIANTS AD PHE-717; AD ILE-717  
 RP AND AD GLY-717.  
 RX MEDLINE=99235601; PubMed=8476439;  
 RA Demian R.B., Rosenzweig R., Miller D.L.;  
 RT "A system for studying the effect (s) of familial Alzheimer disease  
 RT mutations on the processing of the beta-amyloid peptide precursor.";  
 RL Biochem. Biophys. Res. Commun. 192:96-103 (1993).  
 RN [21]  
 RP SEQUENCE OF 656-737 FROM N.A.  
 RX MEDLINE=89392030; PubMed=2675837;  
 RA Johnstone E.M., Chaney M.O., Moore R.E., Ward K.E., Norris F.H.,  
 RA Little S.P.;  
 RT "Alzheimer's disease amyloid peptide is encoded by two exons and shows  
 RT similarity to soybean trypsin inhibitor.";  
 RL Biochem. Biophys. Res. Commun. 163:1248-1255 (1989).  
 RN [22]

Query Match 92.9%; Score 326; DB 1; Length 770;  
 Best Local Similarity 93.4%; Pred. No. 4e-31;  
 Matches 57; Conservative 1; Mismatches 3; Indels 0; Gaps 0;

QY 1 EVNREVSQAEPTPCAAIYHWFDTEGKCAPFFGGCGGNRNNDTEEYCMVCGSA 60  
 DB 285 EVNREVSQAEPTPCAAIYHWFDTEGKCAPFFGGCGGNRNNDTEEYCMVCGSA 344  
 QY 61 I 61  
 DB 345 M 345

RESULT 2  
 A4\_SAIISC STANDARD; PRT; 751 AA.  
 AC Q95241;  
 DT 15-DEC-1998 (Rel. 37, Created)  
 DT 15-DEC-1998 (Rel. 37, Last sequence update)  
 DT 10-OCT-2003 (Rel. 42, Last annotation update)  
 DE Amyloid beta A4 protein precursor (APP) (Alzheimer's disease amyloid  
 protein homolog) [Contains: Soluble APP-alpha (S-APP-alpha); Soluble  
 APP-beta (S-APP-beta); C99; Beta-amyloid protein 42 (Beta-APP42);  
 DE Beta-amyloid protein 40 (Beta-APP40); C83; P3(42); P3(40); Gamma-  
 CTF(59) (Gamma-secretase C-terminal fragment 59); Gamma-CTF(57)  
 DE (Gamma-secretase C-terminal fragment 57); Gamma-CTF(50) (Gamma-  
 secretase C-terminal fragment 50); C31].  
 GN APP.  
 OS Saimiri sciureus (Common squirrel monkey).  
 OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;  
 OC Mammalia; Eutheria; Primates; Platyrrhini; Cebidae; Cebinae; Saimiri.  
 OX NCBI\_TaxID=9521;  
 RN 1]  
 RP SEQUENCE FROM N.A.  
 RC TISSE=Kidney, and Liver;  
 RX MEDLINE=96108492; PubMed=8532114;  
 RA Levy E., Amorim A., Frangione B., Walker L.C.;  
 RT "Beta-amyloid precursor protein gene in squirrel monkeys with  
 cerebral amyloid angiopathy";  
 RL Neurobiol. Aging 16:805-808(1995).  
 CC -1- FUNCTION: Functions as a cell surface receptor and performs  
 physiological functions on the surface of neurons relevant to  
 neurite growth, neuronal adhesion and axonogenesis. Involved in  
 cell mobility and transcription regulation through protein-protein  
 interactions (By similarity). Can promote transcription activation  
 through binding to APB1/Tip60 and inhibit Notch signaling through  
 interaction with Numb (By similarity). Couples to apoptosis-  
 inducing pathways such as those mediated by G(O) and JIP (By  
 similarity). Inhibits G(O) alpha ATPase activity (By similarity).  
 CC Acts as a kinesin I membrane receptor, mediating the axonal  
 transport of beta-secretase and presenilin 1 (By similarity). May  
 be involved in copper homeostasis/oxidative stress through copper  
 ion reduction. In vitro, copper-metalated APP induces neuronal  
 death directly or is potentiated through Cu(II)-mediated low-  
 density lipoprotein oxidation (By similarity). Can regulate  
 extracellular matrix such as heparin and collagen I and IV (By  
 similarity). The splice isoforms that contain the BPT domain  
 possess protease inhibitor activity (By similarity).  
 CC -1- FUNCTION: Beta-amyloid peptides are lipophilic metal chelators  
 with metal-reducing activity. Bind transient metals such as  
 copper, zinc and iron (By similarity).  
 CC -1- FUNCTION: The gamma-CTF peptides as well as the caspase-cleaved  
 peptides, including C31, are potent enhancers of neuronal  
 apoptosis (By similarity).  
 CC -1- SUBUNIT: Binds, via its C-terminal, to the PID domain of several  
 cytoplasmic proteins, including APB family members, the APB  
 family, MAPK1P1, and SHC1. Numb and Dab1 (By similarity). Binding  
 to Dab1 inhibits its serine phosphorylation (By similarity). Also  
 interacts with GPCR-like protein BPP, FPR1, APPB1, IBI, XMS2  
 (via its TPR domain) (By similarity), APPB2 (via BASS) and DDB1.  
 CC In vitro, it binds MAP1 via the MT-binding domains (By

similarity). Associates with microtubules in the presence of ATP  
 and in a kinesin-dependent manner (By similarity).  
 CC -1- SUBCELLULAR LOCATION: Type I membrane protein. Cell surface  
 protein that rapidly becomes internalized via clathrin-coated  
 pits. During maturation, the immature APP (N-glycosylated in the  
 endoplasmic reticulum) moves to the Golgi complex where complete  
 maturation occurs (O-glycosylated and sulfated). After alpha-  
 secretase cleavage, soluble APP is released into the extracellular  
 space and the C-terminal is internalized to endosomes and  
 lysosomes. Some APP accumulates in secretory transport vesicles  
 leaving the late Golgi compartment and returns to the cell  
 surface. Gamma-CTF(59) peptide is located to both the cytoplasm  
 and nuclei of neurons (By similarity).  
 CC -1- ALTERNATIVE PRODUCTS:  
 CC Event-Alternative splicing. Named isoforms=2;  
 CC Comment-Additional isoforms seem to exist;  
 CC Name=APP770;  
 CC Name=Q95241-1; Sequence=Displayed;  
 CC Name=APP695;  
 CC IsoId=Q95241-2; Sequence=Not described;  
 CC -1- DOMAIN: The basolateral sorting signal (BASS) is required for  
 sorting of membrane proteins to the basolateral surface of  
 epithelial cells (By similarity).  
 CC -1- DOMAIN: The NPXY sequence motif found in many tyrosine-  
 phosphorylated proteins is required for the specific binding of  
 the PID domain. However additional amino acids either N- or C-  
 terminal to the NPXY motif are often required for complete  
 interaction. The PID domain-containing proteins which bind APP  
 require the YENPTY motif for full interaction. These interactions  
 are independent of phosphorylation on the terminal tyrosine  
 residue. The NPXY site is also involved in clathrin-mediated  
 endocytosis (By similarity).  
 CC -1- PTM: Proteolytically processed under normal cellular conditions.  
 CC Cleavage by alpha-secretase or alternatively by beta-secretase  
 leads to generation and extracellular release of soluble APP  
 peptides, S-APP-alpha and S-APP-beta, respectively, and the  
 retention of corresponding membrane-anchored C-terminal fragments,  
 C83 and C99. Subsequent processing of C83 by gamma-secretase  
 yields P3 peptides. This is the major secretory pathway and is  
 nonamyloidogenic. Alternatively, presenilin/alpha-secretin-mediated  
 gamma-secretase processing of C99 releases the amyloid beta  
 proteins, amyloid-beta 40 (Abeta40) and amyloid-beta 42 (Abeta42).  
 CC major components of amyloid plaques, and the cytotoxic C-terminal  
 fragments, gamma-CTF(50), gamma-CTF(57) and gamma-CTF(59) (By  
 similarity).  
 CC -1- PTM: Proteolytically cleaved by caspases during neuronal apoptosis  
 (By similarity). Cleavage at Asp-720 by either caspase-3, -8 or -9  
 results in the production of the neurotoxic C31 peptide and the  
 increased production of beta-amyloid peptide (By similarity).  
 CC -1- PTM: N- and O-glycosylated (By similarity).  
 CC Serine phosphorylation in the C-terminal on tyrosine, threonine and  
 serine residues is neuron-specific. Phosphorylation can affect APP  
 processing, neuronal differentiation and interaction with other  
 proteins (By similarity).  
 CC -1- MISCELLANEOUS: Chelation of metal ions, notably copper, iron and  
 zinc, can induce histidine-bridging between beta-amyloid molecules  
 resulting in beta-amyloid-metal aggregates (By similarity).  
 CC Extracellular zinc-binding increases binding of heparin to APP and  
 inhibits collagen-binding (By similarity).  
 CC -1- SIMILARITY: Belongs to the APP family.  
 CC -1- SIMILARITY: Contains 1 BPT/Kunitz inhibitor domain.  
 CC -----  
 CC This SWISS-PROT entry is copyrighted. It is produced through a collaboration  
 CC between the Swiss Institute of Bioinformatics and the EMBL outstation -  
 CC the European Bioinformatics Institute. There are no restrictions on its  
 CC use by non-profit institutions as long as its content is in no way  
 CC modified and this statement is not removed. Usage by and for commercial  
 CC entities requires a license agreement (See <http://www.isb-sib.ch/announce/>  
 CC or send an email to [license@sib-sib.ch](mailto:license@sib-sib.ch)).  
 CC -----  
 CC EMBL: S81024; A014347.1; -;  
 CC HSSP: P05067; 1AAB.  
 CC InterPro: IPR008155; A4\_APP.



CC and in a kinesin-dependent manner (By similarity).

CC -1- SUBCELLULAR LOCATION: Type I membrane protein. Cell surface

CC protein that rapidly becomes internalized via clathrin-coated

CC pits. During maturation, the immature APP (N-glycosylated in the

CC endoplasmic reticulum) moves to the Golgi complex where complete

CC maturation occurs (O-glycosylated and sulfated). After alpha-

CC secretase cleavage, soluble APP is released into the extracellular

CC space and the C-terminal is internalized to endosomes and

CC lysosomes. Some APP accumulates in secretory transport vesicles

CC leaving the late Golgi compartment and returns to the cell

CC surface. Gamma-CRF(59) peptide is located to both the cytoplasm

CC and nuclei of neurons (By similarity).

CC -1- ALTERNATIVE PRODUCTS:

CC Bant-Alternative splicing. Named isoforms=2;

CC Comment=Additional isoforms seem to exist;

CC Name=APP70;

CC IsoId=PS3601-1; Sequence=Displayed;

CC Name=APP695;

CC IsoId=PS3601-2; Sequence=VSP\_000010, VSP\_000011;

CC -1- DOMAIN: The basolateral sorting signal (BaSS) is required for

CC sorting of membrane proteins to the basolateral surface of

CC epithelial cells (By similarity).

CC -1- DOMAIN: The NPY sequence motif found in many tyrosine-

CC phosphorylated proteins is required for the specific binding of

CC the PID domain. However additional amino acid either N- or C-

CC terminal to the NPY motif are often required for complete

CC interaction. The PID domain-containing proteins which bind APP

CC require the YENPTY motif for full interaction. These interactions

CC are independent of phosphorylation on the terminal tyrosine

CC residue. The NPY site is also involved in clathrin-mediated

CC endocytosis (By similarity).

CC -1- PTM: Proteolytically processed under normal cellular conditions.

CC Cleavage by alpha-secretase or alternatively by beta-secretase

CC leads to generation and extracellular release of soluble APP

CC peptides, S-APP-alpha and S-APP-beta, respectively, and the

CC retention of corresponding membrane-anchored C-terminal fragments,

CC C83 and C99. Subsequent processing of C83 by gamma-secretase

CC yields P3 peptides. This is the major secretory pathway and is

CC nonamyloidogenic. Alternatively, presenilin/nicastrin-mediated

CC gamma-secretase processing of C99 releases the amyloid beta

CC proteins, amyloid-beta 40 (Abeta40) and amyloid-beta 42 (Abeta42),

CC major components of amyloid plaques, and the cytotoxic C-terminal

CC fragments, gamma-CRF(50), gamma-CRF(57) and gamma-CRF(59) (By

CC similarity).

CC -1- PTM: Proteolytically cleaved by caspases during neuronal apoptosis

CC (By similarity). Cleavage at Asp-739 by either caspase-3, -8 or -9

CC results in the production of the neurotoxic C31 peptide and the

CC increased production of beta-amyloid peptides (By similarity).

CC -1- PTM: N- and O-glycosylated (By similarity).

CC -1- PTM: Phosphorylation in the C-terminal on tyrosine, threonine and

CC serine residues is neuron-specific. Phosphorylation can affect APP

CC processing, neuronal differentiation and interaction with other

CC proteins (By similarity).

CC -1- MISCELLANEOUS: Chelation of metal ions, notably copper, iron and

CC zinc, can induce histidine-bridging between beta-amyloid molecules

CC resulting in beta-amyloid-metal aggregates (By similarity).

CC Extracellular zinc-binding increases binding of heparin to APP and

CC inhibits collagen-binding (By similarity).

CC -1- SIMILARITY: Belongs to the APP family.

CC -1- SIMILARITY: Contains 1 BPT1/Kunitz inhibitor domain.

CC -----

CC This SWISS-PROT entry is copyright. It is produced through a collaboration

CC between the Swiss Institute of Bioinformatics and the EMBL outstation

CC at the European Bioinformatics Institute. There are no restrictions on its

CC use by non-profit institutions as long as its content is in no way

CC modified and this statement is not removed. Usage by and for commercial

CC entities requires a license agreement (See <http://www.isb-sib.ch/announce/>

CC or send an email to [license@isb-sib.ch](mailto:license@isb-sib.ch)).

CC -----

DR EMBL: M58727, AAA36829.1, -

DR EMBL: M58726, AAA36828.1, -

DR HSSP: P05067, IAP.

DR InterPro: IPR008155; A4\_APP.

DR InterPro: IPR008154; A4\_extra.

DR InterPro: IPR001255; Beta\_APP.

DR InterPro: IPR002223; Kunitz\_BPT1.

DR Pfam: PF02177; A4\_EXTRA, 1.

DR Pfam: PF03494; Beta\_APP, 1.

DR Pfam: PF00014; Kunitz\_BPT1, 1.

DR PRINTS: PR00203; AMYLOID4.

DR PRINTS: PR00759; BASICPTASE.

DR ProDom: PD000222; Kunitz\_BPT1, 1.

DR SMART: SM00006; A4\_EXTRA, 1.

DR SMART: SM00131; Kof, 1.

DR PROSITE: PS00319; A4\_EXTRA, 1.

DR PROSITE: PS00320; A4\_INTRA, 1.

DR PROSITE: PS00280; BPT1\_KUNITZ\_1, 1.

DR PROSITE: PS02279; BPT1\_KUNITZ\_2, 1.

KW Apoptosis; Endocytosis; Cell adhesion; Serine protease inhibitor;

KW Coated pits; Neutrone; Heparin-binding; Metal-binding; Copper; Iron;

KW Zinc; Signal; Transmembrane; Glycoprotein; Phosphorylation;

KW Proteoglycan; Alternative splicing; Amyloid.

FT SIGNAL 1 17

FT CHAIN 1 770

FT CHAIN 18 687

FT CHAIN 18 671

FT CHAIN 672 770

FT CHAIN 672 770

FT CHAIN 672 713

FT CHAIN 688 770

FT CHAIN 688 713

FT CHAIN 688 711

FT CHAIN 712 770

FT CHAIN 712 770

FT CHAIN 721 770

FT CHAIN 721 770

FT CHAIN 740 770

FT TRANSMEM 18 699

FT DOMAIN 700 723

FT DOMAIN 724 770

FT DOMAIN 96 110

FT DOMAIN 181 188

FT DOMAIN 221 341

FT DOMAIN 321 423

FT DOMAIN 491 522

FT DOMAIN 523 540

FT DOMAIN 722 751

FT DOMAIN 230 260

FT DOMAIN 274 280

FT SITE 144 144

FT ACT SITE 301 302

FT SITE 671 672

FT SITE 672 673

FT SITE 687 688

FT SITE 704 704

FT SITE 706 706

FT SITE 711 712

FT SITE 713 714

FT SITE 720 721

FT SITE 724 734

FT SITE 739 740

Query Match 91.7%; Score 322; DB 1; Length 770;

Best Local Similarity 91.8%; Pred. No. 1,2e-30;

Matches 56; Conservative 1; Mismatches 4; Indels 0; Gaps 0;

1 EVMEVCEGEQAEIETPCAAIYHWFDYTEGKCAFFYGGCGGNNNNDTEBYCAVCGSA 60

DB 285 EVFREVCSQAEITGCRAMISRWYDVIEGKCAPFYGGCGGNNNPTEIEYCAVCGSV 344  
QY 61 I 61  
DB 345 M 345

RESULT 4  
A4\_PIG STANDARD; PRT; 770 AA.  
ID P79307; Q29023; Q9TU10;  
AC 01-NOV-1997 (Rel. 35, Created)  
DT 10-OCT-2003 (Rel. 42, Last sequence update)  
DT 10-OCT-2003 (Rel. 42, Last annotation update)  
DE Amyloid beta A4 protein precursor (APP) (ABPP) (Alzheimer's disease  
DE amyloid protein homolog) (contains: Soluble APP-alpha (S-APP-alpha);  
DE Soluble APP-beta (S-APP-beta); C99; Beta-amyloid protein 42 (Beta-  
DE APP42); Beta-amyloid protein 40 (Beta-APP40); C83; P3(42); P3(40);  
DE Gamma-CTF(59) (Gamma-secretase C-terminal fragment 59); Gamma-CTF(57)  
DE (Gamma-secretase C-terminal fragment 57); Gamma-CTF(50) (Gamma-  
DE secretase C-terminal fragment 50); C31].  
OS Sus scrofa (Pig).  
OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;  
OC Mammalia; Eutheria; Cetartiodactyla; Suidae; Sus.  
OX NCBI\_TaxID=9823;  
RN [1]  
RP SEQUENCE FROM N.A.  
RA Kimura A., Takahashi T.,  
RT Amyloid precursor protein 770.";  
RL Submitted (SEP-1999) to the EMBL/GenBank/DBJ databases.  
RN [2]  
RP SEQUENCE OF 1-136 FROM N.A.  
RA Tissue=Small intestine.  
RC Wineroe A.K., Fredholm M.,  
RA "Evaluation and characterization of a porcine small intestine CDNA  
RT library.";  
RL Submitted (JAN-1997) to the EMBL/GenBank/DBJ databases.  
RN [3]  
RP SEQUENCE OF 667-723 FROM N.A.  
RA Tissue=Brain;  
RC MEDLINE=92011079; PubMed=1656157;  
RA Johnson E.M., Chaney M.O., Norris F.H., Pascual R., Little S.P.,  
RT "Conservation of the sequence of the Alzheimer's disease amyloid  
RT peptide in dog, polar bear and five other mammals by cross-species  
RT polymerase chain reaction analysis.";  
RL Brain Res. Mol. Brain Res. 10:299-305 (1991).  
CC -1- FUNCTION: Functions as a cell surface receptor and performs  
CC physiological functions on the surface of neurons relevant to  
CC neurite growth, neuronal adhesion and axonogenesis. Involved in  
CC cell mobility and transcription regulation through protein-protein  
CC interactions (By similarity). Can promote transcription activation  
CC through binding to APBB1/Tipe60 and inhibit Notch signaling through  
CC interaction with Numb (By similarity). Couples to apoptosis-  
CC inducing pathways such as those mediated by G(O) and JIP (By  
CC similarity). Inhibits G(O) alpha ATPase activity (By similarity).  
CC Acts as a kinesin I membrane receptor, mediating the axonal  
CC transport of beta-secretase and presenilin 1 (By similarity). May  
CC be involved in copper homeostasis/oxidative stress through copper  
CC ion reduction (By similarity). In vitro, copper-metallated APP  
CC induces neuronal death directly or is potentiated through Cu(II)-  
CC mediated low-density lipoprotein oxidation (By similarity). Can  
CC regulate neurite outgrowth through binding to components of the  
CC extracellular matrix such as heparin and collagen I and IV (By  
CC similarity).  
CC -1- FUNCTION: Beta-amyloid peptides are lipophilic metal chelators  
CC with metal-reducing activity. Bind transient metals such as  
CC copper, zinc and iron (By similarity).  
CC -1- FUNCTION: The gamma-CTF peptides as well as the caspase-cleaved  
CC peptides, including C31, are potent enhancers of neuronal  
CC apoptosis (By similarity).  
CC -1- SUBUNIT: Binds, via its C-terminal, to the PID domain of several  
CC cytoplasmic proteins, including APBB family members, the APBA

CC family, MAPK8IP1, and SHC1, Numb and Dab1 (By similarity). Binding  
CC to Dab1 inhibits its serine phosphorylation (By similarity). Also  
CC interacts with GPCR-like protein APP, FPR1, APPB1, IRL KMS2  
CC (via its TPR domain) (By similarity), APPB2 (via BASS) and DDB1.  
CC In vitro, it binds MAP7 via the WT-binding domain (By  
CC similarity). Associates with microtubules in the presence of APP  
CC and in a kinesin-dependent manner (By similarity).  
CC SUBCELLULAR LOCATION: Type I membrane protein. Cell surface  
CC protein that rapidly becomes internalized via clathrin-coated  
CC pits. During maturation, the immature APP (N-glycosylated in the  
CC endoplasmic reticulum) moves to the Golgi complex where complete  
CC maturation occurs (O-glycosylated and sulfated). After alpha-  
CC secretase cleavage, soluble APP is released into the extracellular  
CC space and the C-terminal is internalized to endosomes and  
CC lysosomes. Some APP accumulates in secretory transport vesicles  
CC leaving the late Golgi compartment and returns to the cell  
CC surface. Gamma-CTF(59) peptide is located to both the cytoplasm  
CC and nucleus of neurons (By similarity).  
CC -1- DOMAIN: The basolateral sorting signal (BASS) is required for  
CC sorting of membrane proteins to the basolateral surface of  
CC epithelial cells (By similarity).  
CC -1- DOMAIN: The NPXY sequence motif found in many tyrosine-  
CC phosphorylated proteins is required for the specific binding of  
CC the PID domain. However additional amino acids either N- or C-  
CC terminal to the NPXY motif are often required for complete  
CC interaction. The PID domain-containing proteins which bind APP  
CC require the YENPTY motif for full interaction. These interactions  
CC are independent of phosphorylation on the terminal tyrosine  
CC residue. The NPXY site is also involved in clathrin-mediated  
CC endocytosis (By similarity).  
CC -1- PTM: Proteolytically processed under normal cellular conditions.  
CC Cleavage by alpha-secretase or alternatively by beta-secretase  
CC leads to generation and extracellular release of soluble APP  
CC peptides, S-APP-alpha and S-APP-beta, respectively, and the  
CC retention of corresponding membrane-anchored C-terminal fragments,  
CC C83 and C99. Subsequent processing of C83 by gamma-secretase  
CC yields P3 peptides. This is the major secretory pathway and is  
CC nonamyloidogenic. Alternatively, presenilin/nicastrin-mediated  
CC gamma-secretase processing of C99 releases the amyloid beta  
CC proteins, amyloid-beta 40 (Abeta40) and amyloid-beta 42 (Abeta42),  
CC major components of amyloid plaques, and the cytotoxic C-terminal  
CC fragments, gamma-CTF(50), gamma-CTF(57) and gamma-CTF(59) (By  
CC similarity).  
CC -1- PTM: Proteolytically cleaved by caspases during neuronal apoptosis  
CC (By similarity). Cleavage at Asp-739 by either caspase-3, -8 or -9  
CC results in the production of the neurotoxic C31 peptide and the  
CC increased production of beta-amyloid peptides (By similarity).  
CC -1- PTM: N- and O-glycosylated (By similarity).  
CC -1- PTM: Phosphorylation in the C-terminal on tyrosine, threonine and  
CC serine residues is neuron-specific. Phosphorylation can affect APP  
CC processing, neuronal differentiation and interaction with other  
CC proteins (By similarity).  
CC -1- PTM: Extracellular binding and reduction of copper, results in a  
CC corresponding oxidation of Cys-144 and Cys-156, and the formation  
CC of a disulfide bond (By similarity).  
CC -1- MISCELLANEOUS: Chelation of metal ions, notably copper, iron and  
CC zinc, can induce histidine-bridging between beta-amyloid molecules  
CC resulting in beta-amyloid-metal aggregates (By similarity).  
CC Extracellular zinc-binding increases binding of heparin to APP and  
CC inhibits collagen-binding (By similarity).  
CC -1- SIMILARITY: Belongs to the APP family.  
CC -1- SIMILARITY: Contains 1 BPT1/Kunitz inhibitor domain.  
CC This SWISS-PROT entry is copyright. It is produced through a collaboration  
CC between the Swiss Institute of Bioinformatics and the EMBL outstation -  
CC the European Bioinformatics Institute. There are no restrictions on its  
CC use by non-profit institutions as long as its content is in no way  
CC modified and this statement is not removed. Usage by and for commercial  
CC entities requires a license agreement (see <http://www.ebi.ac.uk/announcements>  
CC or send an email to [license@ebi.ac.uk](mailto:license@ebi.ac.uk)).  
CC EMBL, AB033550; BAAG4580.1; -  
CC EMBL, Z84022; CAB06313.1; -

DR EMBL: X56127; CA39592.1; -  
 DR HSSP: P05067; IAP.  
 DR InterPro: IPR008155; A4\_APP.  
 DR InterPro: IPR008154; A4\_extra.  
 DR InterPro: IPR002223; Kunitz\_BPTI.  
 DR Pfam: PF02177; A4\_EXTRA; 1.  
 DR PRINTS: PRO0203; AMYLOIDA4.  
 DR PRINTS: PRO0759; BASICPTASE.  
 DR ProDom: PD000222; Kunitz\_BPTI.  
 DR SMART: SM0006; A4\_EXTRA; 1.  
 DR SMART: SM00131; KU; 1.  
 DR PROSITE: PS00319; A4\_EXTRA; 1.  
 DR PROSITE: PS00320; A4\_INTRA; 1.  
 DR PROSITE: PS00280; BPTI\_KUNITZ\_1; 1.  
 DR PROSITE: PS00279; BPTI\_KUNITZ\_2; 1.  
 DR Apoptosis: Endocytosis; Cell adhesion; Serine protease inhibitor;  
 KW Coiled pits; Neutrons; Heparin-binding; Metal-binding; Copper; Iron;  
 KW Zinc; Signal; Transmembrane; Glycoprotein; Phosphorylation;  
 KW Amyloid.  
 FT SIGNAL 1 17  
 FT CHAIN 18 770  
 FT CHAIN 18 687  
 FT CHAIN 18 671  
 FT CHAIN 672 770  
 FT CHAIN 672 713  
 FT CHAIN 672 711  
 FT CHAIN 688 713  
 FT CHAIN 688 711  
 FT CHAIN 712 770  
 FT CHAIN 714 770  
 FT CHAIN 721 770  
 FT CHAIN 740 770  
 FT DOMAIN 18 699  
 FT TRANSMEM 700 723  
 FT DOMAIN 724 770  
 FT DOMAIN 96 110  
 FT DOMAIN 135 155  
 FT DOMAIN 181 188  
 FT DOMAIN 291 341  
 FT DOMAIN 391 423  
 FT DOMAIN 491 522  
 FT DOMAIN 523 540  
 FT DOMAIN 732 751  
 FT DOMAIN 230 260  
 FT DOMAIN 274 280  
 FT SITE 144 144  
 FT ACT SITE 301 302  
 FT SITE 671 672  
 FT SITE 672 673  
 FT SITE 687 688  
 FT SITE 704 704  
 FT SITE 706 706  
 FT SITE 711 712  
 FT SITE 713 714  
 FT SITE 720 721

Query Match 91.7%; Score 322; DB 1; Length 770;  
 Best Local Similarity 91.8%; Pred. No. 1,2e-30;  
 Matches 56; Conservative 1; Mismatches 4; Indels 0; Gaps 0;

QY 1 EVYREVCSQATGPICRAIYMYFDVTEGKCAFFYGGCGGNRRNFTTEYCAVCGSA 60  
 DB 285 EVYREVCSQATGPICRAIYMYFDVTEGKCAFFYGGCGGNRRNFTTEYCAVCGSV 344

QY 61 I 61  
 DB 345 M 345

RESULT 5  
 ID A4\_RAT  
 AC P08592;  
 DT 01-AUG-1988 (Rel. 08, Created)  
 DT 01-DEC-1992 (Rel. 24, Last sequence update)  
 DT 10-OCT-2003 (Rel. 42, Last annotation update)  
 DE Amyloid beta A4 protein precursor (APP) (Alzheimer's disease amyloid  
 DE protein homolog) (Amyloidogenic glycoprotein) (AG) (Contains: soluble  
 DE APP-alpha (S-APP-alpha); Soluble APP-beta (S-APP-beta); C99; Beta-  
 DE amyloid protein 42 (Beta-APP42); Beta-amyloid protein 40 (Beta-APP40);  
 DE C83; P3(42); P3(40); Gamma-CTF(59) (Gamma-secretase C-terminal  
 DE fragment 59); Gamma-CTF(57) (Gamma-secretase C-terminal fragment 57);  
 DE Gamma-CTF(50) (Gamma-secretase C-terminal fragment 50); C31).  
 GN APP  
 OS Rattus norvegicus (Rat).  
 OC Eukaryota; Metazoa; Chordata; Vertebrata; Euteleostomi;  
 OC Mammalia; Eutheria; Rodentia; Sciurognathi; Muridae; Murinae; Rattus.  
 OX NCBI\_TaxId=10116;  
 RN [1]  
 RP SEQUENCE FROM N.A. (ISOFORM APP695).  
 RC TISSUE=Brain;  
 RX MEDLINE=68312583; PubMed=2900758;  
 RA Shivers B.D., Hilbich C., Multhaup G., Salbaum J.M., Beyreuther K.,  
 RT Seeburg P.H.;  
 RT "Alzheimer's disease amyloidogenic glycoprotein: expression pattern  
 RT in rat brain suggests a role in cell contact."  
 RL EMBO J. 7:1365-1370(1988).  
 RN [2]  
 RP SEQUENCE OF 289-364 FROM N.A.  
 RC TISSUE=Liver;  
 RX MEDLINE=89183625; PubMed=2648331;  
 RA Kang J., Mueller-Hill B.;  
 RT "The sequence of the two extra exons in rat preA4."  
 RL Nucleic Acids Res. 17:2130-2130(1989).  
 RN [3]  
 RP SEQUENCE OF 720-730, AND MASS SPECTROMETRY.  
 RX MEDLINE=21443797; PubMed=11483589;  
 RA Gu Y., Misonou H., Sato T., Dohmae N., Takio K., Ihara Y.;  
 RT "Distinct intramembrane cleavage of the beta-amyloid precursor protein  
 RT family resembling gamma-secretase-like cleavage of Notch."  
 RL J. Biol. Chem. 276:35235-35238(2001).  
 RN [4]  
 RP ALTERNATIVE SPLICING.  
 RX MEDLINE=96187032; PubMed=8624099;  
 RA Sandbink R., Masters C.L., Beyreuther K.;  
 RT "APP gene family. Alternative splicing generates functionally related  
 RT isoforms."  
 RL Ann. N.Y. Acad. Sci. 777:281-287(1996).  
 RN [5]  
 RP TISSUE SPECIFICITY OF APPICAN.  
 RX MEDLINE=95263526; PubMed=7748933;  
 RA Shiota U., Pangalos M.N., Ripellino J.A., Vassiliacopoulos D.,  
 RA Mytilineou C., Margolis R.U., Robakis N.K.;  
 RT "The Alzheimer amyloid precursor proteoglycan (appican) is present in  
 RT brain and is produced by astrocytes but not by neurons in primary  
 RT neural cultures."  
 RL J. Biol. Chem. 270:11839-11844(1995).  
 RN [6]  
 RP TISSUE SPECIFICITY OF ISOFORMS.  
 RX MEDLINE=97150061; PubMed=8996834;  
 RA Sandbink R., Moming U., Masters C.L., Beyreuther K.;  
 RT "Expression of the APP gene family in brain cells, brain development  
 RT and aging."  
 RL Gerontology 43:119-131(1997).  
 RN [7]  
 RP INTERACTION WITH DBP1, AND MUTAGENESIS OF TYR-757; ASN-759 AND  
 RP THR-762.



RA MEDLINE=99127916; PubMed=9930726;  
 RX Matnabe T., Sukegawa J., Temita S., Iijima K.-I., Oguchi S.,  
 RA Suzuki T., Naito A.C., Greengard P.,  
 RT A 127-kDa protein (UV-DB) binds to the cytoplasmic domain of the  
 RT Alzheimer's amyloid precursor protein.";  
 RL J. Neurochem. 72:549-556(1999).  
 RN [8]  
 RP INTERACTION WITH GNAO1 AND MUTAGENESIS OF 732-HIS-HIS-733.  
 RX MEDLINE=99162676; PubMed=10024358.  
 RA Brouillet E., Tremblau A., Galarneau D., Volovitch M., Bouillot C.,  
 RA Valenica C., Prochiantz A., Allingant B.,  
 RT "The amyloid precursor protein interacts with G heterotrimeric  
 RT protein within a cell compartment specialized in signal  
 RT transduction.";  
 RL J. Neurosci. 19:1717-1727(1999).  
 RN [9]  
 RP CHARACTERISTICS OF APPICAN AND MUTAGENESIS OF SER-656.  
 RX MEDLINE=99256193; PubMed=7737970;  
 RA Pangalos M.N., Efthimiopoulos S., Shioi J., Robakis N.K.,  
 RT "The chondroitin sulfate attachment site of appican is formed by  
 RT splicing out exon 15 of the amyloid precursor gene.";  
 RL J. Biol. Chem. 270:10388-10391(1995).  
 RN [10]  
 RP BETA-AMYLOID METAL-BINDING.  
 RX MEDLINE=99316162; PubMed=10386999;  
 RA Huang X., Atwood C.S., Hartshorn M.A., Multhaup G., Goldstein L.E.,  
 RA Scarpa R.C., Cuaungco M.P., Gray D.N., Lim J., Moir R.D., Tanzi R.E.,  
 RA Bush A.I.,  
 RT "The A beta peptide of Alzheimer's disease directly produces hydrogen  
 RT peroxide through metal ion reduction.";  
 RL Biochemistry 38:7609-7616(1999).  
 RN [11]  
 RP BETA-AMYLOID ZINC BINDING.  
 RX MEDLINE=99343552; PubMed=10413512;  
 RA Liu S.T., Howlett G., Barrow C.J.,  
 RT "Histidine-13 is a crucial residue in the zinc ion-induced aggregation  
 RT of the A beta peptide of Alzheimer's disease.";  
 RL Biochemistry 38:9373-9378(1999).  
 RN [12]  
 RP IMPORTANCE OF GLY-704 IN FREE RADICAL PROPAGATION AND MUTAGENESIS OF  
 RP GLY-704.  
 RX MEDLINE=21956095; PubMed=11959460;  
 RA Kaneki J., Varadarajan S., Akengenya M., Butterfield D.A.,  
 RT "Role of glycine-33 and methionine-35 in Alzheimer's amyloid beta-  
 RT peptide 1-42-associated oxidative stress and neurotoxicity.";  
 RL Biochim. Biophys. Acta 1586:190-198(2001).  
 RN [13]  
 RP PHOSPHORYLATION.  
 RX MEDLINE=97239592; PubMed=9085254;  
 RA Oishi M., Naito A.C., Czernik A.J., Lim G.S., Isohara T., Gandy S.E.,  
 RA Greengard P., Suzuki T.,  
 RT "The cytoplasmic domain of Alzheimer's amyloid precursor protein is  
 RT phosphorylated at Thr654, Ser655, and Thr668 in adult rat brain and  
 RT cultured cells.";  
 RL Mol. Med. 3:111-123(1997).  
 RN [14]  
 RP PHOSPHORYLATION ON SER-730.  
 RX MEDLINE=99262094; PubMed=10329382;  
 RA Isohara T., Horuchi A., Matnabe T., Ando K., Czernik A.J., Uno I.,  
 RA Greengard P., Naito A.C., Suzuki T.,  
 RT "Phosphorylation of the cytoplasmic domain of Alzheimer's beta-amyloid  
 RT precursor protein at Ser655 by a novel protein kinase.";  
 RL Biochem. Biophys. Res. Commun. 258:300-305(1999).  
 RN [15]  
 RP PHOSPHORYLATION, INDUCTION, SUBCELLULAR LOCATION, AND MUTAGENESIS OF  
 RP THR-743.  
 RX MEDLINE=99274744; PubMed=10341243;  
 RA Ando K., Oishi M., Takeda S., Iijima K.-I., Isohara T., Naito A.C.,  
 RA Kiriya Y., Greengard P., Suzuki T.,  
 RT "Role of phosphorylation of Alzheimer's amyloid precursor protein  
 RT during neuronal differentiation.";  
 RL J. Neurosci. 19:4421-4427(1999).  
 RN [16]

RP PHOSPHORYLATION ON THR-743.  
 RX MEDLINE=20396193; PubMed=10936190;  
 RA Iijima K.-I., Ando K., Takeda S., Satoh Y., Seki T., Itohara S.,  
 RA Greengard P., Kiriya Y., Naito A.C., Suzuki T.,  
 RT "Neuron-specific phosphorylation of Alzheimer's beta-amyloid precursor  
 RT protein by cyclin-dependent kinase 5.";  
 RL J. Neurochem. 75:1085-1091(2000).  
 RN [17]  
 RP CARBOHYDRATE STRUCTURE OF APPICAN.  
 RX MEDLINE=21463085; PubMed=11479316;  
 RA Tsuchida K., Shioi J., Yamada S., Boghosian G., Wu A., Cai H.,  
 RA Suganaka K., Robakis N.K.,  
 RT "Appican, the proteoglycan form of the amyloid precursor protein,  
 RT contains chondroitin sulfate E in the repeating disaccharide region  
 RT and 4-O-sulfated galactose in the linkage region.";  
 RL J. Biol. Chem. 276:37155-37160(2001).  
 CC -1- FUNCTION: Functions as a cell surface receptor and performs  
 CC physiological functions on the surface of neurons relevant to  
 CC neurite growth, neuronal adhesion and axonogenesis. Involved in  
 CC cell mobility and transcription regulation through protein-protein  
 CC interactions (By similarity). Can promote transcription activation  
 CC through binding to APBB1/Tip60 and inhibit Notch signaling through  
 CC interaction with Numb (By similarity). Couples to apoptosis-  
 CC inducing pathways such as those mediated by G10 and JIP. Inhibits  
 CC G10 alpha Arpase activity. Acts as a kinesin I membrane receptor,  
 CC mediating the axonal transport of beta-secretase and presenilin 1  
 CC (By similarity). May be involved in copper homeostasis/oxidative  
 CC stress through copper ion reduction. Can regulate neurite  
 CC outgrowth through binding to components of the extracellular  
 CC matrix such as heparin and collagen I and IV (By similarity). The  
 CC splice isoforms that contain the BPI domain possess protease  
 CC inhibitor activity (By similarity).  
 CC -1- FUNCTION: Beta-amyloid peptides are lipophilic metal chelators  
 CC with metal-reducing activity. Bind transient metals such as  
 CC copper, zinc and iron. Rat and mouse beta-amyloid peptides bind  
 CC only weakly transient metals and have little reducing activity due  
 CC to substitutions of transient metal chelating residues. Beta-Ap42  
 CC may activate mononuclear phagocytes in the brain and elicit  
 CC inflammatory responses. Promotes both tau aggregation and TRK II-  
 CC mediated phosphorylation (By similarity).  
 CC -1- FUNCTION: Appicans elicit adhesion of neural cells to the  
 CC extracellular matrix and may regulate neurite outgrowth in the  
 CC brain.  
 CC -1- FUNCTION: The gamma-CTP peptides as well as the caspase-cleaved  
 CC peptides, including C31, are potent enhancers of neuronal  
 CC apoptosis (By similarity).  
 CC -1- SUBUNIT: Binds, via its C-terminal, to the PID domain of several  
 CC cytoplasmic proteins, including APPB family members, the APPA  
 CC family, MAPK8IP1, SHC1 and Numb and Dab1 (By similarity). Binding  
 CC to Dab1 inhibits its serine phosphorylation (By similarity). Also  
 CC interacts with GPCR-like protein BPP, PPRL, APPB2, IB1, KNS2  
 CC (via its TPR domain), APPB2 (via Bass) (By similarity) and DDB1.  
 CC In vitro, it binds MAP7 via the MT-binding domains (By  
 CC similarity). Associates with microtubules in the presence of ATP  
 CC and in a kinesin-dependent manner (By similarity). Interacts  
 CC through a C-terminal domain, with GNAO1. Amyloid beta-42 binds  
 CC CHRNA7 in hippocampal neurons (By similarity). Beta-amyloid  
 CC associates with HADH2 (By similarity).  
 CC -1- SUBCELLULAR LOCATION: Type I membrane protein. Cell surface  
 CC protein that rapidly becomes internalized via a clathrin-coated  
 CC pits. During maturation, the immature APP (N-glycosylated in the

Query Match 91.5% Score 321, DB 1; Length 770;  
 Best Local Similarity 94.9%; Pred. NO. 1.6e-30;  
 Matches 56; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 1 EVREVCSEQAEATPCRAAIYHMYFDVTEGKCAFFYGGCGGNNNPDTEBYCAVAGCS 59  
 DB 285 EVREVCSEQAEATPCRAAIYHMYFDVTEGKCAFFYGGCGGNNNPDTEBYCAVAGCS 343  
 RESULT 6  
 A4\_CAVPO



ID A4 CAVPO STANDARD; PRT: 770 AA.  
AC 060495; 060496;  
DT 10-OCT-2003 (Rel. 42, Created)  
DT 10-OCT-2003 (Rel. 42, Last sequence update)  
DT 10-OCT-2003 (Rel. 42, Last annotation update)  
DE Amyloid beta A4 protein precursor (APP) (ABPP) (Alzheimer's disease  
DE amyloid protein homology) [contains: Soluble APP-alpha (S-APP-alpha);  
DE Soluble APP-beta (S-APP-beta); CTF-alpha; CTF-beta; Beta-amyloid  
DE protein 42 (beta-APP42); Beta-amyloid protein 40 (beta-APP40); P3(42);  
DE P3(40); CTF(59) (Gamma-secretase C-terminal fragment 59); Gamma-  
DE CTF(57) (Gamma-secretase C-terminal fragment 57); C31].  
GN APP.  
OS Cavia porcellus (Guinea pig).  
OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;  
OC Mammalia; Eutheria; Rodentia; Hystriognathi; Cavidae; Cavia.  
CX NCBI\_TaxId=10141;  
[1]  
RN SEQUENCE FROM N.A., AND ALTERNATIVE SPLICING.  
RP TISSUE=Brain, and Liver;  
RC MEDLINE=97236426; PubMed=9116031;  
RA Beck M., Mueller D., Bigl V.;  
RT "Amyloid precursor protein in Guinea pigs - complete cDNA sequence and  
RT alternative splicing.";  
RL Biochem. Biophys. Acta 1351:17-21 (1997).  
RN [2]  
RP INTERACTION OF BETA-APP40 WITH APOE.  
RX MEDLINE=98007700; PubMed=9349544;  
RA Martel C.L., Mackic J.B., Matsubara E., Governale S., Miguel C.,  
RA Mao W., McComb J.G., Frangione B., Ghiso J., Zlokovic B.V.;  
RT "Isoform-specific effects of apolipoproteins E2, E3, and E4 on  
RT cerebral capillary sequestration and blood-brain barrier transport of  
RT circulating Alzheimer's amyloid beta.";  
RL J. Neurochem. 69:1995-2004 (1997).  
RN [3]  
RP PROCESSING.  
RX MEDLINE=20084499; PubMed=10619481;  
RA Beck M., Brueckner W.K., Holzer M., Kaap S., Pannicke T., Arendt T.,  
RA Bigl V.;  
RT "Guinea-pig primary cell cultures provide a model to study expression  
RT and amyloidogenic processing of endogenous amyloid precursor  
RT protein.";  
RL Neuroscience 95:243-254 (2000).  
RN [4]  
RP GAMMA-SECRETASE PROCESSING.  
RX MEDLINE=20576391; PubMed=11035007;  
RA Plinix I., Musunuru U., Tun H., Sridharan A., Golde T., Eckman C.,  
RA Ziani-Cherif C., Onstead L., Sambamurti K.;  
RT "A novel gamma-secretase assay based on detection of the putative  
RT C-terminal fragment-gamma of amyloid beta protein precursor.";  
RL J. Biol. Chem. 276:481-487 (2001).  
RN [5]  
RP FUNCTION: Functions as a cell surface receptor and performs  
RP physiological functions on the surface of neurons relevant to  
RP neurite growth, neuronal adhesion and axogenesis. Involved in  
RP cell mobility and transcription regulation through protein-protein  
RP interactions (By similarity). Can promote transcription activation  
RP through binding to ABB1/Tipe0 and inhibit Notch signaling through  
RP interaction with Numb (By similarity). Couples to apoptosis-  
RP inducing pathways such as those mediated by G(O) and JIP (By  
RP similarity). Inhibits G(O) alpha ATPase activity (By similarity).  
RP Acts as a kinesin I membrane receptor, mediating the axonal  
RP transport of beta-secretase and presentin 1 (By similarity). May  
RP be involved in copper homeostasis/oxidative stress through copper  
RP ion reduction (By similarity). In vitro, copper-metalated APP  
RP induces neuronal death directly or is potentiated through Cu(II)-  
RP mediated low-density lipoprotein oxidation (By similarity). Can  
RP regulate neurite outgrowth through binding to components of the  
RP extracellular matrix such as heparin and collagen I and IV (By  
RP similarity). The splice isoforms that contain the BPTI domain  
RP possess protease inhibitor activity (By similarity).  
RN [6]  
RP FUNCTION: Beta-amyloid peptides are lipophilic metal chelators  
RP with metal-reducing activity. Bind transition metals such as  
RP copper, zinc and iron. Beta-amyloid peptides bind to lipoproteins  
RP and apolipoproteins E and J in the CSF and to HDL particles in

CC Plasma, inhibiting metal-catalyzed oxidation of lipoproteins.  
CC -1 FUNCTION: Apolipans elicit adhesion of neural cells to the  
CC extracellular matrix and may regulate neurite outgrowth in the  
CC brain (By similarity).  
CC -1 FUNCTION: The gamma-CTF peptides as well as the caspase-cleaved  
CC peptides, including C31, are potent enhancers of neuronal  
CC apoptosis (By similarity).  
CC -1 SUBUNIT: Binds, via its C-terminal, to the PID domain of several  
CC cytoplasmic proteins, including APPB family members, the APPA  
CC family, MAPK1P1, SRC1 and Numb and Dab1 (By similarity). Also  
CC interacts with GPCR-like protein BPP, FPR1, APBP1, IRI, KNS2  
CC (via its TPR domain), APPB2 (via Bass) and DDB1 (By similarity).  
CC Associates with microtubules in the presence of ATP and in a  
CC kinesin-dependent manner (By similarity). Soluble Abeta40 binds  
CC all three isoforms of APOE, in vitro and in vivo. When lipidated,  
CC APOE3 appears to be the preferred amyloid binding isoform, while  
CC the APOE4 isoform-beta-APP40 complex is capable of being  
CC transported across the blood-brain barrier.  
CC -1 SUBCELLULAR LOCATION: Type I membrane protein. Cell surface  
CC protein that rapidly becomes internalized via clathrin-coated pits  
CC (By similarity). During maturation, the immature APP (N-  
CC glycosylated in the endoplasmic reticulum) moves to the Golgi  
CC complex where complete maturation occurs (O-glycosylated and  
CC sulfated) (By similarity). After alpha-secretase cleavage, soluble  
CC APP is released into the extracellular space and the C-terminal is  
CC internalized to endosomes and lysosomes (By similarity). Some APP  
CC accumulates in secretory transport vesicles leaving the late Golgi  
CC compartment and returns to the cell surface (By similarity). APP  
CC sorts to the basolateral surface in epithelial cells (By  
CC similarity).  
CC -1 ALTERNATIVE PRODUCTS:  
CC Event-Alternative splicing, Named isoforms=2;  
CC Comment-Additional isoforms, missing exons 7, 8 and 15, seem to  
CC exist. The L-isoforms, missing exon 15, are referred to as  
CC apilipans;  
CC Name=APP770;  
CC IsoId=060495-1; Sequence=Displayed;  
CC Name=APP695;  
CC IsoId=060495-2; Sequence=VSP\_007221; VSP\_007222;  
CC TISSUE SPECIFICITY: Isoform APP695 is the major isoform found in  
CC brain. The longer isoforms containing the BPTI domain are  
CC predominantly expressed in peripheral organs such as muscle and  
CC liver.  
CC -1 INDUCTION: Increased levels during neuronal differentiation.  
CC -1 DOMAIN: The basolateral sorting signal (BSSS) is required for  
CC sorting of membrane proteins to the basolateral surface of  
CC epithelial cells.  
CC -1 DOMAIN: The NPXY sequence motif found in many tyrosine-  
CC phosphorylated proteins is required for the specific binding of  
CC the PID domain. However additional amino acids either N- or C-  
CC terminal to the NPXY motif are often required for complete  
CC interaction. The PID domain-containing proteins which bind APP  
CC require the YENPTY motif for full interaction. These interactions  
CC are independent of phosphorylation on the terminal tyrosine  
CC residue (By similarity). The NPXY site is also involved in  
CC clathrin-mediated endocytosis.  
CC -1 PTM: Proteolytically processed under normal cellular conditions.  
CC Cleavage by alpha-secretase or alternatively by beta-secretase  
CC leads to generation and extracellular release of soluble APP  
CC peptides, S-APP-alpha and S-APP-beta, respectively, and the  
CC retention of corresponding membrane-anchored C-terminal fragments,  
CC gamma-secretase yields p3 peptides. This is the major secretory  
CC pathway and is nonamyloidogenic. Alternatively,  
CC presentin/nicstrin-mediated gamma-secretase processing of CTF-  
CC beta releases the amyloid beta proteins, amyloid-beta 40 (Abeta40)  
CC and amyloid-beta 42 (Abeta42), major components of amyloid  
CC plaques, and the corresponding cytotoxic C-terminal fragments  
CC (CTFs).  
CC -1 PTM: Proteolytically cleaved by caspase-3 during neuronal  
CC apoptosis (By similarity).  
CC -1 PTM: N- and O-glycosylated. O-linkage of chondroitin sulfate to  
CC the L-APP isoforms produces the APP proteoglycan core proteins,

CC the apolipans (By similarity).

CC -1- PTM: Phosphorylation in the C-terminal on tyrosine, threonine and

CC serine residues is neuron-specific (By similarity).

CC Phosphorylation can affect APP processing, neuronal

CC differentiation and interaction with other proteins.

CC -1- PTM: Extracellular binding and reduction of copper, results in a

CC corresponding oxidation of Cys-144 and Cys-158, and the formation

CC of a disulfide bond (By similarity).

CC -1- MISCELLANEOUS: Chelation of metal ions, notably copper, iron and

CC zinc, can induce histidine-bridging between beta-amyloid molecules

CC resulting in beta-amyloid-metal aggregates.

CC -1- SIMILARITY: Belongs to the APP family.

CC -1- SIMILARITY: Contains 1 BPTI/Kunitz inhibitor domain.

CC This SWISS-PROT entry is copyright. It is produced through a collaboration

CC between the Swiss Institute of Bioinformatics and the EMBL outstation -

CC the European Bioinformatics Institute. There are no restrictions on its

CC use by non-profit institutions as long as its content is in no way

CC modified and this statement is not removed. Usage by and for commercial

CC entities requires a license agreement (see <http://www.isb-sib.ch/announce/>

CC or send an email to [license@isb-sib.ch](mailto:license@isb-sib.ch)).

CC -----

CC EMBL: X97631; CAA66230.1; -

CC EMBL: X99188; CAA67389.1; -

CC HSPB; F05067; IBA4.

CC InterPro: IPR008155; A4\_APP.

CC InterPro: IPR008154; A4\_extra.

CC InterPro: IPR002223; Kunitz\_BPTI.

CC Pfam: PF00014; Kunitz\_BPTI\_1.

CC PRINTS: PR00203; AMYOTID4.

CC PRINTS: PR00759; BASICPTASE.

CC ProDom: PD000222; Kunitz\_BPTI\_1.

CC SMART; SM00006; A4\_EXTRA; 1.

CC SMART; SM00131; KU; 1.

CC PROSITE; PS00319; A4\_EXTRA; 1.

CC PROSITE; PS00320; A4\_INTRA; 1.

CC PROSITE; PS00280; BPTI\_KUNITZ\_1; 1.

CC PROSITE; PS00779; BPTI\_KUNITZ\_2; 1.

CC KX Apoptosis; Endocytosis; Cell adhesion; Serine protease inhibitor;

CC KX Coated pits; Neutrone; Heparin-binding; Metal-binding; Copper; Iron;

CC KW Zinc; Signal; Transmembrane; Glycoprotein; Phosphorylation;

CC KM Proteoglycan; Alternative splicing; Amyloid.

CC FT SIGNAL 1 17 BY SIMILARITY.

CC FT CHAIN 18 770 AMYLOID BETA A4 PROTEIN

CC FT CHAIN 18 687 SOLUBLE APP-ALPHA (BY SIMILARITY).

CC FT CHAIN 18 671 SOLUBLE APP-BETA (BY SIMILARITY).

CC FT CHAIN 672 770 CTF-ALPHA (BY SIMILARITY).

CC FT CHAIN 672 713 BETA-AMYLOID PROTEIN 42 (BY SIMILARITY).

CC FT CHAIN 672 711 BETA-AMYLOID PROTEIN 40 (BY SIMILARITY).

CC FT CHAIN 688 770 CTF-BETA (BY SIMILARITY).

CC FT CHAIN 688 713 P3(42) (BY SIMILARITY).

CC FT CHAIN 688 711 P3(40) (BY SIMILARITY).

CC FT CHAIN 712 770 GAMMA-CTF(59) (BY SIMILARITY).

CC FT CHAIN 714 770 GAMMA-CTF(57) (BY SIMILARITY).

CC RN

Query Match 90.9%; Score 319; DB 1; Length 770;

Best Local Similarity 90.2%; Pred. No. 2,7e-30;

Matches 55; Conservative 2; Mismatches 4; Indels 0; Gaps 0;

QY 1 EVAREVSGEQAETGPCCRAIYHMYFDYTGKCAPFFYGGCGGNRNNDTEYCYMAVCGSA 60

DB 285 EVAREVSGEQAETGPCCRAIYHMYFDYTGKCAPFFYGGCGGNRNNDTEYCYMAVCGSV 344

QY 61 I 61

DB 345 M 345

RESULT 7

ID A4\_MOUSE STANDARD; PRT; 770 AA.

AC P12023; P97487; P97942; Q99K32

DT 01-OCT-1989 (Rel. 12, Created)

DT 10-OCT-2003 (Rel. 42, Last sequence update)

DT 10-OCT-2003 (Rel. 42, Last annotation update)

DE Amyloid beta A4 protein precursor (APP) (ABPP) (Alzheimer's disease

DE amyloid protein) (Amyloidogenic glycoprotein) (AG) [Contents:

DE Soluble APP-alpha (S-APP-alpha); Soluble APP-beta (S-APP-beta); C99

DE (APP-C99); Beta-amyloid protein 42 (Beta-APP42); Beta-amyloid protein

DE 40 (Beta-APP40); C83; P3(42); P3(40); Gamma-CTF(59) (Gamma-secretase

DE C-terminal fragment 59) (Amyloid intracellular domain 59) (AID(59))

DE (APP-C59); Gamma-CTF(57) (Gamma-secretase C-terminal fragment 57)

DE (Amyloid intracellular domain 57) (AID(57)) (APP-C57); Gamma-CTF(50)

DE (Gamma-secretase C-terminal fragment 50) (Amyloid intracellular domain

DE 50) (AID(50)); C31].

GN APP.

OS Mus musculus (Mouse).

OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;

OC Mammalia; Eutheria; Rodentia; Sciurognathi; Muridae; Mus.

OC NCBI\_Taxid=10090;

RN [1]

RP SEQUENCE FROM N.A. (ISOFORN APP695).

RC TISSUE=Brain;

RX MEDLINE=88106489; PubMed=3322280;

RA Yamada T., Sasaki H., Furuya H., Miyata T., Goto I., Sasaki Y.;

RT "Complementary DNA for the mouse homolog of the human amyloid beta

RL Biochem. Biophys. Res. Commun. 149:665-671(1987).

RN [2]

RP REVISIONS.

RA Yamada T.;

RL Submitted (MAR-1988) to the EMBL/GenBank/DBJ databases.

RN [3]

RP SEQUENCE FROM N.A. (ISOFORN APP695).

RC STRAIN=BALB/c; TISSUE=Brain;

RX MEDLINE=92096458; PubMed=1756177;

RA de Strooper B., van Leuven F., van den Berghe H.;

RT "The amyloid beta protein precursor or proteinase nexin II from mouse

RL Biochim. Biophys. Acta 1129:141-143(1991).

RN [4]

RP SEQUENCE FROM N.A. (ISOFORN APP695).

RC STRAIN=SAMP8; TISSUE=Hippocampus;

RX MEDLINE=21130647; PubMed=11235921.

RA Kumar V.B., Woyas K., Franko K., Choudhary V., Buddhireja C.;

RT "Molecular cloning, expression, and regulation of hippocampal amyloid

RL Biochem. Cell Biol. 79:57-67(2001).

RN [5]

RP SEQUENCE OF 1-19 FROM N.A.

RX MEDLINE=92209998; PubMed=1555768;

RA Izumi R., Yamada T., Yoshikai S.I., Sasaki H., Hattori M.;

RT Sakai Y.;

RT "Positive and negative regulatory elements for the expression of the

RL Alzheimer's disease amyloid precursor-encoding gene in mouse.;"

RN [6]

RP PARTIAL SEQUENCE FROM N.A. (ISOFORN APP770).

RC TISSUE=Breast tumor;

RX MEDLINE=22388257; PubMed=12477932;

RA Strausberg R.L., Feingold E.A., Grouse L.H., Derge J.G.;

RA Klausner R.D., Collins F.S., Wagner L., Shenmen C.M., Schuler G.D.;

RA Altschul S.F., Zeeberg B., Buetow K.H., Schaefer C.F., Bhat N.K.;

RA Hopkins R.F., Jordan H., Moore T., Max S.I., Wang J., Hsieh F.;

RA Diatchenko L., Marusina K., Farmer A.A., Rubin G.M., Hong L.;

RA Stapleton M., Soares M.B., Bonaldo M.F., Casavant T.L., Scheetz T.E.;

RA Brownstein M.J., Usdin T.B., Toshimiyuki S., Carrincci P., Prange C.;

RA Raha S.S., Loggellano N.A., Peters G.J., Abramson R.D., Mullaly S.J.;

RA Bosak S.A., McEwan P.J., McKernan K.J., Malek J.A., Gunaratne P.H.;

RA Richards S., Worley K.C., Hale S., Garcia A.M., Gay L.J., Bullyk S.W.;

RA Villalón D.K., Muzny D.M., Sodergren E.J., Lu X., Gibbs R.A.;

RA Fahy J., Helton E., Kettman M., Madan A.C., Rodriguez S., Sanchez A.;

RA Whiting M., Madan A., Young A.C., Scherchenko Y., Bouffard G.G.;

RA Blakesley A.C., Grimwood J., Schmutz J., Myers R.W.;

RA Butterfield Y.S.N., Krzywinski M.I., Skalek U., Smalins D.E.,  
 RA Scherch A., Schein J.E., Jones S.T.M., Marra W.A.,  
 RT "Generation and initial analysis of more than 15,000 full-length human  
 RT and mouse cDNA sequences.",  
 RL Proc. Natl. Acad. Sci. U.S.A. 99:16899-16903(2002).  
 [7]  
 RP SEQUENCE OF 281-380 FROM N.A., AND ALTERNATIVE SPLICING.  
 RC TISSUE=Brain, and Kidney;  
 RX MEDLINE=89149813; PubMed=2493250;  
 RA Yamada T., Sasaki H., Dohura K., Goto I., Sasaki Y.,  
 RT "Structure and expression of the alternatively-spliced forms of mRNA  
 RT for the mouse homolog of Alzheimer's disease amyloid beta protein  
 RT precursor.",  
 RL Biochem. Biophys. Res. Commun. 158:906-912(1989).  
 [8]  
 RP SEQUENCE OF 289-364 FROM N.A.  
 RC STRAIN=CD-1; TISSUE=Placenta;  
 RX MEDLINE=89345111; PubMed=2569710;  
 RA Fukuchi K., Martin G.M., Deep S.S.,  
 RT "Sequence of the protease inhibitor domain of the A4 amyloid protein  
 RT precursor of Mus domesticus.",  
 RL Nucleic Acids Res. 17:5396-5396(1989).  
 [9]  
 RP SEQUENCE OF 656-737 FROM N.A.  
 RC STRAIN=129/Sv;  
 RA Wragg M.A., Busfield F., Duff K., Korembat K., Capecci M.,  
 RT Loring J.F., Goate A.M.,  
 RT "Introduction of six mutations into the mouse genome using 'Hit and  
 RT Run' gene-targeting: introduction of familial Alzheimer's disease  
 RT mutations into the mouse amyloid precursor protein gene and  
 RT humanized (DEC-196) to the EMBL/GenBank/DBJ databases.  
 [10]  
 RP TISSUE SPECIFICITY OF ALTERNATIVE SPLICED FORMS.  
 RX MEDLINE=93287808; PubMed=8510506;  
 RA Sola C., Mengod G., Ghetti B., Palacios J.M., Triahou L.C.,  
 RT "Regional distribution of the alternatively spliced isoforms of beta  
 RT APP RNA transcript in the brain of normal, heterozygous and  
 RT homozygous weaver mutant mice as revealed by in situ hybridization  
 RT histochemistry.",  
 RL Brain Res. Mol. Brain Res. 17:340-346(1993).  
 [11]  
 RP INTERACTION WITH KNS2.  
 RX MEDLINE=21010507; PubMed=11144355;  
 RA Kamal A., Stokin G.B., Yang Z., Xia C.-H., Goldstein L.S.,  
 RT "Axonal transport of amyloid precursor protein is mediated by direct  
 RT binding to the kinesin light chain subunit of kinesin-I.",  
 RL Neuron 28:449-459(2000).  
 [12]  
 RP C-TERMINAL PROTEIN-PROTEIN INTERACTIONS, AND MUTAGENESIS OF TYR-728;  
 RP THR-743, TYR-757, ASN-759 AND TYR-762.  
 RX MEDLINE=210408156; PubMed=1517249;  
 RA Matsuda S., Yasukawa T., Homma Y., Ito Y., Nikura T., Hiraki T.,  
 RA Hirai S., Ohno S., Kita Y., Kawasumi M., Koyama K., Yamamoto T.,  
 RA Kyriakis J.M., Nishimoto I.,  
 RT "C-jun N-terminal kinase (JNK)-interacting protein-1b/1a/1c/brain-1  
 RT scaffolds Alzheimer's amyloid precursor protein with JNK.",  
 RL J. Neurosci. 21:6597-6607(2001).  
 [13]  
 RP INTERACTION WITH MAPK8IP1, AND PHOSPHORYLATION.  
 RX MEDLINE=22028091; PubMed=11912189;  
 RA Tani H., Iijima K.-I., Hase M., Kirino Y., Yagi Y., Suzuki T.,  
 RT "Interaction of Alzheimer's beta-amyloid precursor family proteins  
 RT with scaffold proteins of the JNK signaling cascade.",  
 RL J. Biol. Chem. 277:20070-20078(2002).  
 [14]  
 RP INTERACTION OF CTF PEPTIDES WITH NUMB.  
 RX MEDLINE=22008109; PubMed=12011466;  
 RA Roncarati R., Sestan N., Scheinfeld M.H., Berechid B.E., Lopez P.A.,  
 RA Meucci O., McGlade J.C., Rakic P., D'Adamo L.,  
 RT "The gamma-secretase-generated intracellular domain of beta-amyloid  
 RT precursor protein Numb and inhibits Notch signaling.",  
 RL Proc. Natl. Acad. Sci. U.S.A. 99:7102-7107(2002).

[15]  
 RP GAMMA-SECRETASE PROCESSING, AND INTERACTION WITH APPB1.  
 RX MEDLINE=21437805; PubMed=11553691;  
 RA Cupers P., Orlans I., Craessaerts K., Annaert W., De Strooper B.,  
 RT "The amyloid precursor protein (APP)-cytoplasmic fragment generated by  
 RT gamma-secretase is rapidly degraded but distributes partially in a  
 RT nuclear fraction of neurons in culture.",  
 RL J. Neurochem. 78:1168-1178(2001).  
 [16]  
 RP FUNCTION: Functions as a cell surface receptor and performs  
 CC physiological functions on the surface of neurons relevant to  
 CC neurite growth, neuronal adhesion and axonogenesis. Involved in  
 CC cell motility and transcription regulation through protein-protein  
 CC interactions. Can promote transcription activation through binding  
 CC to APBB1/Tip60 and inhibit Notch signaling through interaction  
 CC with Numb. Couples to apoptosis-inducing pathways such as those  
 CC mediated by G(0) and JIP. Inhibits G(0) alpha ATPase activity (By  
 CC similarity). Acts as a kinesin I membrane receptor, mediating the  
 CC axonal transport of beta-secretase and presenilin 1. May be  
 CC involved in copper homeostasis/oxidative stress through copper ion  
 CC reduction. Can regulate neurite outgrowth through binding to  
 CC components of the extracellular matrix such as heparin and  
 CC collagen I and IV (By similarity). The splice isoforms that  
 CC contain the BPT1 domain possess protease inhibitor activity (By  
 CC similarity).  
 [17]  
 RP FUNCTION: Beta-amyloid peptides are lipophilic metal chelators  
 CC with metal-reducing activity. Bind transient metals such as  
 CC copper, zinc and iron. Rat and mouse beta-amyloid peptides bind  
 CC only weakly transient metals and have little reducing activity due  
 CC to substitutions of transient metal chelating residues. Beta-APP2  
 CC may activate mononuclear phagocytes in the brain and elicit  
 CC inflammatory responses. Promotes both tau aggregation and TPK II-  
 CC mediated phosphorylation (By similarity).  
 [18]  
 RP FUNCTION: The gamma-CTF peptides as well as the caspase-cleaved  
 CC peptides, including C31, are potent enhancers of neuronal  
 CC apoptosis.  
 [19]  
 RP SUBUNIT: Binds, via its C-terminal, to the PID domain of several  
 CC cytoplasmic proteins, including APBB family members, the APBA  
 CC family, MAPK8IP1, SHC1, Numb and Dab1. Binding to Dab1 inhibits  
 CC its serine phosphorylation. Also interacts with GPCR-like protein  
 CC BPP, FPR1, APPB1, IBL, KNS2 (via its TPR domains), APPB2 (via  
 CC BASS) and DDB1 (By similarity). In vitro, it binds MAP7 via the  
 CC MT-binding domains (By similarity). Associates with microtubules  
 CC in the presence of Arp and in a kinesin-dependent manner (By  
 CC similarity). Interacts, through a C-terminal domain, with GNO1  
 CC (By similarity). Amyloid beta-42 binds GRNAV in hippocampal  
 CC neurons (By similarity). Beta-amyloid associates with HADH2 (By  
 CC similarity).  
 [20]  
 RP SUBCELLULAR LOCATION: Type I membrane protein. Cell surface  
 CC protein that rapidly becomes internalized via clathrin-coated  
 CC pits. During maturation, the immature APP (N-glycosylated in the  
 CC endoplasmic reticulum) moves to the Golgi complex where complete

Query Match 90.3%; Score 317; DB 1; Length 770;  
 Best Local Similarity 93.2%; Pred. No. 4,7e-30;  
 Matches 55; Conservative 0; Mismatches 4; Indels 0; Gaps 0;  
 QY 1 EVREVCSEQAEITGPCRAIYHYFVTEKCAFFYGGCGGRNNFTDEECYMAVCGS 59  
 DB 285 EVREVCSEQAEITGPCRAMISRWYFDVTEKCVFFYGGCGGRNNFTDEECYMAVCGS 343

RESULT 8  
 A4\_MACMU STANDARD; PRT; 76 AA.  
 ID A4\_MACMU  
 AC P29216;  
 DT 01-DEC-1992 (Rel. 24, Created)  
 DT 01-DEC-1992 (Rel. 24, Last sequence update)  
 DT 10-OCT-2003 (Rel. 42, Last annotation update)  
 DE Alzheimer's disease amyloid A4 protein (Fragment).  
 GN APP.  
 OS Macaca mulatta (Rhesus macaque).  
 OS Eukaryota; Metazoa; Chordata; Vertebrata; Euteleostomi;  
 OC Mammalia; Eutheria; Primates; Catarrhini; Cercopithecoidea;

CC Cercopithecinae; Macaca.  
 OX NCBI\_TaxID=9544;  
 RN [1]  
 RP SEQUENCE FROM N.A.  
 RC TISSUE=Brain;  
 RX MEDLINE=90180499; PubMed=2106906;  
 RA Koo E.H., Sisodia S.S., Cork L.C., Unterbeck A., Bayney R.M.,  
 RA Price D.L.;  
 RT "Differential expression of amyloid precursor protein mRNAs in cases  
 of Alzheimer's disease and in aged nonhuman primates.";  
 RL Neuron 4:97-104(1990).  
 CC -1- FUNCTION: Functional neuronal receptor which couples to  
 intracellular signaling pathway through the GTP-binding protein  
 G(O) (By similarity).  
 CC -1- SUBCELLULAR LOCATION: Type I membrane protein.  
 CC -1- ALTERNATIVE PRODUCTS:  
 CC Event=Alternative splicing; Named isoforms=5;  
 CC Comment=Experimental confirmation may be lacking for some  
 isoforms;  
 CC Name=APP(770);  
 CC IsoId=P29216-1; Sequence=Displayed;  
 CC Name=APP(395);  
 CC IsoId=P29216-2; Sequence=Not described;  
 CC Name=APP(563);  
 CC IsoId=P29216-3; Sequence=Not described;  
 CC Name=APP(695);  
 CC IsoId=P29216-4; Sequence=Not described;  
 CC Name=APP(751);  
 CC IsoId=P29216-5; Sequence=Not described;  
 CC -1- SIMILARITY: Belongs to the APP family.  
 CC -1- SIMILARITY: Contains 1 BPT/Kuntz inhibitor domain.  
 CC -----  
 CC This SWISS-PROT entry is copyright. It is produced through a collaboration  
 between the Swiss Institute of Bioinformatics and the EMBL outstation -  
 the European Bioinformatics Institute. There are no restrictions on its  
 use by non-profit institutions as long as its content is in no way  
 modified and this statement is not removed. Usage by and for commercial  
 entities requires a license agreement (See <http://www.isb-sib.ch/announce/>  
 or send an email to [license@isb-sib.ch](mailto:license@isb-sib.ch)).  
 CC -----  
 DR EMBL; X15985; CAA34116.1; -;  
 DR PIR; S06678; S06678.  
 DR HSSP; P05067; 1AAP.  
 DR InterPro; IPR008155; A4\_APP.  
 DR InterPro; IPR002223; Kuntz\_BPTI.  
 DR Pfam; PF00014; Kuntz\_BPTI; 1.  
 DR PRINTS; PR00759; BASICPTASE.  
 DR ProDom; PD000222; Kuntz\_BPTI; 1.  
 DR SMART; SM00311; KU; 1.  
 DR PROSITE; PS00319; A4\_EXTRA; PARTIAL.  
 DR PROSITE; PS00320; A4\_INTRA; PARTIAL.  
 DR PROSITE; PS00280; BPTI\_KUNITZ\_1; 1.  
 DR PROSITE; PS50279; BPTI\_KUNITZ\_2; 1.  
 KW Glycoprotein; Amyloid; Neurone; Alternative splicing;  
 KM Serine protease inhibitor.  
 FT NON TER 1 1  
 FT DOMAIN 1 76 BPTI/KUNITZ INHIBITOR.  
 FT ACT\_SITE 13 14 REACTIVE BOND.  
 FT DISULFID 53 53 BY SIMILARITY.  
 FT DISULFID 12 36 BY SIMILARITY.  
 FT DISULFID 28 49 BY SIMILARITY.  
 FT NON TER 76 76  
 SQ SEQUENCE 76 AA; 8527 MW; 492BF3069AB082A1 CRC64;  
 Query Match 86.6%; Score 304; DB 1; Length 76;  
 Best Local Similarity 91.2%; Pred. No. 1.7e-29;  
 Matches 52; Conservative 1; Mismatches 4; Indels 0; Gaps 0;  
 QY 5 EVCSQAETPCRAATYHWYFDVTEGKCAPFFYGGCGGNRNPDTEYCNAYGSAI 61  
 DB 1 EVCSQAETPCRAATYHWYFDVTEGKCAPFFYGGCGGNRNPDTEYCNAYGSAI 57

RESULT 9  
 APP2\_HUMAN  
 ID APP2\_HUMAN STANDARD; PRT; 763 AA.  
 AC Q06481;  
 DT 01-JUN-1994 (Rel. 29, Created)  
 DT 01-OCT-1996 (Rel. 34, Last sequence update)  
 DT 15-MAR-2004 (Rel. 43, Last annotation update)  
 DE Amyloid-like protein 2 precursor (Amyloid protein homolog) (APPH)  
 DE (CDEI-box binding protein) (CDEBP).  
 GN APLP2 OR APLP2.  
 OS Homo sapiens (Human).  
 OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;  
 OC Mammalia; Eutheria; Primates; Catarrhini; Homnidae; Homo.  
 OX NCBI\_TaxID=9606;  
 RP SEQUENCE FROM N.A.  
 RC TISSUE=Placenta;  
 RX MEDLINE=93250009; PubMed=8485127;  
 RA Sprecher C.A., Grant F.J., Grimm G., O'Hara P.J., Norris F.,  
 RA Norris K., Foster D.C.;  
 RT "Molecular cloning of the cDNA for a human amyloid precursor protein  
 RT homolog: evidence for a multigene family.";  
 RL Biochemistry 32:4481-4486(1993).  
 RN [2]  
 RP SEQUENCE FROM N.A.  
 RC TISSUE=Ovary;  
 RX MEDLINE=95217334; PubMed=7702756;  
 RA von der Kammer H., Hanes U., Klaiding J., Scheit K.H.;  
 RT "A human amyloid precursor-like protein is highly homologous to a  
 RT mouse sequence-specific DNA-binding protein.";  
 RL DNA Cell Biol. 13:1137-1143(1994).  
 RN [3]  
 RP SEQUENCE FROM N.A.  
 RC TISSUE=Brain;  
 RX MEDLINE=94035131; PubMed=8220435;  
 RA Waso W., Gurubhagavatlula S., Paradis M., Romano D.M., Sisodia S.S.,  
 RA Hyman B.T., Neve R.L., Tanzi R.E.;  
 RT "Isolation and characterization of APLP2 encoding a homologue of the  
 RT Alzheimer's associated amyloid beta protein precursor.";  
 RL Nat. Genet. 5:95-99(1993).  
 RN [4]  
 RP SEQUENCE FROM N.A. (ISOFORM 3).  
 RC TISSUE=Lung;  
 RX MEDLINE=22388257; PubMed=12477932;  
 RA Strausberg R.L., Feingold E.A., Grouse L.H., Derge J.G.,  
 RA Klausner R.D., Collins F.S., Wagner L., Shenman C.M., Schuler G.D.,  
 RA Altschul S.F., Zeeberg B., Buetow K.H., Schaefer C.F., Bhat N.K.,  
 RA Hopkins R.F., Jordan H., Moore T., Wax S.I., Wang J., Heish F.,  
 RA Diachenko L., Narusina K., Farmer A.A., Rubin G.M., Hong L.,  
 RA Stapleton M., Soares M.B., Bonaldo M.F., Casavant T.L., Scheetz T.E.,  
 RA Brownstein M.J., USCIN T.B., Toshitsuki S., Carninci P., Prange C.,  
 RA Raha S.S., Loquellano N.A., Peters G.J., Abramson R.D., Mullaby S.J.,  
 RA Bosak S.A., McGowan P.J., McKernan K.J., Malek J.A., Gunaratne P.H.,  
 RA Richards S., Worley K.C., Hale S., Garcia A.M., Gay L.U., Hulyk S.W.,  
 RA Villalón D.K., Muzny D.M., Sodergren E.J., Lu X., Gibbs R.A.,  
 RA Fahey U., Helton E., Kettelman X., Madan A., Rodriguez S., Sanchez A.,  
 RA Whitting M., Madan A., Young A.C., Shevchenko Y., Bouffard G.G.,  
 RA Blakesley R.W., Touchman J.W., Green E.D., Dickson M.C.,  
 RA Rodriguez A.C., Grimwood J., Schmutz J., Myers R.M.,  
 RA Butterfield Y.S.N., Krzywnicki M.I., Skalska U., Smalins D.E.,  
 RA Schnerch A., Schein J.E., Jones S.J.M., Marra M.A.,  
 RT "Generation and initial analysis of more than 15,000 full-length  
 RT human and mouse cDNA sequences.";  
 RL Proc. Natl. Acad. Sci. U.S.A. 99:11699-116903(2002).  
 CC -1- FUNCTION: May play a role in the regulation of hemostasis. The  
 CC soluble form may have inhibitory properties towards coagulation  
 CC factors. May interact with cellular G-protein signaling pathways.  
 CC May bind to the DNA 5'-GTCACATG-3' (CDEI box).  
 CC -1- SUBCELLULAR LOCATION: Type I membrane protein and nuclear  
 CC (potential).  
 CC -1- ALTERNATIVE PRODUCTS:  
 CC Event=Alternative splicing; Named isoforms=3;  
 CC Comment=Additional isoforms seem to exist;

```

CC Name:1;
CC IsoId-Q06481-1; Sequence=Displayed;
CC Name:2;
CC IsoId-Q06481-2; Sequence=VSP_000018;
CC Name:3;
CC IsoId-Q06481-3; Sequence=VSP_000019;
CC -1- TISSUE SPECIFICITY: in placenta, brain, heart, lung, liver, kidney
and endothelial tissues.
CC -1- SIMILARITY: Belongs to the APP family.
CC -1- SIMILARITY: Contains 1 BPT/Kunitz inhibitor domain.
CC -----
CC This SWISS-PROT entry is copyright. It is produced through a collaboration
between the Swiss Institute of Bioinformatics and the EMBL outstation --
the European Bioinformatics Institute. There are no restrictions on its
use by non-profit institutions as long as its content is in no way
modified and this statement is not removed. Usage by and for commercial
entities requires a license agreement (See http://www.isb-sib.ch/announce/
or send an email to license@isb-sib.ch).
CC -----
DR EMBL; S60089; AAC60589.1; -
DR EMBL; L09289; AAA5526.1; -
DR EMBL; Z22572; CAA80295.1; -
DR EMBL; L27631; AAC41701.1; -
DR EMBL; BC000373; AAH00373.1; -
DR PIR; A49321; A49321.
DR HSSP; P05067; IIMP.
DR Genew; HGNC:598; APLP2.
DR MIM; 104775; -
DR GO; GO:0016021; C.integral to membrane; NAS.
DR GO; GO:0005634; C.nucleus; IDA.
DR GO; GO:0003577; F.DNA binding; NAS.
DR GO; GO:0007186; P.G-protein coupled receptor protein signaling. .; NAS.
DR InterPro; IPR008155; A4_APP.
DR InterPro; IPR008154; A4_extra.
DR InterPro; IPR002223; Kunitz_BPTI.
DR Pfam; PR02177; A4_EXTRA; 1.
DR Pfam; PR00014; Kunitz_BPTI; 1.
DR PRINTS; PR08203; AMYLOIDM4.
DR PRINTS; PR08759; BASICPTASE.
DR PRODOM; PD000222; Kunitz_BPTI; 1.
DR SMART; SMO0006; A4_EXTRA; 1.
DR SMART; SMO0131; KU; 1.
DR PROSITE; PS00319; A4_EXTRA; 1.
DR PROSITE; PS00330; A4_INTRA; 1.
DR PROSITE; PS00280; BPTI_KUNITZ_1; 1.
DR PROSITE; PS50279; BPTI_KUNITZ_2; 1.
DR Trasnembrane; Signal; Alternate splicing; DNA-binding;
KW Nuclear protein; Serine protease inhibitor.
FT SIGNAL 1 29
FT CHAIN 30 763
FT DOMAIN 30 692
FT TRANSEM 693 716
FT DOMAIN 717 763
FT DOMAIN 215 280
FT DOMAIN 306 364
FT DOMAIN 215 231
FT ACT_SITE 320 321
FT DISULFID 310 360
FT DISULFID 319 343
FT DISULFID 335 356
FT VASPLIC 308 363
FT VASPLIC 613 624
FT VASPLIC 613 624
FT CONFLICT 543 543
FT SEQ 763 AA; 86955 NM; CAA76DBDB8A28D0 CRC64;
Query Match 57.8%; Score 238; DB 1; Length 763;
Best Local Similarity 64.4%; Pred. No. 1.le-20;
Matches 38; Conservative 11; Mismatches 10; Indels 0; Gaps 0;
3 YREVCSQAATGTCRAAIHWFVDTEBKCAFFYGGCGGRNNRFDREYCMAYCSAI 61

```

```

Db          306 VAAVSOEAMGPGCRAWPEWYFDLSKGCVRPIYGGCGANNFNESEBDYCMAYCKAMI 364

RESULT 10
APP2_RAT
ID APP2_RAT STANDARD; PRT; 765 AA.
AC P15943;
DT 01-APR-1990 (Rel. 14, Created)
DT 01-OCT-1996 (Rel. 34, Last sequence update)
DT 28-FEB-2003 (Rel. 41, Last annotation update)
DE Amyloid-like protein 2 precursor (Sperm membrane protein YMK-II).
GN APP2.
OS Rattus norvegicus (Rat).
OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC Mammalia; Eutheria; Rodentia; Sciurognathi; Muridae; Murinae; Rattus.
OX NCBI_TaxId:10116;
RN [1]
RP SEQUENCE OF 1-627 FROM N.A.
RC STRAIN=Miscar; TISSUE=Brain, and Heart;
RX MEDLINE=94368849; PubMed=8086458;
RA Sandbrink R., Masters C.L., Beyreuther K.;
RT "Complete nucleotide and deduced amino acid sequence of rat amyloid
RT protein precursor-like protein 2 (APP2/APPH): two amino acids length
RT difference to human and murine homologues.";
RL Biochim. Biophys. Acta 1219:167-170(1994).
RN [2]
RP SEQUENCE OF 575-765 FROM N.A.
RC TISSUE=Testis;
RX MEDLINE=90207205; PubMed=1690887;
RA Yan Y.C., Bai Y., Wang L.F., Miao S.Y., Koide S.S.;
RT "Characterization of cDNA encoding a human sperm membrane protein
RT related to A4 amyloid protein.";
RL Proc. Natl. Acad. Sci. U.S.A. 87:2405-2408(1990).
RN [1] SUBCELLULAR LOCATION: Type I membrane protein.
-1- ALTERNATIVE PRODUCTS:
CC Event=Alternative splicing; Named isoforms=4;
CC Name=A;
CC IsoId=P15943-1; Sequence=Displayed;
CC Name=B;
CC IsoId=P15943-2; Sequence=VSP_000021;
CC Name=C;
CC IsoId=P15943-3; Sequence=VSP_000020;
CC Name=D;
CC IsoId=P15943-4; Sequence=VSP_000020, VSP_000021;
CC -1- SIMILARITY: Belongs to the APP family.
CC -1- SIMILARITY: Contains 1 BPTI/Kunitz inhibitor domain.
CC -----
CC This SWISS-Prot entry is copyright. It is produced through a collaboration
CC between the Swiss Institute of Bioinformatics and the EMBL outstation
CC at the European Bioinformatics Institute. There are no restrictions on
CC use by non-profit institutions as long as its content is in no way
CC modified and this statement is not removed. Usage by and for commercial
CC entities requires a license agreement (See http://www.isb-sib.ch/announce/
CC or send an email to license@sib.ch).
CC -----
DR EMBL, X77934; CAA54906.1; -
DR EMBL, M31322; AAA42352.1; -
DR PIR, A35981; A35981.
DR PIR, S42880; S42880.
DR HSSP, P05067; 1MPD.
DR InterPro: IPRO08155; A4 APP.
DR InterPro: IPRO08154; A4 extra.
DR InterPro: IPRO02223; Kunitz_BPTI.
DR Pfam, PRO2177; A4_EXTRA; 1.
DR Pfam, PRO0014; Kunitz_BPTI; 1.
DR PRINTS, PR00203; AMTLOIDM4.
DR PRINTS, PR00759; SASICPTASE.
DR ProDom, PD000222; Kunitz_BPTI; 1.
DR SMART, SM00006; A4_EXTRA; 1.
DR SMART, SM00131; KU; 1.
DR PROSITE, PS00319; A4_EXTRA; 1.
DR PROSITE, PS00320; A4_INTRA; 1.
DR PROSITE, PS00280; BPTI_KUNITZ_1; 1.

```

DR PROSITE; PS50279; BPTI\_KUNITZ\_2; 1.  
KM Transmembrane; Alternative splicing; Serine protease inhibitor;  
KW Signal; Glycoprotein.  
FT CHAIN 1  
FT SIGNAL 29  
FT CHAIN 30  
FT SIGNAL 30  
FT DOMAIN 30  
FT TRANSMEM 695  
FT SIGNAL 718  
FT DOMAIN 719  
FT SIGNAL 765  
FT DOMAIN 218  
FT SIGNAL 308  
FT ACT\_SITE 322  
FT DISULFID 312  
FT DISULFID 312  
FT DISULFID 337  
FT DISULFID 358  
FT DOMAIN 218  
FT CARBOHYD 628  
FT VARSPPLIC 311  
FT VARSPPLIC 616  
FT CONFLICT 575  
FT SEQUENCE 765 AA; 86882 MW; CFS1FCCCE305A0CF CRC64;  
Query Match 67.8%; Score 238; DB 1; Length 765;  
Best Local Similarity 64.4%; Pred. No. 1.1e-20;  
Matches 38; Conservative 11; Mismatches 10; Indels 0; Gaps 0;  
QY 3 VAEVSEQAETGCPRAIYHMYEDYEGKCAPFEYGGCGGNRNPDTEYCMACGSAI 61  
DB 308 VKAVCSQEMTGPCNAVMFRMYFDLSKGVCFIYGGCGGNRNPNFSEEDYCMACVCKTMI 366  
RESULT 11  
A4\_FUGRU STANDARD; PRT; 737 AA.  
AC 093379;  
DT 10-OCT-2003 (Rel. 42, Created)  
DT 10-OCT-2003 (Rel. 42, Last sequence update)  
DT 10-OCT-2003 (Rel. 42, Last annotation update)  
DE Alzheimer's disease amyloid A4 protein homolog precursor [Contains:  
Beta-amyloid protein (Beta-Ap) (A-beta)].  
GN APP.  
OS Fugu rubripes (Japanese pufferfish) (Takifugu rubripes).  
OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;  
OC Actinopterygii; Neopterygii; Teleostei; Euteleostei; Neoteleostei;  
OC Acanthomorpha; Acanthopterygii; Percomorpha; Tetraodontiformes;  
OC Tetraodontidae; Tetraodontidae; Takifugu.  
OX NCBI\_TaxID=31033;  
RN [1]  
RP SEQUENCE FROM N.A.  
RX MEDLINE=98252138; PubMed=9599080;  
RA Villard L., Tassone F., Crnogorac-Jurcovic T., Clancy K., Gardiner K.;  
RT "Analysis of pufferfish homologues of the A4-rich human App gene";  
RL Gene 210:17-24 (1998).  
CC -1- FUNCTION: Functional neuronal receptor which couples to  
intracellular signaling pathway through the GTP-binding protein  
G(O) (By similarity).  
CC -1- SUBCELLULAR LOCATION: Type I membrane protein.  
CC -1- SIMILARITY: Belongs to the APP family.  
CC -1- SIMILARITY: Contains 1 BPTI/Kunitz inhibitor domain.  
CC This SWISS-PROT entry is copyright. It is produced through a collaboration  
between the Swiss Institute of Bioinformatics and the EMBL outstation -  
the European Bioinformatics Institute. There are no restrictions on its  
use by non-profit institutions as long as its content is in no way  
modified and this statement is not removed. Usage by and for commercial  
entities requires a license agreement (See <http://www.ebi.ac.uk/announcements>  
or send an email to [license@ebi.ac.uk](mailto:license@ebi.ac.uk)).  
CC EMBL; AF090120; AAD13392.1; -  
DR HSSP; P05067; IH23.  
DR InterPro; IPR008155; A4\_APP.  
DR InterPro; IPR008154; A4\_extra.

DR InterPro; IPR001255; Beta-APP.  
DR InterPro; IPR002223; Kunitz\_BPTI.  
DR Pfam; PF02177; A4\_EXTRA; 1.  
DR Pfam; PF03494; Beta-APP; 1.  
DR Pfam; PF00014; Kunitz\_BPTI; 1.  
DR PRINTS; PR00203; AMYLOIDA4.  
DR PRINTS; PR00759; BASICPTASE.  
DR PRODOM; PD00006; A4\_EXTRA; 1.  
DR SMART; SM00006; A4\_EXTRA; 1.  
DR SMART; SM00131; KU; 1.  
DR PROSITE; PS00319; A4\_EXTRA; FALSE\_NEG.  
DR PROSITE; PS00320; A4\_INTRA; 1.  
DR PROSITE; PS00288; BPTI\_KUNITZ\_1; 1.  
DR PROSITE; PS50279; BPTI\_KUNITZ\_2; 1.  
KM Glycoprotein; Amyloid; Neurone; Transmembrane; Signal;  
KW Serine protease inhibitor.  
FT CHAIN 1  
FT SIGNAL 18  
FT CHAIN 19  
FT CHAIN 19  
FT CHAIN 639  
FT DOMAIN 19  
FT TRANSMEM 668  
FT TRANSMEM 689  
FT DOMAIN 690  
FT DOMAIN 737  
FT SIGNAL 726  
FT ACT\_SITE 300  
FT ACT\_SITE 301  
FT DISULFID 290  
FT DISULFID 299  
FT DISULFID 315  
FT CARBOHYD 522  
FT SEQUENCE 737 AA; 82856 MW; 6FAD01E3B32B7E2 CRC64;  
Query Match 67.2%; Score 236; DB 1; Length 737;  
Best Local Similarity 62.3%; Pred. No. 1.8e-20;  
Matches 38; Conservative 11; Mismatches 12; Indels 0; Gaps 0;  
QY 1 EVVREYCSQAETGCPRAIYHMYEDYEGKCAPFEYGGCGGNRNPDTEYCMACGSAI 60  
DB 284 EVVRAVCMAQADSGPCRAIYHMYEDYEGKCAPFEYGGCGGNRNPNFSEEDYCMACVCKTMI 343  
QY 61 I 61  
DB 344 L 344  
RESULT 12  
A4\_TETFL STANDARD; PRT; 780 AA.  
AC 073683;  
DT 10-OCT-2003 (Rel. 42, Created)  
DT 10-OCT-2003 (Rel. 42, Last sequence update)  
DT 10-OCT-2003 (Rel. 42, Last annotation update)  
DE Alzheimer's disease amyloid A4 protein homolog precursor [Contains:  
Beta-amyloid protein (Beta-Ap) (A-beta)].  
GN APP.  
OS Tetraodon fluviatilis (Puffer fish).  
OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;  
OC Actinopterygii; Neopterygii; Teleostei; Euteleostei; Neoteleostei;  
OC Acanthomorpha; Acanthopterygii; Percomorpha; Tetraodontiformes;  
OC Tetraodontidae; Tetraodontidae; Tetraodon.  
OX NCBI\_TaxID=47145;  
RN [1]  
RP SEQUENCE FROM N.A.  
RX MEDLINE=98252138; PubMed=9599080;  
RA Villard L., Tassone F., Crnogorac-Jurcovic T., Clancy K., Gardiner K.;  
RT "Analysis of pufferfish homologues of the A4-rich human App gene";  
RL Gene 210:17-24 (1998).  
CC -1- FUNCTION: Functional neuronal receptor which couples to  
intracellular signaling pathway through the GTP-binding protein  
G(O) (By similarity).  
CC -1- SUBCELLULAR LOCATION: Type I membrane protein.  
CC -1- SIMILARITY: Belongs to the APP family.  
CC -1- SIMILARITY: Contains 1 BPTI/Kunitz inhibitor domain.

CC This SWISS-PROT entry is copyright. It is produced through a collaboration  
 CC between the Swiss Institute of Bioinformatics and the EMBL outstation -  
 CC the European Bioinformatics Institute. There are no restrictions on its  
 CC use by non-profit institutions as long as its content is in no way  
 CC modified and this statement is not removed. Usage by and for commercial  
 CC entities requires a license agreement (See [http://www.ebi.ac.uk/announcements/](http://www.ebi.ac.uk/announcements)  
 CC or send an email to [license@ebi.ac.uk](mailto:license@ebi.ac.uk)).

DR EMBL: AF018165; AAC41275.1; --  
 DR HSRP: P05067; IRT3.  
 DR InterPro: IPR008155; A4\_APP.  
 DR InterPro: IPR008154; A4\_EXTRA.  
 DR InterPro: IPR001255; Beta-APP.  
 DR InterPro: IPR002223; Kunitz\_BPTI.  
 DR Pfam: PF02177; A4\_EXTRA.1.  
 DR Pfam: PF03494; Beta-APP.1.  
 DR Pfam: PF00014; Kunitz\_BPTI.1.  
 DR PRINTS: PR00203; AMYLOIDA.  
 DR PRINTS: PR00759; BASICTPASE.  
 DR PRODOM: PD000222; Kunitz\_BPTI.1.  
 DR SMART: SMC0006; A4\_EXTRA.1.  
 DR SMART: SMC0131; KU\_1.  
 DR PROSITE: PS00319; A4\_EXTRA.1.  
 DR PROSITE: PS00320; A4\_INTRA.1.  
 DR PROSITE: PS00280; BPTI\_KUNITZ\_1; FALSE\_NEG.  
 DR PROSITE: PS00279; BPTI\_KUNITZ\_2; 1.  
 DR GlycoProtein: Amyloid; Neurone; Transmembrane; Signal;  
 KW Serine protease inhibitor.  
 FT CHAIN 1 18 POTENTIAL.  
 FT SIGNAL 1 18 ALZHEIMER'S DISEASE AMYLOID A4 PROTEIN  
 FT CHAIN 19 780 HOMOLOG.  
 FT CHAIN 682 724 BETA-AMYLOID PROTEIN (POTENTIAL).  
 FT DOMAIN 19 711 EXTRACELLULAR (POTENTIAL).  
 FT TRANSMEM 712 732 POTENTIAL.  
 FT DOMAIN 733 780 CYTOPLASMIC (POTENTIAL).  
 FT DOMAIN 323 382 BPTI/KUNITZ INHIBITOR.  
 FT SITE 769 772 CLATHRIN-BINDING (BY SIMILARITY).  
 FT DISULFID 327 378 BY SIMILARITY.  
 FT DISULFID 336 361 BY SIMILARITY.  
 FT CARBOHYD 560 560 N-LINKED (GLCNAC. .) (POTENTIAL).  
 SQ SEQUENCE 780 AA; 88238 MW; 60071BB94520191D CRC4;

Query Match 55.7%; Score 195.5; DB 1; Length 780;  
 Best Local Similarity 53.2%; Pred. NO. 1.2e-15;  
 Matches 33; Conservative 10; Mismatches 18; Indels 1; Gaps 1;

QY 1 EVVREVCSEQAEETGCPRAATYHWYFDVTEGKCA-PFFYGGCGGNRRNPPTEECVAVCS 59  
 Db 321 EVVRFMPCMAADTSPCTASMPYFDVDRITWYELMYGGCGGNRRNPFSEECVAVCS 380

QY 60 AI 61  
 Db 381 VV 382

RESULT 13  
 SPT2\_HUMAN STANDARD; PRT; 252 AA.  
 AC 043291; 000271; 014895; 096980;  
 DT 16-OCT-2001 (Rel. 40, Created)  
 DT 16-OCT-2001 (Rel. 40, Last sequence update)  
 DT 15-MAR-2004 (Rel. 43, Last annotation update)  
 DE Kunitz-type protease inhibitor 2 precursor (Hepatocyte growth factor  
 DE activator inhibitor type 2) (HAI-2) (Placental bikunin).  
 GN SPTN2 OR HAI2 OR KOP.  
 OS Homo sapiens (Human).  
 OC Eukaryota; Metazoa; Chordata; Vertebrata; Euteleostomi;  
 OC Mammalia; Eutheria; Primates; Catarrhini; Hominoidea; Homo.  
 OX NCBI\_TaxID=9606;  
 RN [1]  
 RP SEQUENCE FROM N.A.  
 RX MEDLINE=98010584; PubMed=9346890;

RA Kawaguchi T., Qin L., Shimomura T., Kondo J., Matsumoto K., Denda K.,  
 RA Klamura N.;  
 RT "Purification and cloning of hepatocyte growth factor activator  
 RT inhibitor type 2, a Kunitz-type serine protease inhibitor.";  
 RL J. Biol. Chem. 272:27558-27564(1997).  
 RN [2]  
 RP SEQUENCE FROM N.A., AND SEQUENCE OF 28-74.  
 RC TISSUE=Placenta;  
 RX MEDLINE=97277372; PubMed=9115294;  
 RA Marlor C.W., Delaria K.A., Davis G., Muller D.K., Greve J.M.,  
 RA Tamburini P.P.;  
 RT Identification and cloning of human placental bikunin, a novel serine  
 RT protease inhibitor containing two Kunitz domains.";  
 RL J. Biol. Chem. 272:12202-12208(1997).  
 RN [3]  
 RP SEQUENCE FROM N.A.  
 RC TISSUE=pancreatic cancer;  
 RX MEDLINE=98094245; PubMed=9434156;  
 RA Mueller-Pillasch F., Wallrapp C., Bartels K., Varga G., Friess H.,  
 RA Buechler M., Adler G., Gress T.M.;  
 RT Cloning of a new Kunitz-type protease inhibitor with a putative  
 RT transmembrane domain overexpressed in pancreatic cancer.";  
 RL Biochim. Biophys. Acta 1395:88-95(1998).  
 RN [4]  
 RP SEQUENCE FROM N.A., AND VARIANT LEU-200.  
 RC TISSUE=Colon and Ovary;  
 RX MEDLINE=22388257; PubMed=12477932.  
 RA Strausberg R.V., Fellingold E.A., Grouse L.H., Derge J.G.,  
 RA Klausner R.D., Collins P.S., Wagner L., Shenmen C.M., Schuler G.D.,  
 RA Altschul S.F., Zeeberg B., Buetow K.H., Schaefer C.F., Bat N.K.,  
 RA Hopkins R.F., Jordan H., Moore T., Max S.I., Wang J., Hsieh F.,  
 RA Datchenko L., Marzina K., Farmer A.A., Rubin G.M., Hong L.,  
 RA Stapleton M., Soares M.B., Bonaldo M.F., Casavant J.L., Scheetz T.E.,  
 RA Brownstein M.J., Ueda T.B., Tomihata S., Carninci P., Prange C.,  
 RA Raha S.S., Loggiano N.A., Peters G.J., Abramson R.D., Mullaly S.J.,  
 RA Bosak S.A., McEwan P.J., McKernan K.J., Malek J.A., Gunaratne P.H.,  
 RA Richards S., Worley K.C., Hale S., Garcia A.M., Gay L.J., Holys S.W.,  
 RA Villalón D.K., Wozny D.M., Sodergren E.J., Lu X., Gibbs R.A.,  
 RA Fahy J., Heaton E., Kettman M., Madan A., Rodriguez S., Sanchez A.,  
 RA Whiting M., Madan A., Young A.C., Shevchenko Y., Bouffard G.G.,  
 RA Blakesley R.W., Touchman J.W., Green E.D., Dickson M.C.,  
 RA Rodriguez A.C., Grimwood J., Schmutz J., Myers R.M.,  
 RA Butcherfield Y.S.N., Krzywinski M.I., Skalska U., Smalhe D.E.,  
 RA Scherch A., Schein J.E., Jones S.J.M., Marra M.A.;  
 RT "Generation and initial analysis of more than 15,000 full-length  
 RT human and mouse cDNA sequences".  
 RL Proc. Natl. Acad. Sci. U.S.A. 99:16899-16903(2002).  
 CC -1- FUNCTION: Inhibitor of HGF activator. Also inhibits plasmin,  
 CC plasma and tissue kallikrein, and factor Xa.  
 CC -1- SUBCELLULAR LOCATION: Type I membrane protein (Potential).  
 CC -1- TISSUE SPECIFICITY: Expressed in placenta, kidney, pancreas,  
 CC prostate, testis, thymus, and trachea.  
 CC -1- DOMAIN: This inhibitor contains two inhibitory domains.  
 CC -1- SIMILARITY: Contains 2 BPTI/Kunitz inhibitor domains.

CC This SWISS-PROT entry is copyright. It is produced through a collaboration  
 CC between the Swiss Institute of Bioinformatics and the EMBL outstation -  
 CC the European Bioinformatics Institute. There are no restrictions on its  
 CC use by non-profit institutions as long as its content is in no way  
 CC modified and this statement is not removed. Usage by and for commercial  
 CC entities requires a license agreement (See <http://www.ebi.ac.uk/announcements/>  
 CC or send an email to [license@ebi.ac.uk](mailto:license@ebi.ac.uk)).

DR EMBL: AB006534; BAA25024.1; --  
 DR EMBL: U78095; AAC02781.1; --  
 DR EMBL: AF027205; AAB84031.1; --  
 DR EMBL: BC001668; AAH01668.1; --  
 DR EMBL: BC007705; AAH07705.1; --  
 DR EMBL: BC011951; AAH11951.1; --  
 DR EMBL: BC011955; AAH11955.1; --  
 DR EMBL: BC012668; AAH12668.1; --  
 DR HSRP: P05067; IAPP.  
 RX Genew: HGNC:11247; SPTN2.

```

DR MIM; 605124; .
DR GO; GO:0005576; C:extracellular; TAS.
DR GO; GO:0016021; C:integral to membrane; TAS.
DR GO; GO:0005625; C:soluble fraction; TAS.
DR GO; GO:0004867; F:serine protease inhibitor activity; TAS.
DR GO; GO:0006929; P:cell motility; TAS.
DR InterPro; IPR002223; Kunitz_BPTI.
DR Pfam; PF00014; Kunitz_BPTI.
DR PRINTS; PR00759; BASICPTASE.
DR ProDom; PD000222; Kunitz_BPTI; 2.
DR SMART; SM00131; KU; 2.
DR PROSITE; PS00280; BPTI_KUNITZ_1; 2.
DR PROSITE; PS00279; BPTI_KUNITZ_2; 2.
DR Serine protease inhibitor; Repeat; Glycoprotein; Transmembrane;
KW Signal; Polymorphism.
FT SIGNAL 1 27
FT CHAIN 28 252
FT DOMAIN 28 197
FT TRANSMEM 198 218
FT DOMAIN 219 252
FT DOMAIN 133 183
FT DOMAIN 133 183
FT DISULFID 38 88
FT DISULFID 47 71
FT DISULFID 63 84
FT ACT SITE 48 49
FT DISULFID 133 183
FT DISULFID 142 156
FT DISULFID 158 179
FT ACT SITE 143 144
FT CARBOHYD 57 57
FT CARBOHYD 94 94
FT VARIANT 200 200
FT CONFLICT 3 3
FT CONFLICT 11 11
FT CONFLICT 53 53
FT CONFLICT 240 240
SQ SEQUENCE 252 AA; 28228 MW; A7D336C0ECB2B CRC64;

Query Match 48.1%; Score 169; DB 1; Length 252;
Best Local Similarity 52.8%; Pred. No. 5.9e-13;
Matches 28; Conservative 6; Mismatches 19; Indels 0; Gaps 0;

QY 5 EVCSQAEATGPCRAAIYHMYFDVTEGKCAPEYGGCGGGRNNPDTEYCMAYC 57
DB 131 EYCTANAVTGPCRASFPWYFDVERNSCNFTYGGCGGGRNNPDTEYCMAYC 183

RESULT 14
ID ISH1_STOHE STANDARD; PRT; 55 AA.
AC P31713;
DT 01-JUL-1993 (Rel. 26, Created)
DT 01-JUL-1993 (Rel. 26, Last sequence update)
DT 28-FEB-2003 (Rel. 41, Last annotation update)
DE Kunitz-type proteinase inhibitor SHP-1.
OS Stenohelorus helianthus (Caribbean sea anemone) (Stichodactyla
OC Eukaryota; Metazoa; Cnidaria; Anthozoa; Zantharia; Actinaria;
OC Stichodactylidae; Stichodactyla.
OX NCBI_TaxID=6123;
RN [1]
RP SEQUENCE.
RX MEDLINE=97179757; PubMed=9027993;
RA Delfin J., Martinez I., Antuch W., Morea V., Gonzalez Y.,
RA Rodriguez R., Marquez M., Sarayan A., Larionova N., Diaz J.,
RA Padron G., Chavez M.;
RT "Purification, characterization and immobilization of proteinase
RT inhibitor from Stichodactyla helianthus.",
RL Toxicol 34:1367-1376(1996).
RN [2]
RP STRUCTURE BY NMR, AND DISULFIDE BONDS.

```

```

RX MEDLINE=93215644; PubMed=8462542;
RA Antuch W., Berndt K.D., Chavez M.A., Delfin J., Wuehrich K.;
RT "The NMR solution structure of a Kunitz-type proteinase inhibitor
RT from the sea anemone Stichodactyla helianthus.",
RL Eur. J. Biochem. 212:675-684(1993).
CC -1- FUNCTION: Active against serine, cysteine, and aspartic
CC proteinases.
CC -1- SIMILARITY: Contains 1 BPTI/Kunitz inhibitor domain.
CC PIR; S30332; S30332.
DR PDB; 1SHF; 11-TAN-94.
DR InterPro; IPR002223; Kunitz_BPTI.
DR Pfam; PF00014; Kunitz_BPTI; 1.
DR PRINTS; PR00759; BASICPTASE.
DR ProDom; PD000222; Kunitz_BPTI; 1.
DR SMART; SM00131; KU; 1.
DR PROSITE; PS00280; BPTI_KUNITZ_1; 1.
DR PROSITE; PS00279; BPTI_KUNITZ_2; 1.
DR Serine protease inhibitor; 3d-structure.
KW Signal; Polymorphism.
FT SIGNAL 3 53
FT DISULFID 12 36
FT DISULFID 28 49
FT ACT SITE 13 14
FT HELIX 2 4
FT STRAND 17 22
FT TURN 23 26
FT STRAND 27 32
FT TURN 36 37
FT STRAND 43 43
FT HELIX 46 53
SQ SEQUENCE 55 AA; 6116 MW; 532B96E3127000D4 CRC64;

Query Match 47.9%; Score 168; DB 1; Length 55;
Best Local Similarity 51.9%; Pred. No. 1.8e-13;
Matches 27; Conservative 6; Mismatches 19; Indels 0; Gaps 0;

QY 6 VCSEQAEATGPCRAAIYHMYFDVTEGKCAPEYGGCGGGRNNPDTEYCMAYC 57
DB 2 ICSEPKVGRCKGYPFRFYDSETKCTPFTYGGCGGGRNNPDTEYCMAYC 53

RESULT 15
ID SEPT2_MOUSE STANDARD; PRT; 252 AA.
AC Q9WU03; Q9WU04; Q9WU05;
DT 16-OCT-2001 (Rel. 40, Created)
DT 16-OCT-2001 (Rel. 40, Last sequence update)
DT 28-FEB-2003 (Rel. 41, Last annotation update)
DE Kunitz-type proteinase inhibitor 2 precursor (Hepatocyte growth factor
DE activator inhibitor type 2) (HAI-2).
GN SPINT2 OR HAI2.
OS Mus musculus (Mouse).
OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC Mammalia; Eutheria; Rodentia; Sciurognathi; Muridae; Murinae; Mus.
OX NCBI_TaxID=10090;
RN [1]
RP SEQUENCE FROM N.A., AND ALTERNATIVE SPLICING.
RX STRAIN=BALB/c;
RX MEDLINE=93160423; PubMed=10049781.
RA Itoh H., Kataoka H., Hamasuna R., Kitamura N., Kono M.;
RT "Hepatocyte growth factor activator inhibitor type 2 lacking the first
RT Kunitz-type serine proteinase inhibitor domain is a predominant
RT product in mouse but not in human."
RL Biochem. Biophys. Res. Commun. 255:740-748(1999).
CC -1- FUNCTION: Inhibitor of HGF activator.
CC -1- SUBCELLULAR LOCATION: Type I membrane protein (Potential).
CC -1- ALTERNATIVE PRODUCTS:
CC Event=Alternative splicing; Named isoforms=3;
CC Name=1;
CC IsoId=Q9WU03-1; Sequence=Displayed;
CC Name=2;
CC IsoId=Q9WU03-2; Sequence=VSP_003034;
CC Name=3;
CC IsoId=Q9WU03-3; Sequence=VSP_003034, VSP_003035, VSP_003036;

```



```

CC -!- TISSUE SPECIFICITY: Isoform 2 is more predominantly expressed than
CC isoform 1.
CC -!- DOMAIN: This inhibitor contains two inhibitory domains.
CC -!- SIMILARITY: Contains 2 BPTI/Kunitz inhibitor domains.
CC -----
CC This SWISS-PROT entry is copyright. It is produced through a collaboration
CC between the Swiss Institute of Bioinformatics and the EMBL outstation -
CC the European Bioinformatics Institute. There are no restrictions on its
CC use by non-profit institutions as long as its content is in no way
CC modified and this statement is not removed. Usage by and for commercial
CC entities requires a license agreement (See http://www.isb.ch/announce/
CC or send an email to license@isb.ch).
CC -----
DR EMBL; AF099016; AAD22172.1; -
DR EMBL; AF099019; AAD22173.1; -
DR EMBL; AF099020; AAD22174.1; -
DR HSSP; P05067; ICAO.
DR MGD; MGI:1336031; Spint2.
DR InterPro; IPR002223; Kunitz_BPTI.
DR Pfam; PF00014; Kunitz_BPTI_2.
DR PRINTS; PR00759; BASICPTASE.
DR ProDom; PD000222; Kunitz_BPTI_2.
DR SMART; SM00131; KU; 2.
DR PROSITE; PS00280; BPTI_KUNITZ_1; 2.
DR PROSITE; PS00279; BPTI_KUNITZ_2; 2.
KW Serine protease inhibitor; Repeat; Glycoprotein; Transmembrane;
KW Signal; Alternative splicing.
FT SIGNAL 1 27
FT CHAIN 28 252 KUNITZ-TYPE PROTEASE INHIBITOR 2.
FT DOMAIN 28 197 EXTRACELLULAR (POTENTIAL).
FT TRANSMEM 198 218 POTENTIAL.
FT DOMAIN 219 252 CYTOPLASMIC (POTENTIAL).
FT DOMAIN 38 88 BPTI/KUNITZ INHIBITOR 1.
FT DOMAIN 133 183 BPTI/KUNITZ INHIBITOR 2.
FT DISULFD 38 88 BY SIMILARITY.
FT DISULFD 47 71 BY SIMILARITY.
FT DISULFD 63 84 BY SIMILARITY.
FT ACT_SITE 49 49 REACTIVE BOND (BY SIMILARITY).
FT DISULFD 133 183 BY SIMILARITY.
FT DISULFD 142 166 BY SIMILARITY.
FT DISULFD 158 179 BY SIMILARITY.
FT ACT_SITE 143 144 REACTIVE BOND (BY SIMILARITY).
FT CARBOHD 57 57 N-LINKED (GLCNAC. . .) (POTENTIAL).
FT CARBOHD 94 94 Missing (in isoform 2 and isoform 3).
FT VARSPLIC 37 93 /FTid=VSP_003034.
FT VARSPLIC 114 128 PRKQASDLSAEIFN -> CFVELSVAAFLFYA (in
FT isoform 3).
FT VARSPLIC 129 252 /FTid=VSP_003035.
FT VARSPLIC 252 252 Missing (in isoform 3).
FT SEQUENCE 252 AA: 27914 MW: 829486924 Da P8F CRC64;
SQ

```

Query Match 45.9%; Score 161; DB 1; Length 252;  
 Best Local Similarity 45.5%; Pred. No. 5.2e-12;  
 Matches 25; Conservative 10; Mismatches 20; Indels 0; Gaps 0;

```

QY 3 VREVSGEAGTGPCAAATYHWYPTVTEGKCAPFYGGCGGRNNPDTREYCAVVC 57
DB 34 VHSQGVSKVVGKCRASIPRWVINITDSQCFYVGGCBGKNNYQSKRECLDKC 88

```

Search completed: April 8, 2004, 09:32:13  
 Job time : 12 secs

GenCore version 5.1.6  
Copyright (c) 1993 - 2004 CompuGen Ltd.

OM protein - protein search, using sw model

Run on: April 8, 2004, 09:30:32 ; Search time 40 seconds

(without alignments)  
481.165 Million cell updates/sec

Title: US-10-076-604-208  
Perfect score: 351  
Sequence: 1 EVVREVCSEQAETGFCRAI.....GNRNNPDEYCMAYCGSA 61

Scoring table: BLOSUM62  
Gapop 10.0 , Gapext 0.5

Searched: 1017041 seqs, 315518202 residues

Total number of hits satisfying chosen parameters: 1017041

Minimum DB seq length: 0  
Maximum DB seq length: 2000000000

Post-processing: Minimum Match 0%  
Maximum Match 100%

Listing first 45 summaries

Database :

SPTREMBL\_25:\*  
1: sp.\_archaea:\*  
2: sp.\_bacteria:\*  
3: sp.\_fungi:\*  
4: sp.\_human:\*  
5: sp.\_invertebrate:\*  
6: sp.\_mammal:\*  
7: sp.\_mhc:\*  
8: sp.\_organelle:\*  
9: sp.\_phage:\*  
10: sp.\_plant:\*  
11: sp.\_rodent:\*  
12: sp.\_virus:\*  
13: sp.\_vertebrate:\*  
14: sp.\_unclassified:\*  
15: sp.\_viral:\*  
16: sp.\_bacteria:\*  
17: sp.\_archaea:\*

Pred. No. is the number of results predicted by chance to have a score greater than or equal to the score of the result being printed, and is derived by analysis of the total score distribution.

# SUMMARIES

Result No.	Score	Query Match	Length	DB ID	Description
1	31.9	90.9	160	11	Q9QZ78
2	31.4	89.5	751	13	Q9DGJ7
3	28.8	82.1	747	13	Q91963
4	23.8	67.8	523	4	Q14594
5	23.8	67.8	738	13	Q90W28
6	23.8	67.8	751	11	Q60709
7	22.8	67.8	763	11	Q61482
8	22.3	63.5	82	13	Q7Z2T3
9	17.9	51.0	3198	5	Q9U8G8
10	16.8	47.9	2772	5	Q9YAV4
11	16.8	47.9	2776	5	Q869A0
12	16.8	47.9	2898	5	Q86829
13	16.7	47.6	137	6	Q9BD10
14	16.3	46.4	759	5	Q81T91
15	16.1	45.9	195	11	Q9D8Q8
16	16.1	45.9	1572	5	Q44938

17	160	45.6	2225	5	Q45881	Q45881 caenorhabdi
18	158	45.0	143	4	Q86TP9	Q86TP9 homo sapien
19	158	45.0	984	5	Q9GQJ2	Q9GQJ2 calliacis
20	158	45.0	984	5	Q9GQJ1	Q9GQJ1 calliacis
21	157	44.7	142	5	Q8MPJ2	Q8MPJ2 boophilus m
22	157	44.7	1487	5	Q8MPV5	Q8MPV5 caenorhabdi
23	157	44.7	1558	5	Q81710	Q81710 caenorhabdi
24	157	44.7	2167	5	Q76840	Q76840 caenorhabdi
25	156	44.4	142	5	Q8MPJ3	Q8MPJ3 boophilus m
26	155	44.2	82	5	Q8MV34	Q8MV34 ixodes scap
27	153	43.6	342	13	P70004	P70004 xenopus lae
28	153	43.6	342	13	Q7SZ46	Q7SZ46 xenopus lae
29	152	43.3	133	6	Q8HZ45	Q8HZ45 papio papio
30	152	43.3	277	13	Q8AYE1	Q8AYE1 brachydanio
31	152	43.3	279	13	Q7Z242	Q7Z242 brachydanio
32	151	43.0	1949	5	Q8MXG3	Q8MXG3 caenorhabdi
33	148	42.2	83	13	Q90WAO	Q90WAO pseudonaja
34	148	42.2	83	13	Q90WAI	Q90WAI pseudonaja
35	147	41.9	349	11	Q9DBJ9	Q9DBJ9 mus musculu
36	147	41.9	349	11	Q9Z5M1	Q9Z5M1 mus musculu
37	146	41.6	979	4	Q8N4Z1	Q8N4Z1 homo sapien
38	144	41.0	154	6	Q9N0X3	Q9N0X3 ovis aries
39	144	41.0	507	11	Q9D3K4	Q9D3K4 mus musculu
40	144	41.0	507	11	Q9J704	Q9J704 mus musculu
41	143	40.7	151	4	P78491	P78491 homo sapien
42	143	40.7	2174	5	Q9GCR0	Q9GCR0 drosophila
43	142	40.5	1743	5	Q9XMX5	Q9XMX5 caenorhabdi
44	141	40.2	132	5	Q9VOT9	Q9VOT9 drosophila
45	141	40.2	234	6	Q7YRQ8	Q7YRQ8 bos taurus

## ALIGNMENTS

RESULT 1  
ID Q9QZ78 PRELIMINARY, PRT; 160 AA.  
AC Q9QZ78;  
DT 01-MAY-2000 (TRENBLER, 13, Created)  
DI 01-MAY-2000 (TRENBLER, 13, Last sequence update)  
DT 01-JUN-2003 (TRENBLER, 24, Last annotation update)  
DE Putative amyloid protein (Fragment).  
OS Cavia sp.  
OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;  
OC Mammalia; Eutheria; Rodentia; Hystriognathi; Caviidae; Cavia.  
CX NCBI\_TaxId=10143;  
RN [1]  
RP SEQUENCE FROM N.A.  
RC TISSUE=Lens;  
RA Friederike P.H., Carper D., Farnsworth J.P., Zigler J.S.;  
RT "Prlon and Alzheimer precursor protein expression in a hereditary  
RT guinea pig cataract.";  
RL Submitted (OCT-1999) to the EMBL/GenBank/DBJ databases.  
DR EMBL; AF197164; AF08934.1; -  
DR HSBP; P05067; IAP.  
DR GO; GO:0004867; F:serine protease inhibitor activity; IEA.  
DR InterPro; IPR002223; Kunitz\_BPTI.  
DR Pfam; PF00014; Kunitz\_BPTI; 1.  
DR PRINTS; PR00759; BASICTPASE.  
DR PRODOM; PD000222; Kunitz\_BPTI; 1.  
DR SMART; SM00131; KU; 1.  
DR PROSITE; PS00280; BPTI\_KUNITZ\_1; 1.  
DR PROSITE; PS50279; BPTI\_KUNITZ\_2; 1.  
KW Protease inhibitor; Serine protease inhibitor.  
FT NON\_TER 1  
FT NON\_TER 160  
SQ SEQUENCE 160 AA; 17424 MW; 9F28C3B92BF747C1 CRC64;  
Query Match 90.9%; Score 31.9; DB 11; Length 160;  
Best Local Similarity 90.2%; Pred. No. 8.6e-35;  
Matches 55; Conservative 2; Mismatches 4; Indels 0; Gaps 0;  
QY 1 EVVREVCSEQAETGFCRAIYHWYFDVTEGKCAPFYGGGGRNNPDEYCMAYCGSA 60

Db 61 EVREVCSEQAEFTGCRSMISRWYFDTEGKCAPFYGGCGGNRNNPDEEYCMAYCGSV 120  
 QY 61 I 61  
 Db 121 M 121

## RESULT 2

Q9DGJ7 PRELIMINARY; PRT; 751 AA.  
 AC Q9DGJ7;  
 DT 01-MAR-2001 (TREMBLrel. 16, Created)  
 DT 01-MAR-2001 (TREMBLrel. 16, Last sequence update)  
 DT 01-JUN-2003 (TREMBLrel. 24, Last annotation update)  
 DE Beta-amyloid precursor protein 751 isoform.  
 OS Gallus gallus (Chicken).  
 OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;  
 OC Archosauria; Aves; Neognathae; Galliformes; Phasianidae; Phasianinae;  
 OC Gallus.  
 OX NCBI\_TaxID=9031;  
 RN [1]  
 RP SEQUENCE FROM N.A.  
 RA Satosa M., Rodolose A., Scirbas V.;  
 RT "Cloning of full-length chicken beta-amyloid precursor protein  
 isoforms";  
 RT Submitted (JUL-2000) to the EMBL/GenBank/DBJ databases.  
 RL EMBL; AP2892219; AAC00594.1; -.  
 DR HSRP; P05067; IBA4.  
 DR GO; GO:0016020; C:membrane; IEA.  
 DR GO; GO:0004867; F:serine protease inhibitor activity; IEA.  
 DR InterPro; IPR008155; A4\_APP.  
 DR InterPro; IPR008154; A4\_extra.  
 DR InterPro; IPR002223; Kunitz\_BPTI.  
 DR Pfam; PF02177; A4\_EXTRA; 1.  
 DR Pfam; PF03494; Beta-APP; 1.  
 DR Pfam; PF00014; Amylitz\_BPTI; 1.  
 DR PRINTS; PR00203; AMYLOIDA4.  
 DR PRINTS; PR00759; BASICPTASE.  
 DR Prodom; PD000222; Kunitz\_BPTI; 1.  
 DR SMART; SM00006; A4\_EXTRA; 1.  
 DR SMART; SM00131; KU; 1.  
 DR PROSITE; PS00319; A4\_EXTRA; 1.  
 DR PROSITE; PS00320; A4\_INTRA; 1.  
 DR PROSITE; PS00280; BPTI\_KUNITZ\_1; 1.  
 DR PROSITE; PS00279; BPTI\_KUNITZ\_2; 1.  
 KW Protease inhibitor; Serine protease inhibitor  
 SEQUENCE 751 AA; 84705 MW; E78E9413A8033D84 CRC64;

Query Match 89.5%; Score 314; DB 13; Length 751;  
 Best Local Similarity 88.5%; Pred. No. 2.2e-33;  
 Matches 54; Conservative 2; Mismatches 5; Indels 0; Gaps 0;  
 QY 1 EVREVCSEQAEFTGCRSMISRWYFDTEGKCAPFYGGCGGNRNNPDEEYCMAYCGSV 60  
 Db 285 EVREVCSEQAEFTGCRSMISRWYFDTEGKCAPFYGGCGGNRNNPDEEYCMAYCGSV 344  
 QY 61 I 61  
 Db 345 L 345

## RESULT 3

Q91963 PRELIMINARY; PRT; 747 AA.  
 AC Q91963;  
 DT 01-NOV-1996 (TREMBLrel. 01, Created)  
 DT 01-NOV-1996 (TREMBLrel. 01, Last sequence update)  
 DT 01-JUN-2003 (TREMBLrel. 24, Last annotation update)  
 DE APP747.  
 GN APP747.  
 OS Xenopus.

OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;  
 OC Amphibia; Batrachia; Anura; Mesobatrachia; Pipidae; Pipidae;  
 OC Xenopodinae.  
 OX NCBI\_TaxID=8353;  
 RN [1]  
 RP SEQUENCE FROM N.A.  
 RX MEDLINE=93129227; PubMed=1282805;  
 RA Okado H., Okamoto H.;  
 RT "A Xenopus homologue of the human beta-amyloid precursor protein:  
 development and regulation of its gene expression";  
 RT Biochem Biophys Res Commun. 189:1561-1568(1992).  
 RL EMBL; S52417; AAB24853.1; -.  
 DR HSRP; P05067; IH23.  
 DR GO; GO:0016020; C:membrane; IEA.  
 DR GO; GO:0004867; F:serine protease inhibitor activity; IEA.  
 DR InterPro; IPR008155; A4\_APP.  
 DR InterPro; IPR008154; A4\_extra.  
 DR InterPro; IPR001255; Beta-APP.  
 DR InterPro; IPR002223; Kunitz\_BPTI.  
 DR Pfam; PF02177; A4\_EXTRA; 1.  
 DR Pfam; PF03494; Beta-APP; 1.  
 DR Pfam; PF00014; Amylitz\_BPTI; 1.  
 DR PRINTS; PR00203; AMYLOIDA4.  
 DR PRINTS; PR00759; BASICPTASE.  
 DR Prodom; PD000222; Kunitz\_BPTI; 1.  
 DR SMART; SM00131; KU; 1.  
 DR PROSITE; PS00319; A4\_EXTRA; 1.  
 DR PROSITE; PS00320; A4\_INTRA; 1.  
 DR PROSITE; PS00280; BPTI\_KUNITZ\_1; 1.  
 DR PROSITE; PS00279; BPTI\_KUNITZ\_2; 1.  
 KW Protease inhibitor; Serine protease inhibitor.  
 SEQUENCE 747 AA; 84893 MW; A75E81855681D948 CRC64;

Query Match 82.1%; Score 288; DB 13; Length 747;  
 Best Local Similarity 80.3%; Pred. No. 6.6e-30;  
 Matches 49; Conservative 5; Mismatches 7; Indels 0; Gaps 0;

QY 1 EVREVCSEQAEFTGCRSMISRWYFDTEGKCAPFYGGCGGNRNNPDEEYCMAYCGSV 60  
 Db 281 EVREVCSEQAEFTGCRSMISRWYFDTEGKCAPFYGGCGGNRNNPDEEYCMAYCGSV 340  
 QY 61 I 61  
 Db 341 I 341

## RESULT 4

Q14594 PRELIMINARY; PRT; 523 AA.  
 AC Q14594;  
 DT 01-NOV-1996 (TREMBLrel. 01, Created)  
 DT 01-NOV-1996 (TREMBLrel. 01, Last sequence update)  
 DT 01-JUN-2003 (TREMBLrel. 24, Last annotation update)  
 DE Binding protein (Fragment).  
 OS Homo sapiens (Human).  
 OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;  
 OC Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.  
 OX NCBI\_TaxID=9606;  
 RN [1]  
 RP SEQUENCE FROM N.A.  
 RC TISSUE=Brain;  
 RA Vostrov A.A., Qutischke W.W., Schwarzman A.L., Blangy A., Cuzin F.,  
 RA Wesley U.V., Hages N.G., Goldgaber D.;  
 RT "Cloning of a protein that binds to a recognition sequence in the APP  
 promoter";  
 RT Submitted (AUG-1993) to the EMBL/GenBank/DBJ databases.  
 RL EMBL; L23113; AAA36032.1; -.  
 DR HSRP; P05067; ICA0.  
 DR GO; GO:0004867; F:serine protease inhibitor activity; IEA.  
 DR InterPro; IPR008155; A4\_APP.  
 DR InterPro; IPR002223; Kunitz\_BPTI.  
 DR Pfam; PF00014; Kunitz\_BPTI; 1.  
 DR PRINTS; PR00203; AMYLOIDA4.



RESULT 7  
ID Q61482 PRELIMINARY; PRT; 763 AA.  
AC Q61482;  
DT 01-NOV-1996 (TREMBLrel. 01, Created)  
DT 01-NOV-1996 (TREMBLrel. 01, Last sequence update)  
DT 01-JUN-2003 (TREMBLrel. 24, Last annotation update)  
DE CDEI-binding protein CDEBP.  
GN CDEBP.  
OS Mus musculus (Mouse).  
OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;  
OC Mammalia; Eutheria; Rodentia; Sciurognathi; Muridae; Murinae; Mus.  
OX NCBI\_TaxID=10090;  
RN [1]  
RP SEQUENCE FROM N.A.  
RC STRAIN=B6;  
RX MEDLINE=9629736; PubMed=8661100;  
RA Yang Y., Martin L., Cuzin F., Mattei M.G., Rassoulzadegan M.;  
RT "Genomic structure and chromosomal localization of the mouse CDEI-  
binding protein CDEBP (APLP2) gene and promoter sequences.";  
RL Genomics 35:24-29(1996).  
RN [2]  
RP SEQUENCE FROM N.A.  
RC STRAIN=B6;  
RA Luc M., Yang Y.;  
RL Submitted (OCT-1995) to the EMBL/GenBank/DBJ databases.  
DR EMBL; U37485; AAB38114.1; JOINED.  
DR EMBL; U37468; AAB38114.1; JOINED.  
DR EMBL; U37469; AAB38114.1; JOINED.  
DR EMBL; U37470; AAB38114.1; JOINED.  
DR EMBL; U37471; AAB38114.1; JOINED.  
DR EMBL; U37472; AAB38114.1; JOINED.  
DR EMBL; U37473; AAB38114.1; JOINED.  
DR EMBL; U37474; AAB38114.1; JOINED.  
DR EMBL; U37475; AAB38114.1; JOINED.  
DR EMBL; U37476; AAB38114.1; JOINED.  
DR EMBL; U37477; AAB38114.1; JOINED.  
DR EMBL; U37478; AAB38114.1; JOINED.  
DR EMBL; U37479; AAB38114.1; JOINED.  
DR EMBL; U37480; AAB38114.1; JOINED.  
DR EMBL; U37481; AAB38114.1; JOINED.  
DR EMBL; U37482; AAB38114.1; JOINED.  
DR EMBL; U37483; AAB38114.1; JOINED.  
DR EMBL; U37484; AAB38114.1; JOINED.  
DR HSSP; P05067; IWP.  
DR GO; GO:0004867; F:serine protease inhibitor activity; IEA.  
DR InterPro; IPR008155; A4\_APP.  
DR InterPro; IPR008154; A4\_extra.  
DR InterPro; IPR002223; Kunitz\_BPTI.  
DR Pfam; PF00177; A4\_EXTRA; 1.  
DR Pfam; PF00014; Kunitz\_BPTI; 1.  
DR PRINTS; PR00203; AMYLOIDA.  
DR PRODOM; PR00759; BASICPTASE.  
DR SMART; SMO0006; A4\_EXTRA; 1.  
DR SMART; SMO0131; KU; 1.  
DR PROSITE; PS00319; A4\_EXTRA; 1.  
DR PROSITE; PS00320; A4\_INTRA; 1.  
DR PROSITE; PS00280; BPTI\_KUNITZ\_1; 1.  
DR PROSITE; PS0279; BPTI\_KUNITZ\_2; 1.  
KW Protease inhibitor; Serine protease inhibitor.  
SQ SEQUENCE 763 AA; 86716 MW; 2C0C7780180619A6 CRC64;

Query Match 67.8%; Score 238; DB 11; Length 763;  
Best Local Similarity 64.4%; Pred. No 3.5e-23;  
Matches 38; Conservative 11; Mismatches 10; Indels 0; Gaps 0;

CY 3 VREVCSEAGTGPCRAAIYHYFVDTGKCAPFFYGGCGGGRNNFTDEYCAVCGSAI 61  
DB 306 VKAVCSQEAHTGPCRAAVPRWYFDLSKGCVRFTYGGCGGGRNNFSESDYCAVCGSAI 364

RESULT 8  
ID Q72273 PRELIMINARY; PRT; 82 AA.  
AC Q72273;  
DT 01-JUN-2003 (TREMBLrel. 24, Created)  
DT 01-JUN-2003 (TREMBLrel. 24, Last sequence update)  
DT 01-OCT-2003 (TREMBLrel. 25, Last annotation update)  
DE Amyloid protein b (Fragment).  
GN APPB.  
OS Brachydanio rerio (Zebrafish) (Danio rerio).  
OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;  
OC Actinopterygii; Neopterygii; Teleostei; Ostariophysi; Cypriniformes;  
OC Cyprinidae; Danio.  
OX NCBI\_TaxID=7955;  
RN [1]  
RP SEQUENCE FROM N.A.  
RA Groth C., Lardelli M.;  
RT "Kunitz-type protease inhibitor domain of zebrafish appb.";  
RL Submitted (APR-2003) to the EMBL/GenBank/DBJ databases.  
DR EMBL; AY271744; AAP22956.1; -.  
DR GO; GO:0004867; F:serine protease inhibitor activity; IEA.  
DR InterPro; IPR002223; Kunitz\_BPTI.  
DR Pfam; PF00014; Kunitz\_BPTI; 1.  
DR PRINTS; PR00759; BASICPTASE.  
DR PRODOM; PD000222; Kunitz\_BPTI; 1.  
DR SMART; SMO0131; KU; 1.  
DR PROSITE; PS00280; BPTI\_KUNITZ\_1; 1.  
DR PROSITE; PS0279; BPTI\_KUNITZ\_2; 1.  
FT NON\_TER 82  
FT NON\_TER 82  
SQ SEQUENCE 82 AA; 8874 MW; 0723D4AC6585B349 CRC64;

Query Match 63.5%; Score 223; DB 13; Length 82;  
Best Local Similarity 60.7%; Pred. No 3.2e-22;  
Matches 37; Conservative 9; Mismatches 15; Indels 0; Gaps 0;

CY 1 EVREVCSEAGTGPCRAAIYHYFVDTGKCAPFFYGGCGGGRNNFTDEYCAVCGSAI 60  
DB 16 EVRAVCVAPARGSPCHAKLPRWYFVAERKGRCAFTFGCGGGRNNFSESDYCAVCGSS 75

CY 61 I 61  
DB 76 V 76

RESULT 9  
ID Q9U8G8 PRELIMINARY; PRT; 3198 AA.  
AC Q9U8G8;  
DT 01-MAY-2000 (TREMBLrel. 13, Created)  
DT 01-MAY-2000 (TREMBLrel. 13, Last sequence update)  
DT 01-OCT-2003 (TREMBLrel. 25, Last annotation update)  
DE Lacunin precursor.  
OS Manduca sexta (Tobacco hawkmoth) (Tobacco hornworm).  
OC Eukaryota; Metazoa; Arthropoda; Hexapoda; Insecta; Pterygota;  
OC Neoptera; Endopterygota; Lepidoptera; Glossata; Ditrysia; Sphingioidea;  
OC Sphingidae; Sphinginae; Manduca.  
OX NCBI\_TaxID=7130;  
RN [1]  
RP SEQUENCE FROM N.A.  
RA MEDLINE=99457716; PubMed=10528409;  
RA Nard J.B., Martos R., Walden K.K., Lampe D.J., Robertson H.M.;  
RT "Expression of lacunin, a large multidomain extracellular matrix  
protein, accompanies morphogenesis of epithelial monolayers in Manduca  
sexta.";  
RL Insect Biochem. Mol. Biol. 29:883-897(1999).  
DR EMBL; AF078161; AAF04457.1; -.  
DR HSSP; P12111; 2KNT.  
DR GO; GO:0004867; F:serine protease inhibitor activity; IEA.  
DR InterPro; IPR004094; Anticarsin.  
DR InterPro; IPR007110; IG-1-like.  
DR InterPro; IPR003598; IG\_C2.  
DR InterPro; IPR002223; Kunitz\_BPTI.

```

DR InterPro; IPR000884; TSP1.
DR InterPro; IPR008197; WAP.
DR Pfam; PF02822; Anticstain; 4.
DR Pfam; PF00047; Ig; 2.
DR Pfam; PF00014; Kunitz_BPTI; 10.
DR Pfam; PF00090; tsp_1; 5.
DR Pfam; PF00095; wap_1.
DR PRINTS; PR00759; BASICTPASE.
DR PRODOM; PD000222; Kunitz_BPTI; 10.
DR SMART; SM00408; IGc2; 2.
DR SMART; SM00131; KU; 10.
DR SMART; SM00209; TSP1; 7.
DR SMART; SM00217; WAP; 1.
DR PROSITE; PS00317; 4-DISULFIDE CORE; 1.
DR PROSITE; PS02860; BPTI_KUNITZ_1; 8.
DR PROSITE; PS0279; BPTI_KUNITZ_2; 10.
DR PROSITE; PS50835; IG LIKE; 2.
DR PROSITE; PS50092; TSP1; 5.
KW Immunoglobulin domain; Protease inhibitor; Serine protease inhibitor;
KW Signal.
SQ SEQUENCE 3198 AA; 349364 MW; AB4ACD459C0D9134 CRC64;
FT SIGNAL.

Query Match 51.0%; Score 179; DB 5; Length 3198;
Best Local Similarity 53.6%; Pred. No. 1,4e-14;
Matches 30; Conservative 5; Mismatches 21; Indels 0; Gaps 0;

CY 5 EVGGEQAEPTPCRAITHWYFDVTEGKCAPFYGGCGGNRNFTDEYCMANCGSA 60
DB 2204 EMCMEKDPGPDCTETETRWYDYKLGKCVTFEYGGCGGNRNPNTEYCGYCGTA 2259

RESULT 10
Q9VAV4 PRELIMINARY; PRT; 2772 AA.
ID Q9VAV4; Q9VAV3; (TrEMBLrel. 13, Created)
DT 01-MAY-2000 (TrEMBLrel. 24, Last sequence update)
DT 01-JUN-2003 (TrEMBLrel. 25, Last annotation update)
DE CO33103-PB.
GN PPN.
OS Drosophila melanogaster (Fruit fly).
OC Eukaryota; Metazoa; Arthropoda; Hexapoda; Insecta; Pterygota;
OC Neoptera; Endopterygota; Diptera; Brachycera; Muscomorpha;
OC Ephydroidea; Drosophilidae; Drosophila.
OX NCBI_TaxId=7227;
RN [1]
RP SEQUENCE FROM N.A.
RX MEDLINE=20196006; PubMed=10731132;
RA Adams M.D., Gelniker S.E., Holt R.A., Evans C.A., Gocayne J.D.,
RA Amanatides P.G., Scherer S.E., Li P.W., Hoskins R.A., Galie R.F.,
RA George R.A., Lewis S.E., Richards S., Ashburner M., Henderson S.N.,
RA Sutton G.G., Mortan J.R., Zandell M.D., Zhang Q., Chen L.X.,
RA Brandon R.C., Rogers Y.H., Blazet R.G., Champe M., Pfeiffer B.D.,
RA Wan K.H., Doyle C., Baxter E.G., Heit G., Nelson C.R., Gabor G.L.,
RA April J.P., Agbayani A., An H.U., Andrews-Pfannkoch C., Baldwin D.,
RA Ballew R.M., Basu P.V., Baxendale J., Bayraktaroglu L., Beasley E.M.,
RA Beeson K.Y., Benos P.V., Bertan B.P., Bhandari D., Bolshakov S.,
RA Borikova D., Botchan M.R., Bouck J., Brokstein P., Broctier P.,
RA Burris K.C., Busam D.A., Butler H., Cadieu E., Center A., Chandra I.,
RA Cherry J.M., Cawley S., Dahlke C., Davenport L.B., Davies P.,
RA de Pablos B., Delcher A., Deng Z., Mays A.D., Dew I., Dietz S.M.,
RA Dodson K., Doup L.E., Downes M., Dugan-Rocha S., Dunkov B.C., Dunn P.,
RA Durbin K.J., Evangelista C.C., Ferraz C., Ferreira S., Fleischmann W.,
RA Foster C., Gabrielian A.S., Gary N.S., Gelbart W.M., Glasser K.,
RA Glisdek A., Gong F., Gorrell J.H., Gu Z., Guan P., Harris M.,
RA Harris N.L., Harvey D., Heiman T.J., Hernandez J.R., Houck J.,
RA Hostin D., Houston K.A., Howland T.J., Wei M.H., Ibegwan C.,
RA Jalali M., Kalush F., Karpen G.H., Ke Z., Kamilson J.A., Ketchum K.A.,
RA Kimmel B.B., Kodira C.D., Kraft C., Kravitz S., Kuip D., Lai Z.,
RA Lascko P., Lei Y., Levitsky A.A., Li J., Li Z., Liang Y., Lin X.,
RA Liu X., Mattei B., McIntosh T.C., McLeod M.P., McPerson D.,
RA Merkulov G., Milshina N.V., Modyaty C., Morris J., Moshrefi A.,

```

```

RA Mount S.M., Moy M., Murphy B., Murphy L., Muzny D.M., Nelson D.L.,
RA Nelson D.R., Nelson K.A., Nixon K., Nusken D.R., Pacleb J.M.,
RA Palazzo M., Pittman G.S., Pan S., Pollard J., Puri V., Reese M.G.,
RA Reinert K., Remington K., Saunders R.D., Scheeler F., Shen H.,
RA Shue B.C., Siden-Klamos I., Simpson M., Skupski M.P., Smith T.,
RA Spier E., Spradling A.C., Stapleton M., Strong R., Sun E.,
RA Swirskas R., Tector C., Turner R., Venter E., Wang A.H., Wang X.,
RA Wang Z.Y., Wasserman D.A., Weinstein G.M., Weisenbach J.,
RA Williams S.M., Woodgett, Worley K.C., Wu D., Yang S., Yao Q.A., Ye J.,
RA Yeh R.F., Zaveri J.S., Zhan M., Zhang G., Zhao C., Zheng L.,
RA Zhang X.H., Zhong F.N., Zhong W., Zhou X., Zhu S., Zhu X.,
RA Gibbs R.A., Myers E.W., Rubin G.M., Venter J.C.;
RT "The genome sequence of Drosophila melanogaster."
RL Science 287:2185-2195(2000).
RN [2]
RP SEQUENCE FROM N.A.
RA Celinker S.E., Adams M.D., Kronmiller B., Wan K.H., Holt R.A.,
RA Evans C.A., Gocayne J.D., Amanatides P.G., Brandon R.C., Rogers Y.,
RA Banton J., An H., Baldwin D., Banton J., Beeson K.Y., Busam D.A.,
RA Carlson J.W., Center A., Champe M., Davenport L.B., Dietz S.M.,
RA Dodson K., Dorsett V., Doup L.E., Doyle C., Dresnek D., Farfan D.,
RA Ferreira S., Friese E., Galie R.F., Gary N.S., George R.A.,
RA Gonzalez M., Houck J., Hoskins R.A., Hostin D., Howland T.J.,
RA Ibegwan C., Jalali M., Kruse D., Li P., Mattei B., Moshrefi A.,
RA McIntosh T.C., Moy M., Murphy B., Nelson C., Nelson K.A., Nunoo J.,
RA Pacleb J., Paragas V., Park S., Patel S., Pfeiffer B.,
RA Phouanavong S., Pittman G.S., Puri V., Richards S., Scheeler F.,
RA Stapleton M., Strong R., Swirskas R., Tector C., Tyler D.,
RA Williams S.M., Zaveri J.S., Smith H.O., Venter J.C., Rubin G.M.;
RT "Sequencing of Drosophila melanogaster genome."
RL Submitted (MAR-2000) to the EMBL/GenBank/DBJ databases.
RN [3]
RP SEQUENCE FROM N.A.
RA Miera S., Crosby M.A., Matthews B.B., Bayraktaroglu L., Campbell K.,
RA Hradecky P., Huang Y., Kaminker J.S., Prochuk S.E., Smith C.D.,
RA Tupy J.L., Bergman C.M., Bertan B.P., Carlson J.W., Celinker S.E.,
RA Clump M.E., Drysdale R.A., Emmert D., Friese E., de Grey A.D.N.J.,
RA Harris N.L., Kronmiller B., Marshall B., Millburn G., Richter J.,
RA Russo S., Seale S.M.J., Smith E., Shu S., Smutnick F.,
RA Whitfield E.O., Ashburner M., Gelbart W.M., Rubin G.M., Mungall C.J.,
RA Lewis S.E.;
RT "Annotation of Drosophila melanogaster genome."
RL Submitted (MAR-2000) to the EMBL/GenBank/DBJ databases.
RN [4]
RP SEQUENCE FROM N.A.
RA Flybase;
RL Submitted (SEP-2002) to the EMBL/GenBank/DBJ databases.
RN [5]
RP SEQUENCE FROM N.A.
RA Flybase;
RL Submitted (FEB-2003) to the EMBL/GenBank/DBJ databases.
DR EMBL; AB003765; ACP56794.3; -
DR GO; GO:0005564; Cytoplasmic membrane; IDA.
DR InterPro; IPR006209; BGF-like.
DR InterPro; IPR005599; Ig.
DR InterPro; IPR007110; Ig-like.
DR InterPro; IPR003598; Ig_c2.
DR InterPro; IPR002223; Kunitz_BPTI.
DR InterPro; IPR000884; TSP1.
DR InterPro; IPR008197; WAP.
DR Pfam; PF00047; Ig; 3.
DR Pfam; PF00014; Kunitz_BPTI; 12.
DR Pfam; PF00090; tsp_1; 5.
DR Pfam; PF00095; wap_1.
DR PRINTS; PR00759; BASICTPASE.
DR PRODOM; PD000222; Kunitz_BPTI; 10.
DR SMART; SM00408; IGc2; 3.
DR SMART; SM00131; KU; 10.
DR SMART; SM00209; TSP1; 7.
DR SMART; SM00217; WAP; 1.
DR PROSITE; PS00317; 4-DISULFIDE CORE; 1.
DR PROSITE; PS02860; BPTI_KUNITZ_1; 9.

```



SEQUENCE FROM N.A.

RC TISSUE=Testis;  
RA Sivaehammam P., Hall S.H., Hamil K.G., French F.S., O'Rand M.G.,  
RT Richardson R.T.;  
RT "Characterization of monkey and mouse Egrin, a protease inhibitor from  
RT epididymis and testis";  
RL Submitted (FEB-2001) to the EMBL/GenBank/DBJ databases.  
DR EMBL: AF346415; AAK3137.1; -  
DR HSSP: P05067; ICAO.  
DR GO: GO:0004867; F:serine protease inhibitor activity; IEA.  
DR InterPro: IPR002223; Kunitz\_BPTI.  
DR Pfam: PF00014; Kunitz\_BPTI; 1.  
DR Pfam: PF00055; Wap; 1.  
DR PRINTS: PR00759; BasicPTASE.  
DR ProDom: PD000222; Kunitz\_BPTI; 1.  
DR SMART: SM00131; KU; 1.  
DR SMART: SM00217; WAP; 1.  
DR PROSITE: PS00280; BPTI\_KUNITZ\_1; 1.  
DR PROSITE: PS00279; BPTI\_KUNITZ\_2; 1.  
KW Protease inhibitor; Serine protease inhibitor.  
SQ SEQUENCE 137 AA; 15773 MW; F397AF4E065D626B CRC64;

Query Match 47.6%; Score 167; DB 6; Length 137;  
Best Local Similarity 50.0%; Pred. No. 1,9e-14;  
Matches 27; Conservative 6; Mismatches 21; Indels 0; Gaps 0;

QY 4 REVCSEQATGTCRAAIYHYWYDVBGKCAPFFYGGCGGNRNNDTEECYCAVC 57  
DB 74 KDVCSMFKETGCPCLAFIPRWYDKEREICTEFYGGCGGNRNNDTEECYCAVC 127

RESULT 14

Q81T91 PRELIMINARY; PRT; 759 AA.  
AC Q81T91;  
DT 01-MAR-2003 (TREMBLrel. 23, Created)  
DT 01-MAR-2003 (TREMBLrel. 23, Last sequence update)  
DT 01-OCT-2003 (TREMBLrel. 23, Last annotation update)  
DE Kunitz-like protease inhibitor precursor.  
OS Ancylostoma caninum (Dog hookworm).  
OC Eukaryota; Metazoa; Nematoda; Chromadorea; Rhabditida; Strongylida;  
OC Ancylostomatidae; Ancylostomatidae; Ancylostomatinae; Ancylostoma.  
OX NCBI\_TaxID=29170;  
RN [1]  
RP SEQUENCE FROM N.A.  
RC STRAIN=Baltime;  
RA Hawdon J.M., Datu B., Crowell M.;  
RT "Molecular cloning of a novel multi-domain Kunitz-type Proteinase  
RT inhibitor from the Hookworm Ancylostoma caninum";  
RT Submitted (JUL-2002) to the EMBL/GenBank/DBJ databases.  
DR EMBL: AF533590; AAN1061.1; -  
DR GO: GO:0008233; F:peptidase activity; IEA.  
DR GO: GO:0004867; F:serine protease inhibitor activity; IEA.  
DR InterPro: IPR002223; Kunitz\_BPTI.  
DR Pfam: PF00014; Kunitz\_BPTI; 12.  
DR PRINTS: PR00759; BasicPTASE.  
DR ProDom: PD000222; Kunitz\_BPTI; 10.  
DR SMART: SM00131; KU; 12.  
DR PROSITE: PS00280; BPTI\_KUNITZ\_1; 10.  
DR PROSITE: PS00279; BPTI\_KUNITZ\_2; 12.  
KW Signal; Protease.  
FT SIGNAL 1  
SQ SEQUENCE 759 AA; 84886 MW; C431A3C3F418F40A CRC64;

Query Match 46.4%; Score 163; DB 5; Length 759;  
Best Local Similarity 47.4%; Pred. No. 4.1e-13;  
Matches 27; Conservative 9; Mismatches 21; Indels 0; Gaps 0;

QY 1 EYVREVCSEQATGTCRAAIYHYWYDVBGKCAPFFYGGCGGNRNNDTEECYCAVC 57  
DB 513 EPEKETGCPCLAFIPRWYDKEREICTEFYGGCGGNRNNDTEECYCAVC 569

RESULT 15

Q9D808 PRELIMINARY; PRT; 195 AA.  
AC Q9D808;  
DT 01-JUN-2001 (TREMBLrel. 17, Created)  
DT 01-JUN-2001 (TREMBLrel. 17, Last sequence update)  
DT 01-JUN-2003 (TREMBLrel. 24, Last annotation update)  
DE Serine protease inhibitor, kunitz type 2.  
GN SPINT2.  
OS Mus musculus (Mouse).  
OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;  
OC Mammalia; Eutheria; Rodentia; Sciurognathi; Muridae; Murinae; Mus.  
OX NCBI\_TaxID=10090;  
RN [1]  
RP SEQUENCE FROM N.A.  
RC STRAIN=C57BL/6J; TISSUE=Pancreas;  
RX MEDLINE=21085660; PubMed=11217851;  
RA Kawai U., Shinagawa A., Shibata K., Yoshino M., Itoh M., Ishii Y.,  
RA Aizawa T., Hara A., Fukunishi Y., Kono H., Adachi J., Fukuda S.,  
RA Saito T., Okazaki Y., Gojohori T., Bono H., Kasukawa T., Saito R.,  
RA Kadota K., Matsuda H.A., Ashburner M., Batalov S., Casavant T.,  
RA Fleischmann W., Gaasterland T., Gissi C., King B., Kochiwa H.,  
RA Kuehl P., Lewis S., Matsuo Y., Nikaido I., Pesole G., Quackenbush J.,  
RA Schiraldi L.M., Staubli F., Suzuki R., Tomita M., Wagner L., Washio T.,  
RA Sakai K., Okido T., Furuno M., Aono H., Baldarelli R., Barsh G.,  
RA Blake J., Boffelli D., Bojunga N., Carninci P., de Bonard M.F.,  
RA Brownstein M.J., Bull C., Fletcher C., Fujita M., Gariboldi M.,  
RA Guatincioni S., Hill D., Hofmann M., Hume D.A., Kamiya M., Lee N.H.,  
RA Lyons P., Marchionni L., Mashima U., Mazzarelli G., Mombauts P.,  
RA Nordone P., Ring B., Ringwald M., Rodriguez I., Sakamoto N.,  
RA Sasaki H., Sato K., Schoenbach C., Seya T., Shibata Y., Storch K.-F.,  
RA Suzuki H., Toyooka K., Wang K.H., Welter C., Whitaker C., Wilming L.,  
RA Wynshaw-Boris A., Yoshida K., Hasegawa Y., Kawaji H., Kohsaki S.,  
RA Hayashizaki Y.;  
RT "Functional annotation of a full-length mouse cDNA collection";  
RL Nature 409:685-690(2001).  
DR EMBL: AK007792; BAB25258.1; -  
DR HSSP: P05067; IAP.  
DR MGD; MGI:133603; Spint2.  
DR GO: GO:0004867; F:serine protease inhibitor activity; IEA.  
DR InterPro: IPR002223; Kunitz\_BPTI.  
DR Pfam: PF00014; Kunitz\_BPTI; 1.  
DR PRINTS: PR00759; BasicPTASE.  
DR ProDom: PD000222; Kunitz\_BPTI; 1.  
DR SMART: SM00131; KU; 1.  
DR PROSITE: PS00280; BPTI\_KUNITZ\_1; 1.  
DR PROSITE: PS00279; BPTI\_KUNITZ\_2; 1.  
KW Protease inhibitor; Serine protease inhibitor.  
SQ SEQUENCE 195 AA; 21705 MW; 1ABD76CEFF175DB1 CRC64;

Query Match 45.9%; Score 161; DB 11; Length 195;  
Best Local Similarity 49.1%; Pred. No. 1.8e-13;  
Matches 26; Conservative 8; Mismatches 19; Indels 0; Gaps 0;

QY 5 EYVSEQATGTCRAAIYHYWYDVBGKCAPFFYGGCGGNRNNDTEECYCAVC 57  
DB 74 EYVPRATVPCRAAIYHYWYDVBGKCAPFFYGGCGGNRNNDTEECYCAVC 126

Search completed: April 8, 2004, 09:34:13  
Job time : 42 secs